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Abstract 
Systemic sclerosis (SSc) is an inflammatory connective tissue disorder of unknown 
aetiology, characterised by progressive fibrosis of skin and internal organs. The correct 
epithelial-mesenchymal interactions are essential for skin homeostasis and tissue repair, 
but little is known about these interactions in SSc. Moreover, epithelial cells were 
demonstrated to secrete cytokines and growth factors influencing phenotype and 
proliferation rate of fibroblasts. SSc epithelial cells have recently been shown to take on 
an activated phenotype similar to wound healing. Therefore, this thesis aims to further 
characterise SSc epidermis using immunohistochemistry, mRNA assays, and 
phosphoarrays. Furthermore evidence of SSc keratinocytes releasing factors capable of 
promoting fibrosis is explored, using immunoassays for proteins secretion and in vitro 
experiments on primary fibroblasts and HaCaT cells. Additionally, this thesis also 
addresses the question if SSc epidermis contributes to increased number of contractile 
fibroblasts via epithelial-to–mesenchymal transition.  
This thesis demonstrates that the SSc epidermis has expanded thickness, and 
hypertrophied cells, as well as altered expression pattern of terminal differentiation 
markers. It also is releasing profibrotic and proinflammatory mediators, CTGF and 
S100A9, which are considered targets for novel therapies in rheumatology.  In addition, 
it illustrates that S100A9 signalling via TLR4 is capable of promoting fibroblast 
responses in addition to its known proinflammatory effects.  Also the CTGF induction 
and active profibrotic signaling is shown to affect cells in the upper dermis adjacent to 
the abnormally differentiated epidermis, consistent with cross-talk activation of the 
local fibroblasts. These changes in the epithelial layer may have a role in the SSc 
pathogenesis and contribute to the inflammation and fibrosis seen in the disease.  
Despite active Smad signaling seen to affect the adjacent papillary dermis in active SSc 
consistent with cross-talk, no evidence of full EMT in the SSc epidermis was found. 
However, I report changes consistent with partial EMT process resembling those seen 
during wound re-epithelialisation. 
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1.1  Systemic sclerosis  
1.1.1 Definition and classification 
Systemic sclerosis (SSc) is a clinically heterogeneous multisystem rheumatic connective 
tissue disorder. A hallmark feature of SSc is, evolving over time, autoimmunity, 
inflammation, and vasculopathy, which lead to fibrosis (Kahaleh and LeRoy, 1999). 
Although, these processes are common to all forms of SSc, their extent varies between 
different forms.  
As SSc clinical findings are often seen in other medical conditions The American College 
of Rheumatology (ACR) set specific criteria for the classification of SSc (LeRoy et al., 
1988, 1980). They require meeting one major criterion or two minor criteria: 
 
Major criterion: 
• proximal diffuse sclerosis (skin thickening and tightening, non-pitting induration), 
which may affect the entire extremities, face, neck, and trunk. 
 
Minor criteria: 
• sclerodactyly fingers and/or toes 
• digital pitting scars or loss of substance of the digital finger pads  
• bibasilar pulmonary fibrosis. 
However, recently the ACR/EULAR have modified the 1980 ACR criteria for SSc 
classification to ensure that more patients will be classified correctly as having the 
disease (van den Hoogen et al., 2013). It was decided that skin thickening of the fingers 
extending proximal to the metacarpophalangeal joints is sufficient for patient to be 
classified as having SSc. However, if that symptom is not present, other symptoms need 
to apply, such as skin thickening of the fingers, fingertip lesions, telangiectasia, abnormal 
nailfold capillaries, interstitial lung disease or pulmonary arterial hypertension, 
Raynaud’s phenomenon, and SSc-related autoantibodies. 
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SSc patients are classified into subsets depending on the pattern of their skin 
involvement. The main forms are: diffuse cutaneous SSc (dcSSc) and limited cutaneous 
SSc (lcSSc). Other forms include overlap syndrome with features of other connective 
tissue disorders such as systemic lupus erythematosus (SLE), inflammatory arthritis, and 
systemic sclerosis sine scleroderma form with little or no skin sclerosis, despite other 
features of systemic sclerosis (Poormoghim et al., 2000). In addition there is a localized 
form, which involves one area of the skin and underlying tissues, most often developing 
in childhood (localized SSc, morphea). 
 
1.1.1.1  Limited cutaneous systemic sclerosis (lcSSc) 
In lcSSc skin involvement is restricted to the extremities, but face and neck are usually 
also affected. Patients typically experience long history of Raynaud’s phenomenon, often 
associated with recurrent digital ulcers. Other manifestations include cutaneous 
telangiectasis, subcutaneous calcinosis and oesophageal involvement.  Lung fibrosis is 
less common, but vascular complications are seen more frequently. Patients are tested 
positive for anti-centromere antibodies however, anti-fibrillarin (U3RNP), anti-
topisomerase-1 (ATA) and anti-RNA polymerase I and III antibodies may also be found. 
 
1.1.1.2  Diffuse cutaneous systemic sclerosis (dcSSc) 
The classical early presentation of dcSSc is a sudden onset of inflammatory changes in 
the skin and internal organs. Pain and swelling of the extremities often occurs, and 
affected skin is typically itchy, with loss or change in hair growth. Symptoms of 
Raynaud’s phenomenon develop simultaneously with other features or once the disease is 
established. Pulmonary, myocardial, and gastrointestinal tract involvement, as well as 
hypertensive renal crises, contribute to the significant morbidity and mortality. Whereas, 
the hallmark auto-antibodies for dcSSc include ATA, U3RNP and ARA. The skin 
sclerosis may remit after several years, despite progression of internal organ disease.  
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1.1.2  Epidemiology 
SSc is a relatively rare disease, with estimated prevalence between 1 and 2 per 10,000 of 
population. Higher prevalence is recorded in North America and European ancestry 
population when compared to Asian origin groups (Barnes and Mayes, 2012). The 
incidence is estimated to be 1 in 100,000 per year (Mayes, 1997). As with most 
autoimmune diseases, female are 6 times more often affected than male (Silman et al., 
1988). The only exception is environmentally triggered disease, which is more common 
in men (Silman and Jones, 1992). 
 
1.1.3  Scleroderma pathogenesis 
SSc pathogenesis is complex and not well understood. It is believed that an initial 
stimulus in a susceptible individual triggers a combination of immunological, 
inflammatory, and microvascular processes, which result in fibroblast activation and 
extracellular matrix (ECM) deposition, leading to skin and internal organ fibrosis 
(Jimenez and Bashey, 1977, Abraham and Varga, 2005, Abraham et al., 2007, Matucci-
Cerinic et al., 2013). 
Activated fibroblasts, in SSc lesions persist as myofibroblasts, with enhanced ability to 
produce collagens, adhere, and contract extracellular matrix (ECM) (Jimenez et al., 
1986). Proposed mechanisms responsible for fibroblast activation include persistent and 
inappropriate expression of pro-fibrotic growth factors (Sato et al., 2000), stimulation by 
autoantibodies, cross talk from immune activated endothelial cells, and an important role 
for the epidermis (Aden et al., 2010). Mechanisms and feasibility of potential therapeutic 
targets were recently reviewed by Denton and Ong (Denton and Ong, 2013). Figure 1.1 
summarises the interplay of inflammatory, fibrotic and vascular influences contributions 
to the disease. 
It is unclear what initiates fibrotic process in the SSc skin. Factors suggested to be 
implicated in the pathogenesis of SSc include infection agents, environmental triggers 
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and genetic factors. Although link between infectious agents and SSc is not clear, several 
microbes were identified to play a potential role (Arnson et al., 2009). The most 
commonly associated include Helicobacter pylori (Radic et al., 2012, Yazawa et al., 
1998), Toxoplasma gondi (Shapira et al., 2012), hepatitis B virus, cytomegalovirus 
(CMV) (Arnson et al., 2009), and parvovirus B19 (Ohtsuka and Yamazaki, 2004, 
Zakrzewska et al., 2009), as well as most recently Epstein-Barr virus (Farina et al., 2014). 
 
Figure 1.1. Inflammatory, fibrotic and vascular contributions to the disease.  
from Derret-Smith 2012 (Derrett-Smith, 2013) 
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From environmental factors linked to occurrence of SSc exposure to polyvinyl chloride, 
silica dust, aromatic and aliphatic organic solvents, epoxy resins and formaldehyde are 
typically cited (Cowie, 1987, Silman and Jones, 1992, Nietert et al., 1999, Nietert and 
Silver, 2000, McCormic et al., 2010, Makol et al., 2011). 
Some genetic predispositions for SSc have also been identified, however there are many 
conflicting reports. These differences might be due to ethnicity and discrepancies in 
particular subsets inclusion criteria. Most genes are linked to the inflammatory aspects of 
the disease with the strongest links to class II MHC haplotype (Gilchrist et al., 2001, 
Mayes et al., 2014). Other genetic associations with SSc include STAT4 (Dieude et al., 
2009a, Rueda et al., 2009), IRF5 (Dieude et al., 2010, Dieude et al., 2009a, Dieude et al., 
2009b), PTPN22 (Dieude et al., 2008, Diaz-Gallo et al., 2011), BANK1 (Dieude et al., 
2009b, Rueda et al., 2010), CD247  (Radstake et al., 2010, Dieude et al., 2011), CTGF 
promoter (Kawaguchi et al., 2009, Fonseca et al., 2007), fibrillin-1 (Tan et al., 2001), IL-
10 (Hudson et al., 2005), IL-1 (Kawaguchi et al., 2003), MCP1 (Carulli et al., 2008, 
Karrer et al., 2005) and COL1A2  (Hata et al., 2000). As well as more recently identified 
TNIP1 (Allanore et al., 2011), KIAA0319L, PXK and JAZF1 (Martin et al., 2013), and 
interferon- and transforming growth factor β-regulated genes (Christmann et al., 2014) 
 
1.1.4  Skin involvement 
Skin is an organ clinically affected in the vast majority of SSc cases and an early 
detectable marker of disease activity. The level of skin involvement in SSc patients is 
clinically assessed using the modified Rodnan skin score (mRSS) (Clements et al., 1993, 
Furst et al., 1998), which measure thickness of 17 areas at different body sites, grading 
them between 0 (normal) and 3 (severe thickening). The total skin score is a sum of 
individual skin assessment from all the sites and ranges between 0-51, the higher the 
score, the greater the extent and severity of skin thickening.  
A link between the severity of skin involvement and visceral complications in dcSSc was 
first recognized in the 1960s and since then has been confirmed in a number of studies 
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(Clements et al., 2000, Shand et al., 2007, Steen and Medsger, 2001, DeMarco et al., 
2002, Clements et al., 1990). Most recently the correlation between skin involvement and 
gene expression and the severity of interstitial lung disease was demonstrated (Assassi et 
al., 2013, Cottrell et al., 2014). The correlation between baseline skin score and disease 
severity and mortality in SSc patients, has been proposed as a useful disease predictor, 
and demonstrates the overall importance of skin pathology in the disease process 
(Clements et al., 2000). The majority of dcSSc patients develop the maximal skin score 
early in disease (Shand et al., 2007). Rapid increase in the mRSS in the early stage of 
disease is associated with a significantly increased risk of developing renal crisis (Steen 
et al., 1984). Consistent with skin involvement representing a window into this systemic 
disease, Steen and colleagues have demonstrated that, improvement in skin score of SSc 
patients is associated with improved survival (Steen and Medsger, 2001). Therefore, as a 
surrogate measure of disease severity, almost universally clinically affected, and an easily 
accessible organ, skin became important in studies on SSc.   
Cutaneous manifestations usually start to develop on hands, and although they are mainly 
confined to the extremities they can extend to the trunk. Involved skin is characterised by 
oedema that is later replaced by thickened skin, followed by changes in skin 
pigmentation, alopecia (hair loss) and loss of sebaceous glands. Digital ulcers on the 
fingertips, contracted joints, restricted mouth opening and hardening of the mouth area 
(microstomia) are also among common SSc features (Denton and Black, 2004). Typical 
clinical presentations of dcSSc skin are shown in Figure 1.2. 
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Figure 1.2. Typical clinical presentation of dcSSc.  
Classical features of dcSSc: (a) microstomia, (b) pigmentation changes, (c) skin tightening and 
(d) digital ulcers. 
 
  
a b#
c# d#
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The histological changes, which occur in involved skin depend on disease duration and 
are similar to those observed in wound healing (Fig.1) (Aden et al., 2008). Early lesions 
contain inflammatory cell infiltrates and have up-regulated expression of pro-
inflammatory cytokines such as IL-6 (Khan et al., 2012), IL-8, TNFα, CCL20 
(Yamamoto, 2008), and MCP-1  (Tao et al., 2011), as well as increased levels of 
adhesion molecules, such as intracellular cell adhesion protein (ICAM) (Majewski et al., 
1991), vascular cell adhesion protein (VCAM) or P-selectin (Koch et al., 1993). While in 
later stages the inflammation is resolved, and there is a loss of normal tissue architecture 
due to increased deposition of collagen and other extracellular matrix (ECM) proteins 
(Rodnan et al., 1979, Torres and Sanchez, 1998, Martin et al., 2012). In addition, blood 
vessels and sweat glands undergo atrophy, and subcutaneous fat layer may become 
reduced.  
More recent report showed increased amount of collagen, myofibroblast accumulation, 
the mean epidermal thickness and the frequency of focal exocytosis, and the mononuclear 
cellular infiltration differed in clinically involved skin (Van Praet et al., 2011). Moreover, 
the authors demonstrated that all of the parameters except for mononuclear cellular 
infiltration, correlated with the skin score. In addition they have observed parakeratosis 
and proliferation of the intima in a minority of the SSc biopsies.  
However, changes in SSc are not restricted to involved skin, studies of uninvolved skin 
from SS patients have also revealed differences from healthy skin. For instance reports 
have shown a significant decrease in fibrillin-1 (Wipff et al., 2010), and MMP-1 while 
TIMP-1, and HGF genes expression increased (Frost et al., 2012) in clinically involved 
and uninvolved dcSSc skin in comparison to control skin. Furthermore, gene expression 
studies of SSc skin have demonstrated that patients may be sub-divided based upon their 
gene expression profiles: proliferating, inflammatory and fibrotic (Whitfield et al., 2003, 
Milano et al., 2008). 
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1.2  The epidermis 
1.2.1  Definition 
The epidermis is the outermost layer of the skin, the biggest organ in human body. It 
forms a mechanical and physical barrier protecting the body from water loss and 
pathogens. It consists of a stratified epithelium, constantly renewing under normal 
conditions and after injury, by maintaining a population of actively dividing cells in the 
hair follicles and innermost layer (Niemann and Watt, 2002). The cells in the epidermis 
are predominantly keratinocytes, but also include Langerhans cells, Merkel cells, and 
melanocytes. 
Epidermal keratinocytes form four distinct layers: basal, spinous, granular, and cornified. 
As cells grow they migrate from basal location through the spinous, and granular layers, 
to the outermost cornified position, from which they are constantly shed. That change 
from proliferating keratinocyte into a dead, flattened part of stratum corneum is called 
cornification or terminal differentiation (Fuchs, 1990).  
 
1.2.2  Terminal differentiation 
Terminal differentiation begins when basal cells withdraw from the cell cycle and lose 
adherence to the basement membrane moving upwards towards the skin surface. In the 
spinous layers, cells strengthen their cytokeratin filaments framework, essential for 
mechanical strength, before moving into the granular layers (Candi et al., 2005). The 
outermost cornified layer consists of terminally differentiated, dead and flattened 
keratinocytes tightly attached to each other by corneodesmosomes, which become 
proteolytically degraded to facilitate desquamation (Simpson et al., 2011). Figure 1.3 
shows a schematic of terminally differentiating epidermis including change in protein 
expression. 
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Figure 1.3. Terminal differentiation of a healthy epidermis.  
TG-transglutaminase (from Candi et al., 2005)  
 
Keratins K5 and K14 are the main structural proteins in proliferating keratinocytes that, 
assemble into keratin intermediate filaments. These filaments extend from desmosomes 
towards the nuclear lamina and together with tubulin and actin form cytoskeleton of the 
keratinocytes. Triggered by a signal, basal keratinocyte migrates towards the spinous 
layer losing its mitotic ability and beginning to synthesize new structural proteins and 
calcium dependent transglutaminase (TG) enzymes characteristic to cornification. The 
newly synthesized K1 and K10 replace K5 and K14. Later cells acquire keratohyalin 
granules containing pro-filaggrin, which during differentiation becomes proteolyticaly 
cleaved and released. Filaggrin aggregates keratin filaments into bundles leading to the 
collapse of the cells into a flattened shape characteristic to corneocytes in the stratum 
corneum. Simultaneously, cells produce other structural proteins such as loricrin and 
involucrin, which become cross-linked by calcium dependent TG1 and TG5. In addition, 
lipids, small proline-rich proteins and S100 proteins family members (S100A7, S100A10 
and S100A11) are present in the assembled cornified envelope.  
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In normal epidermis the proliferation rate of basal keratinocytes layer is accurately 
balanced by desquamation of the cornified layer to constantly rejuvenate the epidermis. 
Several factors have been implicated as being able to switch the balance between 
proliferation and terminal differentiation with recent developments showing growing 
importance of ECM (Watt and Huck, 2013). Those factors promoting differentiation of 
keratinocytes, include increased Ca2+ concentration (Boyce and Ham, 1983, Celli et al., 
2011), TGF-β (Matsumoto et al., 1990) and p38 MAPK signalling (Eckert et al., 2002), 
rounded cell shape (Watt et al., 1988), and decreased cell contact with the ECM (Watt et 
al., 1993) and physically restrained area for growth (Watt and Green, 1981). Whereas, 
HGF (Matsumoto et al., 1991) and JNK (Gazel et al., 2006) signalling was reported to 
inhibit differentiation of epithelial cells and promote keratinocytes proliferation. 
Defects in the formation of the cornified envelope are responsible for disrupted epidermis 
homeostasis and result in disease, including lamellar ichthiosis in patients carrying 
mutation in TG1 gene (Huber et al., 1995), Vohwinkel syndrome and progressive 
symmetric erythrokeratodermia linked to abnormal loricrin (Maestrini et al., 1996, Ishida-
Yamamoto et al., 1997) and epidermolytic hyperkeratosis due to K1 and K10 mutations.   
 
1.2.3  Epidermis in SSc and other fibrotic skin diseases 
Recently the importance of epidermal genes on the phenotype was demonstrated in 
mouse mutants, showing not only implications in skin abnormalities but also indications 
of systemic effects (Liakath-Ali et al., 2014). There is increasing evidence supporting a 
key role for the epidermis in promoting dermal fibrosis in keloids (excessive scaring 
which extends beyond the initial site off injury), hypertrophic scaring (excessive scaring 
restricted to the initial site off injury) and SSc. Activated keratinocytes are found in 
hypertrophic scars as well as in SSc.  
In hypertrophic scars decreased production of keratinocytes derived IL-1a (which 
stimulate matrix degradation) and increased PDGF (which increase matrix production) 
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was reported, which lead to decreased catabolism of dermal matrix and increased 
formation of ECM (Niessen et al., 2001). The result was replicated in another study, 
where co-culture of hypertrophic keratinocytes with normal wound myofibroblasts/ 
hypertrophic myofibroblasts/ fibroblasts induced thicker dermis due to increased 
synthesis of collagen and decreased MMP-1 as well as increased proliferation of dermal 
cells (Bellemare et al., 2005). Additionally, hypertrophic keratinocytes where shown to 
have increased secretion of TIMP-1, inhibitor of matrix degrading MMPs, which 
correlates with dermal thickness (Simon et al., 2011). 
Whereas in keloids, keratinocytes where described to increase proliferation and decrease 
apoptosis of co-cultured fibroblasts (Funayama et al., 2003), as well as overexpress 
VEGF (Ong et al., 2007). They were also shown to have upregulated TGF-β receptors 
and Smad2/3 phosphorylation in co-cultured fibroblasts (Phan et al., 2005). Further 
studies demonstrated that fibroblasts co-cultured with keloid keratinocytes produced 
more ECM proteins and had increased levels of TGF-β  activity (Xia et al., 2004). In 
other preliminary study our group showed that SSc epidermis promotes fibroblast 
activation and fibroblast CTGF expression via IL-1α, in 3-D co-culture (Aden et al., 
2010). More recent findings show RXFP1 increased TLR4 expression in SSc 
keratinocytes, which was suggested to also play a role in activation of fibroblasts in SSc 
skin (Bhattacharyya et al., 2013). Whereas, cathepsin V, a proteolytic enzyme modulating 
angiogenic processes, collagen degradation and keratinocyte differentiation, were 
significantly decreased in SSc skin, including keratinocytes (Noda et al., 2013). 
Although, the majority of studies over the last few decades were performed on the 
dermis, some studies showed changes in the epidermis. It remains unclear if the changes 
seen in the SSc epidermis are initiated by environmental insult or are secondary to dermal 
changes, such as altered properties of ECM. 
Confocal laser scanning microscopy revealed that SSc epidermis is hypertrophic with a 
large number of melanocytes and increased melanin content (Sauermann et al., 2002). 
This confirmed previous observations of changes in skin pigmentation in SSc, which can 
31 
 
be severe and widespread (Tabata et al., 2000, Pope et al., 1996). TGF-β, which is 
important in epidermal-dermal interactions during wound healing and closely linked to 
SSc pathogenesis, was found to be expressed throughout the SSc epidermis (Rudnicka et 
al., 1994, Querfeld et al., 1999). 
Immunohistological studies have also shown enhanced expression of cytokines (IL-6), 
adhesion molecules (VCAM and P-selectin in granular layer) and CD44 (in spinous and 
granular layers) in SSc epidermis (Koch et al., 1993). ET-1 (Tabata et al., 2000), 
monocyte chemo-attractant protein-1 (MCP-1) (Distler et al., 2001), VEGF (Davies et al., 
2006) and IL-21 receptor (IL-21R) (Distler et al., 2005) have also been demonstrated to 
be up-regulated in the epidermis in SSc. 
Previous data from our group have suggested that SSc epidermis is activated, with 
delayed keratinocyte differentiation and changes resembling those seen during wound 
healing (Aden et al., 2008). SSc keratinocytes express K6 and K16, which are normally 
present during wound healing but not in homeostasis. In addition K14 expression in SSc 
epidermis is not limited to the basal layer, but is expressed throughout epidermal layers 
(Figure 1.4), whereas K1/K10 expression is delayed. Also α6 integrin, which is 
responsible for the adhesion of basal cells to the basement membrane, is not restricted to 
basal cells in SSc.  
Proteomic analysis demonstrated altered abundance of specific proteins in SSc skin, and 
pointed to increased expression of ECM proteins, proteins associated with contractility 
and mobility, but also oxidative stress and protein folding (Aden et al., 2008). Moreover, 
data showed activation of stress-induced mitogen-activated protein kinase (MAPK) in 
SSc and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in SSc 
epidermis as well as phosphorylation of c-Jun, and p38. Phosphorylation of HGF 
receptor, c-Met was also enhanced in involved skin of SSc patients (Aden et al., 2010). 
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Figure 1.4. Expression of CK14 in healthy and SSc skin and cutaneous wound. 
(from Aden et al., 2008) 
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1.3  Epithelial-mesenchymal interactions 
1.3.1  Background 
The epidermal-dermal cross-talk in healthy skin is well documented. Correct epithelial-
mesenchymal interactions are essential in embryogenesis, skin homeostasis (Szabowski 
et al., 2000, Maas-Szabowski et al., 2000) and repair (Werner et al., 2007, El Ghalbzouri 
and Ponec, 2004). When disrupted it can result in pathogenesis, such as tumor formation 
(Bhowmick et al., 2004). These interactions are based on the production of soluble 
autocrine and paracrine factors, cell-matrix interactions (Gailit and Clark, 1994, Watt and 
Fujiwara, 2011), and direct cell-cell contact (Waelti et al., 1992).  
Skin fibroblasts and keratinocytes are source of: growth factors - soluble molecules that 
influence growth and differentiation of cells, cytokines - signalling molecules released by 
cells in danger e.g. upon injury, and chemokines attracting immune cells of both adaptive 
and innate system to the site of injury/infection. They can act in autocrine, or paracrine 
manner or both. Their appropriate concentrations are essential for skin homeostasis and 
wound healing, and if the balance is shifted they create an environment for pathological 
events like fibrosis (Hogaboam et al., 1998). The key soluble factors involved in 
epithelial-mesenchymal cross-talk are summarised in a table below. 
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Table 1.1. Key soluble factors involved in epithelial-mesenchymal cross-talk. 
Soluble factor Cell type producing Function Relevance to fibrotic diseases 
Growth factors 
Fibroblast growth 
factor – 2 (FGF-2/ 
bFGF) 
Major source  KC; others 
include FB, macrophages 
and EC 
Angiogensis and FB 
proliferation during wound 
healing   
↑ in SSc serum (Hummers et al., 2009, 
Kadono et al., 1996) and SSc skin 
(Lawrence et al., 2006) ; ↑ in keloid skin 
(Funayama et al., 2003) 
Hepatocyte growth 
factor (HGF/SF) 
Upon injury by 
mesenchymal and EPC 
Proliferation and migration 
of EPC during wound 
healing  
↑ in SSc serum (Beirne et al., 2009) and SSc 
skin (Frost et al., 2012);  HGF ↓ collagen 
synthesis  
Vascular endothelial 
growth factor 
(VEGF) 
Upon injury mainly by KC 
and macrophages.  
 
Angiogenic, mitogenic for 
EC; chemoattractant to 
monocytes,  
↑ in dcSSc skin KC (Davies et al., 2006)  
and skin of mouse scleroderma models 
(Zhou et al., 2007); ↑ in SSc serum 
(Hummers et al., 2009) 
Platelet derived 
growth factor 
(PDGF) 
 
Include EPC, EC and, FB 
at the site of injury 
Proliferation, survival and 
migration of mesenchymal 
cells; ↑ collagen 
production and cell 
adhesion  
PDGF-AA (Yamakage et al., 1992) and 
PDGF-BB and its receptor ↑ in SSc skin 
(Gay et al., 1989, Klareskog et al., 1990); ↑ 
in SSc serum (Hummers et al., 2009)  
Granulocyte 
macrophage-colony 
stimulating factor 
(GM-CSF) 
Include FB, EPC in 
response to immune 
activation and pro-
inflammatory cytokines.  
Stimulate KC and 
hematopoietic cells 
proliferation and 
differentiation  
↑ expression of GM-CSF receptor on SSc 
dermal FB (Postiglione et al., 2002); in SSc 
FB blocks deposition of type I collagen, and 
↑ production of fibronectin and tenascin 
(Postiglione et al., 2005).  
Connective tissue 
growth factor 
(CTGF/CTGF) 
Include FB, EC and KC Proliferation and migration 
of EC and FB, ECM 
production 
Polymorphism associated with SSc 
(Fonseca et al., 2007, Kawaguchi et al., 
2009, Kovalenko et al., 2009, Granel et al., 
2010); ↑ in serum (Sato et al., 2000), plasma 
and dermal interstitial fluid (Dziadzio et al., 
2005) and skin of SSc patients (Igarashi et 
al., 1996); constitutively overexpressed in 
SSc fibroblasts (Denton and Abraham, 
2001). 
Cytokines 
Interleukin 1 alpha 
(IL-1α) 
Constitutively by EPC; 
upon stimulation by 
variety of cells including 
FB and immune cells 
Proinflammatory; ↑ 
expression of 
antimicrobial peptides in 
KC; important in cross talk 
between KC and FB via 
AP-1 proteins. 
Polymorphism in IL1A gene ↑ susceptibility 
to SSc and its severity (Kawaguchi et al., 
2003); constitutively expressed by SSc FB 
(Kawaguchi, 1994); production associated 
with ↑ proliferation, pro-collagen synthesis, 
PDGF and IL-6 production (Kawaguchi et 
al., 1999); used by SSc KC to activate 
dermal FB (Aden et al., 2010); no 
significant difference in SSc patients sera 
when compared with healthy controls 
(Needleman et al., 1992). 
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Interleukin 1 beta 
(IL-1β) 
 Proinflammatory; ↑ cell 
proliferation and 
differentiation 
SSc FB show ↑ sensitivity to exogenous IL-
1β (Kawaguchi et al., 1993); constitutively 
expressed by SSc FB (Kawaguchi, 1994) 
Interleukin 1 
receptor antagonist 
(IL-1ra) 
Intracellular form (icIL-
1ra) constitutively 
produced by KC during 
differentiation; 
extracellular form secreted 
by damaged KC and 
monocytes 
Competitive inhibitor of 
IL-1, anti-inflammatory 
IcIL-1ra ↑ in SSc FB (Higgins et al., 1999); 
might contribute to differentiation of FB 
into myofibroblasts and downregulation of 
collagenase expression. (Kanangat et al., 
2006).  
Interleukin 6 (IL-6) Include KC, FB, EC and 
macrophages.  
Important in early 
inflammation and wound 
healing.  
↑ in SSc FB (Kadono et al., 1998, Koch et 
al., 1993, Kondo et al., 2001) and serum of 
SSc patients (Gillitzer and Goebeler, 2001, 
Needleman et al., 1992); levels correlate 
with skin thickness score (Sato et al., 2001). 
Chemokines 
Interleukin 8 (IL-8) Several cell types  Proinflammatory, 
angiogenic, 
chemoattractant, activator 
of neutrophils,  
↑ expression by SSc FB (Kadono et al., 
1998, Koch et al., 1993) and in serum of 
SSc patients (Codullo et al., 2011) 
Macrophage 
inflammatory protein 
3 alpha (MIP-3α/ 
CCL20/ LARC) 
Constitutively at low 
levels by KC and EC; 
induced in other cell types 
including FB  
Chemoattracts DC, T-cells 
and B-cells; important in 
skin and mucosa 
homeostasis and immune 
protection  
↑ along with its receptor CCR6 in early SSc 
skin (Tao et al., 2011). 
 
Monocyte 
chemoattractant 
protein -1 (MCP-
1/CCL2/ MCAF) 
Monocytes and 
macrophages major 
source; other include EPC, 
EC and FB  
Recruits monocytes, 
memory T-cells, NK cells 
eosinophiles, basophiles, 
DC and LC  
Polymorphism in the promoter region linked 
with SSc (Karrer et al., 2005); ↑ in SSc 
patients serum (Hasegawa et al., 1999) and 
kidney fibrosis (Lloyd et al., 1997a, Lloyd 
et al., 1997b); ↑ collagen and TGFβ 
production by  FB (Gharaee-Kermani et al., 
1996) 
S100A9 (MRP14, 
calgranulin B) 
Neutrophils and 
monocytes; activated by 
environmental stress 
(Marionnet et al., 2003) 
and IL-1α (Bando et al., 
2007) EPC and EC 
Binds calcium, pro-
inflammatory, 
antimicrobial, integrin 
synthesis and actin 
reorganization; ↓ KC 
proliferation and 
differentiation  
↑ in BAL of patients with idiopatic 
pulmonary fibrosis (Bargagli et al., 2011); 
profibrotic (Meyer et al., 2011, Shibata et 
al., 2004); ↑ in SSc patients saliva (Giusti et 
al., 2007); inhibits MMPs (Isaksen and 
Fagerhol, 2001),  
KC - keratinocytes; FB - fibroblasts; EPC - epithelial cells; EC – endothelial cells; DC - dendritic cells; LC 
- Langerhan’s cells; BAL – bronchoalveolar lavage; ↑ - increase; ↓ - decrease;  
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In embryogenesis epithelial-mesenchymal interaction is critical; for example, TGF-β 
mediated cross-talk is involved in lung and palate formation (Shannon and Hyatt, 2004, 
Kaartinen et al., 1995). The importance of these interactions in adult skin started to 
emerge in 1970s, when Rheinwald and Green demonstrated that keratinocytes require the 
presence of fibroblasts for efficient growth (Rheinwald and Green, 1975). In the same 
year Rubin identified fibroblast-derived keratinocyte growth factor (KGF) and shown its 
ability to stimulate keratinocytes proliferation (Rubin et al., 1995). Later we learnt from 
epithelial-mesenchymal co-culture studies that keratinocytes can stimulate fibroblasts via 
interleukin 1 (IL-1) (Maas-Szabowski and Fusenig, 1996, Waelti et al., 1992) to secrete 
growth factors and cytokines essential for growth of epithelial cells, such as KGF, HGF 
(Weng et al., 1997, Gron et al., 2002), IL-6 or GM-CSF (Smola et al., 1993, Grossman et 
al., 1989). Critical for this paracrine loop is a transcription factor, activator protein-1 (AP-
1) (Szabowski et al., 2000, Nowinski et al., 2004), regulating expression of genes 
responsible for keratinocytes proliferation and differentiation. Another growth factor 
released by keratinocytes is PDGF, which main role is to stimulate growth of fibroblast 
(Ansel et al., 1993).  
Epithelial-mesenchymal interactions may also affect the phenotype of cells. For instance 
fibroblast feeders allow maintenance of stem cell populations within the basal cell layer 
of keratinocytes (Rheinwald and Green, 1975). Another example are fibroblasts, which 
become contractile much quicker in co-cultures with epithelial cells than in monolayers, 
due to the increased TGF-β release in such co-cultures (Shephard et al., 2004b). TGF-β, 
known to be released from keratinocytes after wounding, penetrates to the underlying 
dermis and stimulates fibroblasts to produce collagen (Yang et al., 2001). Another TGF-β 
superfamily member, activin also enhances ECM production and induces differentiation 
of fibroblasts into myofibroblasts; however, in contrast to TGF-β1 it does not seem to 
affect keratinocytes proliferation but induces terminal differentiation (Hubner et al., 
1999). In contrary, IL-1α delays full differentiation of fibroblasts into contractile 
myofibroblasts (Shephard et al., 2004a, Shephard et al., 2004b).  
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The ultimate importance of epithelial-mesenchymal interactions was confirmed in 
microarray analysis of fibroblast gene expression after 48hr co-culture with keratinocytes. 
It showed up-regulation of 243 genes and down-regulation of 100 genes in response to 
keratinocyte-derived factors (Nowinski et al., 2004). The up-regulated genes included 
cytokines and chemokines (GRO-α, MCP-2, IL-8, G-CSF), proteins involved in 
proliferation (cyclin B1), pro-angiogenic (VEGF), regulating ECM production and 
remodeling (prolyl 4-hydroxylase, MMP-1 and -3, HAS-2, lysyl hydroxylase 2, 
fibromodulin and PAI-1). Whereas, tetranectin and WISP-2 were among genes shown to 
be down regulated. Unsurprisingly, most of the genes were regulated by keratinocytes 
derived IL-1α. Shepard’s study on differential mRNA expression patter of fibroblast co-
cultured with epidermal cells added to the up-regulated genes list, among others COX-22, 
MCP-1, α-SMA, calponin, ET-1, heparin binding EGF and CTGF (Shephard et al., 
2004a). 
Another example of close interactions between keratinocytes and fibroblast is synthesis 
of the basement membrane, separating epidermis from dermis, to which both types of 
cells contribute (Smola et al., 1998). Laminin 5 was shown to have epithelial origin while 
collagen VII, to be produced by both keratinocytes and fibroblasts (Marinkovich et al., 
1993).  
Epithelial-mesenchymal cross-talk is also based on cell-ECM interactions, which were 
recently reviewed by Watt and Eckes (Watt and Fujiwara, 2011, Eckes et al., 2010). The 
ECM provides scaffolding for the adhesion and migration of cells. ECM components 
include collagens, elastin, proteoglycans, fibronectin, laminins and proteins such as 
thrombospondin. Many of them can bind and modify activity of growth factors and 
cytokines, preventing them from degradation or act as reservoir from which they can be 
rapidly released (Flaumenhaft and Rifkin, 1991, Hynes, 2009). To contact with ECM 
cells use integrins and epidermal stem cells that are in the closest proximity to the dermis 
express the highest level of these receptors (Jones and Watt, 1993). Reduction of integrin 
expression or loss of contact with ECM triggers cell detachment from basal membrane 
and terminal differentiation (Watt, 2002). Loss of β1 and α3 integrins leads to impaired 
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wound healing and is associated with stronger inflammatory response, and enhanced 
TGF-β1 signalling (Grose et al., 2002).  
Contact with ECM also transmits mechanical tension onto cells, which then modulates 
gene expression and leads to cell cytoskeleton reorganization. A combination of 
increased mechanical tension and TGF-β1 is responsible for differentiation of fibroblasts 
into myofibroblasts (Wipff et al., 2010) and enhanced collagen expression, forming an 
autocrine loop (Lindahl et al., 2002). Moreover, high tension down-regulates many 
proteases while up-regulating protease inhibitors (Chiquet et al., 2009). These 
observations clearly demonstrate that increased mechanical tension and up-regulation of 
ECM proteins, during wound healing and in fibrotic diseases, contributes to wound 
closure and scar formation and can further perpetuate pro-fibrotic changes.  
 
1.3.2  Normal wound healing 
If the skin barrier is breached, a wound healing process is initiated to re-establish its 
integrity. The wound healing cascade of events is highly regulated (Werner and Grose, 
2003) and can be divided into three phases: blood clotting and inflammation, new tissue 
formation, and tissue remodeling (Gurtner et al., 2008).  These phases although having a 
sequential order, overlap. The importance of wound healing and contribution of epithelial 
stem cells to the process was recently reviewed (Arwert et al., 2012)  
Instantly after the injury until day 5 an inflammatory phase is induced, during which, 
blood and water loss are prevented by formation of a platelet plug followed by fibrin 
matrix. At the same time, inflammatory cells including neutrophils, monocytes and mast 
cells are attracted to the site of the injury. Inflammatory cells, protect from bacterial 
infection, remove dead tissue, but also secrete growth factors and cytokines. Low 
molecular weight compounds are also released from serum of injured blood vessels and 
degranulating platelets   
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On day 1-2 after injury, the second phase begins and lasts for up to three weeks. During 
this stage of wound healing, proliferation and migration of cells leads to formation of a 
new tissue. The process is initiated by absence of neighboring cells, release of mitogens 
(e.g. HGF, FGF-2 and EGF), and chemoattractants from degranulating platelets and 
infiltrating inflammatory cells, as well as up-regulation of their receptors. Keratinocytes 
from the wound edge and injured appendages become activated, release IL-1α and 
migrate forward between the epidermis and the fibrin clot, attaching to exposed collagen 
fibers. The leading edge keratinocytes change their integrin expression and release matrix 
metalloproteinase 1 (MMP-1) to allow degradation of the connective tissue on the way. 
Keratinocytes behind the leading edge proliferate and differentiate, restoring epidermal 
barrier function. Simultaneously, a latent form of TGF-β, bound to ECM becomes 
activated.  
Shortly after, formation of new blood vessels (angiogenesis) is initiated, promoted by 
VEGF and FGF-2. Fibroblasts from the edge of the wound and attracted from the bone 
marrow proliferate, stimulated by PDGF and release factors stimulating re-
epithelialisation, such as EGF, HGF and FGF. Soon after TGF-β induces fibroblasts 
differentiation into myofibroblasts, these then contract bringing the edges of the wound 
together. Along with fibroblasts, myofibroblasts synthesize ECM proteins, including 
fibronectin, and collagens type I and III. Simultaneously, new nerve endings develop 
around the wound edge. The resulting wound connective tissue is known as granulation 
tissue, because of the granular appearance of the numerous capillaries. 
Finally, 2-3 weeks after injury the last remodeling phase begins and can last as long as 2 
years. The activated cells return to a non-activated phenotype, some cells in the wound 
undergo apoptosis, others exit the wound, and a scar replaces the fibroblast-rich 
granulation tissue. Collagen remodeling during scar formation is dependent on continued 
synthesis and catabolism of collagen, controlled by MMPs secreted by epidermal cells, 
macrophages, endothelial cells, and fibroblasts themselves (Werner and Grose, 2003, 
Werner et al., 2007, Singer and Clark, 1999, Faler et al., 2006). 
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1.3.4  Fibroblasts and myofibroblasts  
Fibroblasts are mesenchymal cells, which provide structural framework for many tissues 
and play a crucial role in the control of connective tissue homeostasis. When activated, 
they are the main cell type responsible for the synthesis of collagen and other ECM 
components, during wound healing and tissue fibrosis. Additionally, they contribute to 
tissue contraction and wound closure by generating fractional forces during migration 
into the wound and by differentiation into highly contractile myofibroblast (Tomasek et 
al., 2002, Desmouliere et al., 2005).  
During fibrogenesis, fibroblasts become highly activated and undergo transition into 
myofibroblasts, with morphology and biochemical characteristics between those of the 
fibroblast and the smooth muscle cell (Gabbiani et al., 1971). Myofibroblasts express 
αSMA, as well as an array of stress fibers in their cytoplasm (Desmouliere et al., 2003), 
which allow them to remodel and contract ECM. Compared to fibroblasts myofibroblasts 
have also increased proliferation and migration, as well as enhanced ability to produce 
cytokines and ECM (Guarino et al., 2009, Desmouliere et al., 2003). Abundant quantities 
of myofibroblasts are present in sites of inflammation and tissue repair, where they 
contract connective tissue in order to close the wound (Guarino et al., 2009). However, 
the created scar is often stiff and disrupts function of the surrounding cells leading to 
tissue dysfunction and even organ failure (McAnulty, 2007). It has been suggested that it 
is a combination of TGFβ, IL-1β, and increased matrix stiffens that is responsible for a 
differentiation of fibroblasts into myofibroblasts (Leung et al., 2007).  
 
1.3.5  Fibrosis as pathological wound healing 
Physiological wound healing is self-limiting. A failure of the wound healing process to 
undergo normal resolution means that keratinocytes remain activated and myofibroblasts 
persist in the granulation tissue, continuing the deposition of ECM. These pathological 
events are thought to be a key to promote the development of fibrotic disorders such as 
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hypertrophic scarring, keloid formation and SSc (Abraham et al., 2007). 
Normal fibroblast function, including their collagen production, is closely regulated in 
response to tissue requirement. Once sufficient ECM is laid down and re-epithelialisation 
is completed they either return to the quiescent state or undergo apoptosis. This ensures 
restoration of organ function, and allows cellular and collagen interactions, leading to 
gradual remodeling and strengthening of the scar (O'Kane and Ferguson, 1997). 
However, if fibroblasts remain activated, ECM secretion continues and tissue contraction 
persists, leading to matrix stiffening, formation of pathological scar and ultimately 
fibrosis (Kuhn and McDonald, 1991). Furthermore, fibroblasts from SSc lesional skin 
demonstrate capacity to produce more soluble collagen than the controls (LeRoy, 1974). 
It is not well understood what causes the switch from normal responsive fibroblast to 
unresponsive, and persistently activated one, contributing to damaging fibrosis. Some of 
the possible explanations include persistent activation of fibroblasts by immune cells, 
environmental stress or cell injury, as well as inappropriate expression and/or persistence 
of fibrosis enhancing growth factors (Tomasek et al., 2002). 
The origin of myofibroblast in fibrotic diseases such as SSc is disputable. Figure 1.5 
shows proposed different ways of myofibroblast generation that include differentiated 
resident fibroblasts, epithelial and endothelial cells that underwent epithelial- and 
endothelial-to-mesenchymal transition, pericytes, or smooth muscle cells, as well as bone 
marrow derived circulating progenitor cells (fibrocytes) (Abraham et al., 2007, Hinz et 
al., 2007). However, recently, multiple lineage tracing was used to determine the origin 
of fibroblasts in kidney fibrosis lesions. The authors concluded that the majority of the 
myofibroblasts were derived from local fibroblasts, followed by recruitment of bone 
marrow derived cells, the endothelial-to-mesenchymal transition and the epithelial-to-
mesenchymal (LeBleu et al., 2013). 
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Figure 1.5. Origin of myofibroblasts. 
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1.4  Transforming Growth Factor β (TGF-β) 
TGF-β is a multifunctional cytokine, belonging to a large superfamily, which apart from 
TGF-β proteins includes, bone morphogenetic proteins (BMPs), inhibins, activins, 
Growth Differentiation Factors (GDFs), Glial-derived Neurotrophic Factors (GDNFs), 
Nodal, Lefty, and Mülllerian Inhibiting Substance (MIS). A wide range of receptors is 
able to bind TGF-β superfamily ligands and transduce signal (Fig.1.6).  
 
 
Figure 1.6. Receptors transducing cannonical signalling of TGF-β superfamily. 
 
A family of mammalian TGF-β proteins consists of proteins designated TGF-β1–3. 
However, this thesis focuses on the TGF-β1 isoform most strongly linked to the 
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1.4.1  TGF-β signalling  
The canonical TGF-β signalling pathway is Smad-dependent. In the absence of ligand, 
TGF-β receptor type 1 (TβRI) and TβRII are present as homodimers in the plasma 
membrane (Gilboa et al., 1998). After activation TGFβ binds TβRII leading to formation 
of a complex with TβRI. TβRII contains a constitutively active serine/threonine kinase, 
which phosphorylates and activates the kinase domain of the type I receptor, ALK5.  
ALK5 then phosphorylates cytoplasmic receptor associated Smads 2 and 3 (R-Smads), 
which form a heterodimer with Smad4, which is subsequently transported to the nucleus 
(Roberts, 1999). In the nucleus the Smad complex represses expression of some genes 
while activating others. Figure 1.7 shows a schematic representation TGF-β signalling 
pathway. 
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Figure 1.7. Cannonical TGF-β signalling pathway 
 
The high degree of signalling specificity and versatility of TGF-β is possible due to 
availability of different combinations of interactions in a cell and context dependent 
fashion. The signalling responses can be regulated by differential type I and type II 
receptor interactions, Smad complex formation, receptor and Smad interactions with 
accessory proteins, and crosstalk of the Smads with other signalling pathways.  
However, TGF-β can also signal via non-canonical pathways such as MAPK. Abnormal 
TGF-β signalling is associated with several fibrotic diseases, including SSc, where 
constitutive activation of R- Smads in fibroblasts was reported (Ihn et al., 2006).  
Smad%2/3%
Latent%TGFβ1% TGFβ1%
TGFβRI%TGFβRI% cytoplasm%
nucleus%
PP
P
Smad%7%
Smad%2/3%
Smad%4%
Smad%2/3%Smad%2/3% PP
Smad%4%
Smad%2/3%Smad%2/3% PP
Smad%4%
Co?factor%
Gene%transcripCon%
DNA% Co?A%
46 
 
1.4.2  Regulation of the TGF-β  
Due to powerful pleiotropic effects of TGF-β, its signalling must be closely regulated. 
There are mechanisms contributing to both enhancement and suppression of these 
responses. The principal way, in which biological activity of TGF-β is controlled, is its 
release in latent form. The latent precursors, called latent TGFβ complex (LTGF-β), 
consists of a mature TGF-β dimer non-covalently bound to its latency associated peptide 
(LAP). In addition LTGF-β can also be coupled with latent TGF-β binding proteins 
(LTBP) (Rifkin, 2005).  
TGF-β becomes activated after proteolytic cleavage of LAP and LTBP (Javelaud and 
Mauviel, 2004) by several proteases such as, thrombospondin-1 (Schultz-Cherry and 
Murphy-Ullrich, 1993), MMP-2 and-9 (Sato and Rifkin, 1989, Yu and Stamenkovic, 
2000), or by binding to integrin αvβ6 (Annes et al., 2003). Moreover, the exposure to 
reactive oxygen species was also shown to regulate TGF-β signalling (Jain et al., 2013). 
Downstream TGF-β signalling leads also to expression of proteins enhancing cellular 
responses to TGF-β, and therefore further increasing wound healing and fibrosis. They 
include ED-A fibronectin and CTGF, known to promote fibroblast proliferation, matrix 
production, granulation tissue formation, migration, adhesion and contraction of collagen 
matrix (Shi-wen et al., 2000, Chen et al., 2001, Crean et al., 2002). In contrary, tumor 
necrosis factor-α (TNF-α) and interferon-ϒ (IFN-ϒ) suppress TGF-β signalling. TNF-α 
was shown to repress Smad3-dependent signalling, as well as TGF-β induction of 
collagen and CTGF (Abraham et al., 2000). IFN-ϒ inhibits TGF-β induced collagen 
synthesis (Higashi et al., 2003). 
TGF-β is rapidly induced after injury and can be detected throughout the wound healing 
process (Kane et al., 1991). Its release enhances attraction of immune cells and 
fibroblasts to the site, which then release more TGF-β. TGF-β also inhibits proliferation 
of epithelial cells, but stimulate fibroblast proliferation and ECM synthesis (Trojanowska, 
2002), simultaneously inhibiting ECM degradation by down-regulating MMP-1, and up-
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regulating tissue inhibitors of MMPs (TIMPs) (Ihn, 2005). Although beneficial in wound 
healing, in other situations excess collagen deposition by fibroblasts leads to scar 
formation and fibrosis which is a feature of many connective tissue diseases, including 
SSc (Krieg et al., 2007).  
 
1.4.3  TGF-β in SSc and other fibrotic diseases 
The accumulation of collagen in tissue fibrosis is a consequence of an imbalance between 
enhanced production and deposition, and impaired degradation of ECM. TGF-β is one of 
the key drivers of fibrosis, responsible for creating such an imbalance. It facilitates 
differentiation of fibroblasts into ECM overproducing myofibroblasts, while it 
simultaneously decreases levels of ECM degrading MMPs (Varga and Jimenez, 1986, 
Overall et al., 1989). Moreover, it also decreases proliferation of epithelial cells (Murphy 
et al., 1991), which is known to lead to impaired wound healing and contributes to 
scaring tissue formation. 
Increased levels of TGF-β and its receptors were reported in fibroblasts form 
hypertrophic scars (Schmid et al., 1998), keloids (Chin et al., 2001), as well as at the 
leading edge of dermal lesions of SSc patients (Querfeld et al., 1999). Moreover, 
increased phosphorylation of Smad3 in keloids and SSc strongly suggests the importance 
of TGF-β/Smad signalling in pathogenesis of these fibrotic skin diseases (Phan et al., 
2005, Verrecchia et al., 2006, Mori et al., 2003). However, results of the studies on the 
early and established SSc have demonstrated, Smad mediated TGF-β involvement in the 
initiation of fibrotic change, but Smad-independent maintenance of disease (Holmes et 
al., 2001).  
Additionally, a reduced expression of inhibitory Smad7 was reported in involved skin of 
SSc patients when compared to uninvolved skin of the same patient (Dong et al., 2002). 
Still, other studies have shown no difference in the expression of Smad7 by dermal 
fibroblasts (Holmes et al., 2001, Mori et al., 2003). Animal studies have shown that 
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Smad3 deletion protects animals form cutaneous fibrosis (Flanders et al., 2002), while 
levels of nuclear Smad3 are elevated in animal models of fibrosis (Takagawa et al., 
2003). Moreover, TGF-β also stimulates epithelial cells to undergo epithelial to 
mesenchymal transition (EMT) (Zavadil and Bottinger, 2005), which was also shown to 
contribute to fibrosis  (Guarino et al., 2009, Takahashi et al., 2013). 
 
1.4.4  Epithelial-mesenchymal transition (EMT) 
1.4.4.1  Definition 
EMT is an important mechanism of embryo- and organogenesis(Thiery and Sleeman, 
2006), and in adult life is reactivated during inflammation and wound healing. However, 
studies also showed involvement of EMT in pathological processes, such as fibrosis and 
formation of many types of cancer and their metastasis (Kalluri and Neilson, 2003, 
Kalluri and Weinberg, 2009, Lopez-Novoa and Nieto, 2009). Both developmental and 
pathological EMTs are characterised by a spectrum of changes in morphology, gene 
expression and signalling pathways. 
 
During EMT epithelial cells undergo changes including, loss of cell-to-cell contact, due 
to decreased expression of proteins responsible for attachment, such as E-cadherin or 
desmoplakin; up-regulation of matrix degrading proteases, which digest the epithelial 
basement membrane allowing cell migration through the basement membrane; actin re-
arrangement leading to change in cell shape to spindle and fibroblast like. As an effect of 
these changes, epithelial cells lose their epithelial characteristics and acquire 
mesenchymal cells properties. These changes seem to be Smad-3 dependent and are 
correlated with decreased expression of epithelial cell markers and induction of 
mesenchymal cell markers and transcription factor Snail (Hoot et al., 2008). There are 
several examples where factors implicated in EMT are known to be abnormally 
expressed in SSc and they include: 
- Growth factors and cytokines: TGF-β, EGF, HGF, FGF and CTGF 
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- ECM components through integrins 
- Wnt proteins, Notch 
- Hypoxia 
- ROS 
- Mechanical stress  
 
1.4.4.2  Main characteristics of epithelial and mesenchymal cells 
In typical epithelium, cells form a sheet, within which they are closely connected by: 
intracellular junctions, such as tight junctions, desmosomes, adherent junctions and gap 
junctions. This allows the epithelial sheet to form three-dimensional (3D) structures and 
keep the structural integrity, but also inhibit cells movement and dissociation from the 
epithelium. Another characteristic of epithelial sheets is polarisation in an apical-basal 
pattern, which results in differences between cells, depending on their location within the 
epithelium. In contrast, mesenchymal cells do not form regular layers of cells or form 
intracellular junctions. Mesenchymal cells have elongated shape, end-to-end polarity and 
can migrate freely within tissues and produce ECM. 
 
1.4.4.3  Types of EMT 
EMT can be divided into 3 major types, type 1 seen in embryogenesis and gastrulation, 
type 2 observed in wound healing and fibrosis, and type 3 leading to cancer formation 
(Kalluri and Neilson, 2003, Zeisberg and Neilson, 2009). Each type is characterised by 
different events and expression of proteins. Presence of certain EMT markers is common 
to all types, however others are expressed only in particular types of EMT (Zeisberg and 
Neilson, 2009). A short characteristic of the main EMT types and their markers are 
presented in the Table 1.2 (adapted from Zeisberg et al., 2009). 
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Table 1.2 Types and markers of EMT.  
 Type 1 EMT Type 2 EMT Type 3 EMT 
Characterisation Epithelial-
mesenchymal 
transitions; primitive 
epithelial cells 
transform into 
mesenchymal cells  
Epithelial – 
fibroblast transitions; 
secondary epithelial/ 
endothelial cells 
transform into 
fibroblasts 
inflammation 
Carcinoma-
metastatic 
transitions; epithelial 
carcinoma cells 
migrate and form 
secondary tumor 
nodule 
Examples Embryogenesis, 
gastrulation 
Wound healing 
(transient and self 
limiting EMT) and 
fibrosis (persistent 
EMT) 
Tumor metastasis 
Markers of EMT 
Cell surface 
N-cadherin 
E-cadherin 
ZO-1 
 
Acquired  
Diminished 
Diminished 
 
Acquired 
Diminished 
Diminished 
 
NA 
Diminished 
Diminished 
Cytoskeletal 
FSP-1 
α-SMA 
Vimentin 
Cytokeratin 
 
Acquired  
NA 
Acquired  
Diminished 
 
Acquired  
Acquired  
Acquired  
Diminished 
 
Acquired  
Acquired  
NA 
Diminished 
ECM proteins 
Type I collagen 
Type III collagen 
Type IV collagen 
Fibronectin 
Laminin 1 
Laminin 5 
 
Acquired  
Acquired  
Diminished 
Acquired  
Diminished  
Acquired  
 
NA 
NA 
Diminished 
Acquired  
Diminished 
Acquired  
 
Acquired  
Acquired  
Diminished 
NA 
Diminished 
NA 
Transcription factors 
Snail 1 
Snail 2 (Slug) 
ZEB1 
FOXC2 
Ets-1 
Twist 
Goosecoid 
 
Acquired  
Acquired  
Acquired  
Acquired  
Acquired  
Acquired  
Acquired  
 
Acquired  
Acquired  
Acquired  
Acquired  
Acquired  
Acquired  
Acquired  
 
Acquired  
Acquired  
Acquired  
NA 
Acquired  
Acquired  
NA 
MicroRNAs 
miR200 
miR205 
miR155 
miR21 
miR29 
miR9 
 
Diminished 
Diminished 
Increased 
Increased 
Increased 
Increased 
 
Diminished 
Diminished 
NA 
Increased 
Increased 
Increased 
 
Diminished 
Diminished 
Increased 
Increased 
Increased 
Increased 
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To demonstrate EMT process a few criteria should be met simultaneously. They include 
switch from E-cadherin to N-cadherin, at least partial loss of epithelial markers (e.g. 
cytokeratin) with gain of mesenchymal markers (e.g. vimentin, FSP-1), as well as 
phenotypic changes characteristic to EMT: shift to spindle shape morphology and loss of 
polarity, enhanced migration and resistance to apoptosis. In addition, cell should maintain 
the phenotype after removal of the stimuli.  
However, apart from the 3 main types of EMT mentioned above a partial EMT was also 
identified. During a complete EMT, epithelial cells undergo an extreme change in their 
phenotype to become mesenchymal cells. While, during a partial EMT, epithelial cells do 
not undergo the whole transition process into a fibroblasts, and are characterized by an 
intermediate phenotype.  A phenotype consistent with partial EMT has been described in 
wound healing, where cell-cell contact become loose, and cells can still revert to 
epithelial phenotype (Arnoux et al., 2008), and breast cancer where epithelial cells 
express several of EMT markers, while still maintaining epithelial phenotype (Sarrio et 
al., 2008, Chao et al., 2012), as well as in renal and liver fibrosis (Iwano et al., 2002, 
Zeisberg et al., 2007). 
 
1.4.4.4  Relevance of EMT in fibrosis 
A persistent inflammation leads to release of cytokines into the microenvironment of 
epithelial cells, leading to their activation. Furthermore, it can cause epithelial cells to 
lose polarity and undergo transition into fibroblasts. Cells can then migrate through the 
degraded basement membrane. Originated in this way fibroblasts become activated by 
inflammatory signals and start to produce ECM, which accumulate leading to tissue 
fibrosis (Fig 1.8).  
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Figure 1.8. EMT in fibrosis.  
 
Implication of EMT process in fibrosis of different organs was discovered (Guarino et al., 
2009, Flier et al., 2010), including skin (Takahashi et al., 2013). A link between EMT and 
lung fibrosis is well established (Kim et al., 2006, Chilosi et al., 2003, Willis et al., 2005, 
Yasukawa et al., 2013), but in case of fibrosis of other organs, such as kidney it is more 
disputable and other than Iwano’s (Iwano et al., 2002), cell tracking studies were negative 
(Humphreys et al., 2010, Hertig et al., 2008, Koesters et al., 2010). Activation of Wnt-β 
signalling involved in EMT has been reported in alveolar epithelial type II cells in animal 
models of pulmonary fibrosis and IPF patients, as well as in skin, liver, kidney and 
cardiac fibrosis (Wei et al., 2011, Baarsma et al., 2011). Recently, two groups reported 
evidence for EMT associated changes in SSc skin (Nakamura et al., 1995, Gillespie et al., 
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2011), however, these reports were not followed by more extensive studies. EMT could 
link the changes found in the SSc epidermis, with the persistent myofibroblast phenotype 
seen in the underlying dermis.  
 
1.4.5   Connective tissue growth factor (CTGF) 
1.4.5.1  Structure and function 
CTGF, often used as readout of downstream TGF-β signalling, is a 36-38 kDa protein, a 
member of CCN family (Leask and Abraham, 2006) also known as CCN2. This molecule 
consists of four domains and a hinge region, which can be proteolyticaly cleaved to 
generate N- and C-terminal fragments. The C-terminal fragment can be additional 
cleaved to generate small C-terminal fragment containing domain 4. Domains of the C-
terminal fragment regulate fibroblast proliferation, while the N-terminal fragment 
domains mediate collagen synthesis and myofibroblast differentiation (Grotendorst and 
Duncan, 2005). As shown in figure 1.9 the each domain interacts with different ligands. 
However some ligands can interact with more than one domain. 
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Figure 1.9. CTGF structure and its binding partners.  
IGF-BP - insulin-like growth factor-binding protein domain; VWFC - von Willebrand factor type 
C repeat domain; TSP-1 - thrombospondin repeat type 1 domain; BMP - bone morphogenetic 
protein; HSPG - heparan sulphate proteoglycan; IGF - insulin-like growth factor; LRP - 
lipoprotein receptor-related protein; TGF-β - transforming growth factor-β; VEGF - vascular 
endothelial growth factor. 
 
CTGF expression is mainly regulated at the transcriptional level. Its induction is mediated 
by TGF-β/Smad pathway via a Smad binding element within the proximal promoter (de 
Winter et al., 2008). CTGF is important for the formation of connective tissues and 
angiogenesis during development (Ivkovic et al., 2003, Perbal, 2004), but also later in 
adult life, CTGF is involved in a wide range of cellular processes, including proliferation, 
migration, adhesion, matrix production, and wound healing (Shi-Wen et al., 2008). The 
schematic of main signalling pathways directly stimulated by CTGF are shown in Figure 
1.10. 
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Figure 1.10. Signalling pathways and biological actions directly stimulated by 
CTGF.  
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1.4.5.2  CTGF in fibrosis 
CTGF has been shown to be up-regulated in excessive scaring and various fibrotic 
diseases, including pulmonary (Lasky et al., 1998, Pan et al., 2001), liver (Gressner et al., 
2006, Kovalenko et al., 2009) and cardiac (Kemp et al., 2004) fibrosis, as well as SSc. In 
SSc polymorphisms in the CTGF promoter region influence its transcription and 
expression, and were found to be associated with more severe disease (Kovalenko et al., 
2009, Granel et al., 2010, Fonseca et al., 2007). Several reports emphasized the important 
pathophysiological role of CTGF in SSc. Elevated levels of serum CTGF compared to 
controls were described in diffuse SSc, and linked to pulmonary complications (Sato et 
al., 2000). The highest CTGF levels were found in patients within 3 years of disease 
onset, and therefore suggest the role of CTGF as a marker of on-going fibrosis. Another 
study has found that plasma and dermal interstitial fluid levels for N-CTGF are 
significantly elevated in SSc and correlate with severity of skin disease (Dziadzio et al., 
2005). Surprisingly, the study did not found significant changes in the levels of full-
length CTGF or C-CTGF.  
In SSc, CTGF overexpression is reported to be present in the fibrotic skin in early and 
established disease (Igarashi et al., 1996), in contrast to TGF-β1 mainly up-regulated 
early in the disease (Higley et al., 1994). This suggests, that CTGF not only mediates 
many of the downstream effects of TGF-β signalling, but can also promote fibrosis 
independently of TGF-β. Consistent with that, stimulation of normal fibroblasts with 
TGF-β induces CTGF via Smad3 binding site located within CTGF promoter. However, 
no reduction in CTGF promoter activity is observed in SSc dermal fibroblast with 
mutated Smad binding site. The SSc fibroblasts were reported to constitutively 
overexpress CTGF, which mRNA and protein levels are increased despite the absence of 
TGF-β (Denton and Abraham, 2001). The maintenance of the fibrotic phenotype in SSc 
fibroblasts was shown to be Smad independent, but instead dependent on ET-1 and SP1 
(Holmes et al., 2003, Holmes et al., 2001, Shi-wen et al., 2007).  
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Another study went further and proved that CTGF is not only responsible for 
maintenance of fibrosis, but also development of fibrotic changes. It reported that mice 
with fibroblast-specific expression of CTGF develop a spontaneous fibrogenic 
phenotype, including thickening of the dermis, without prior TGF-β stimulation 
(Sonnylal et al., 2010). 
Other examples of CTGF pro-fibrotic properties, include association of increased CTGF 
mRNA and protein level with myofibroblast accumulation and collagen deposition in 
radiation fibrosis (Vozenin-Brotons et al., 2003), and protection from liver fibrosis with 
CTGF siRNA (Li et al., 2006). Animal studies with tight skin mouse and bleomycin 
induced fibrosis models have confirmed the importance of CTGF in the development of 
fibrosis (Bonniaud et al., 2004, Liu et al., 2010). 
 
1.5  Inflammation 
Inflammation is an adaptive process triggered by infection, tissue injury or tissue stress in 
order to eradicate microbial agents, repair damaged tissue, and restore homeostasis 
(Fig.1.11). The process is characterized by vasodilation of the local blood vessels and  
increased blood flow, increased permeability of the capillaries leading to leakage of fluid 
into the interstitial space; migration of granulocytes and monocytes into the tissue, and 
swelling. Responsible for these  reactions are immune cells, local cells e.g. keratinocytes 
and endothelial cells, as well as chemical mediators, released from injured or activated 
cells to co-ordinate the development of the inflammatory response.  These mediators 
include: complement, coagulation and fibrinolytic systems reaction products, 
neuropeptides (kinins and tachykinins), eicosanoids, platelet activating factor, histamine, 
serotonin (5-HT), prostaglandins, nitric oxide, cytokines (e.g. IL-1 and IL-6) and 
chemokines. 
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Figure 1.11. Inducers and possible outcomes of inflammation. 
 
1.5.1  Types of inflammation 
There are  three distinct phases of inflammatory responses:  an acute transient phase, 
characterized by local vasodilation and increased  capillary permeability, followed by a 
delayed, sub acute phase, characterized  by infiltration of leukocytes and phagocytic cells, 
and a chronic proliferative  phase, with tissue degeneration and fibrosis. Redness, 
swelling, heat and pain are hallmarks of acute inflammation, which in normal conditions 
resolves itself. However, if the stimulus triggering inflammation persists it leads to 
chronic inflammation and disease. The production of growth factor, proteases and 
reactive oxygen species (ROS) by neutrophils and macrophages results in tissue damage, 
fibroblast proliferation, collagen accumulation and fibrosis. Chronic inflammation is 
characterised by simultaneous inflammation and repair processes, regulated by an 
interaction between cytokines promoting inflammatory cell recruitment/activation, and 
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growth factors that promote healing. The main differences between acute and chronic 
inflammation are summarised in the table below (Table 1.3).  
 
 
Table 1.3 Differences between acute and chronic inflammation. 
Features Acute Inflammation Chronic Inflammation 
Onset Rapid Delayed 
Duration  <3 weeks) >6 weeks 
Cause • Physical/chemical 
insult 
• Pathogen 
• Tissue necrosis 
• Persistent infection 
• Presence of a foreign 
object 
• Autoimmunity 
Main type of cells 
involved 
• Neutrophils 
• Macrophages 
• Lymphocytes 
• Macrophages 
• Fibroblasts 
Edema Present Absent 
Angiogenesis Absent Present 
Fibrosis Absent Present 
Pathogenic processes • Increased blood flow 
• Increased capillary 
permeability 
• Neutrophils migration 
• Recruitment and 
activation of leukocytes 
• Macrophage and 
lymphocytes infiltration 
• Tissue damage (ROS, 
hydrolytic enzymes and 
inflammatory responses) 
• Angiogenesis 
• Granuloma formation 
• Fibrosis 
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Additionally, the inflammation might be also divided into microbial induced and sterile. 
During the microbial induced inflammation, the innate immune system is involved in an 
early response. Highly conserved pathogen associated molecular patterns (PAMPs) or 
virulence factors of bacteria, fungi or viruses, become recognised by pattern recognition 
receptors (PRRs), expressed on innate immune cells such as dendritic cells, macrophages 
and neutrophils. A wide range of PPRs was discovered over the time consisting of:  
• toll like receptors (TLRs) - transmembrane proteins located at the cell surface or 
in endosomes,  
• RIG-I-like receptors (RLRs) - intracellular proteins primarily involved in antiviral 
responses,  
• NOD-like receptors (NLRs) – cytoplasmic receptors,  
• C-type lectin receptors (CLRs) – trans-membrane receptors characterized by the 
presence of a carbohydrate binding domain,  
• absence in melanoma 2 (AIM2) -like receptors- characterized by the presence of a 
pyrin domain and a DNA binding HIN domain, involved in the detection of 
intracellular microbial DNA.  
Following ligand binding, these receptors rapidly induce host innate immune responses 
and activate downstream signalling pathways, such as NF-κβ, MAPK and IFN type I 
pathways, that culminate in the induction of inflammatory responses mediated by various 
cytokines and chemokines, which subsequently leads to the eradication of the pathogen. 
Sterile inflammation typically occurs in the absence of microorganisms and is induced as 
a result of trauma, ischaemia-reperfusion or chemical injury. Typical examples of sterile 
inflammation are asbestosis - where chronic inhalation of asbestos leads to persistent 
activation of alveolar macrophages and result in pulmonary interstitial fibrosis, and 
atherosclerosis, where cholesterol crystals engulfed by macrophages cause the activation 
and recruitment of inflammatory cells, endothelial cell dysfunction and plaque formation. 
As in microbial induced inflammation, during sterile inflammation the recruitment of 
neutrophils and macrophages and the production of pro-inflammatory cytokines and 
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chemokines (particularly TNF and IL1) occur. However, the PPRs instead of recognizing 
PAMPs, bind Damage-Associated Molecular Patterns (DAMPs), host derived non-
microbial stimuli, which are released following tissue injury or cell death. 
 
1.5.2  Damage-Associated Molecular Patterns (DAMPs). 
DAMPs also known, as alarmins are endogenous factors that are under normal 
physiological conditions present intracellularly, and thus hidden from the immune 
system. However, during cellular stress or injury, they become released into the 
extracellular environment by dying cells and become available to bind PPRs, and trigger 
sterile inflammation. Classical example of intracellular DAMPs are released from 
necrotic cells chromatin associated protein high-mobility group box 1 (HMGB1), heat 
shock proteins (HSPs), and purine metabolites such as ATP12 and uric acid. S100A8 and 
S100A9 are other examples of intracellular DAMPs that in physiological conditions have 
a role in migration and cytoskeletal metabolism. However, cell damage or activation of 
phagocytes triggers their release into the extracellular space, where they become danger 
signals that activate immune cells and vascular endothelium. Additionally, DAMPs can 
be located extracellularly and become released from damaged ECM during tissue injury. 
The ECM fragments, such as hyaluronan, heparan sulphate and biglycan, are generated 
by proteolytic degradation of ECM, by enzymes released from dying cells or proteases 
promoting tissue repair and remodeling. Figure 1.12 below represents the schematic of 
DAMPs signal transduction pathway. 
Increased serum levels of DAMPs have been associated with many inflammatory 
diseases, including arthritis, atherosclerosis, Crohn’s disease and cancer (Pullerits et al., 
2008, Brezniceanu et al., 2003, Berntzen et al., 1989, Cesaro et al., 2012). Therapeutic 
strategies are being developed to regulate the expression of these DAMPs for the 
treatment of these diseases. 
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Figure 1.12.  DAMPs signalling.  
(From www.invivogen.com) 
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1.5.3  Skin as immune organ 
Skin, as the first line of defense against microbes and physical, chemical and mechanical 
damage, has evolved complex immune-surveillance mechanisms that control tolerance 
and immune responses in the skin. The main resident-immune cells in the epidermis are 
Langerhans cells, but T cells (mainly CD8+) can also be found. Whereas the dermis 
contains many specialized immune cells, including macrophages, DCs, CD4+ T helper 
cells, γδ T cells and natural killer T cells, as well as mast cells and fibroblasts. Dermis 
also comprises lymphatic and vascular canals, enabling cell migration. 
Barrier disruption e.g. due to UV light, irritants or infection, triggers a coordinated 
immune response to maintain skin homeostasis (Fig. 1.13). Although, resident immune 
cells are essential for re-establishing homeostasis, they can also contribute to tissue 
pathology such as fibrosis. Epidermal Langerhans detect danger signals in the skin 
however; keratinocytes have also this ability, and upon stimulation produce pro-
inflammatory cytokines, which activate dermal DCs and plasmacytoid DCs (pDCs). 
Activation of pDCs leads to release of IFN-α and therefore, further stimulation of dermal 
DCs, which leads to activation, and clonal expansion of resident memory CD4+ and 
CD8+ T cells. In turn, T cell release pro-inflammatory cytokines and chemokines, further 
stimulating epithelial and mesenchymal cells, and thus magnifying the inflammatory 
response. In addition, resident T cells migrate into the epidermis and engage in an 
immune–epithelial cell cross talk. Fibroblasts contribute to the local inflammatory 
response by producing TNF and IL-6, while natural killer T cells produce TNF and IFN-
γ. 
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Figure 1.13 Skin immune response.  
(From Nestle et al., 2009) 
Historically, the epidermis was considered to be just a passive mechanical barrier that 
forms surface of the body, preventing microbes from entering deeper tissues and fluid 
loss. The sources of cytokines in the skin were thought to be limited to dermal dendritic 
cells, epidermal Langerhans cell, melanocytes, and migrating lymphocytes. However, 
keratinocytes are also major contributors to epidermal cytokine production (Grone, 
2002). Since 1970s reports started to emerge that challenged the view of immunologically 
passive epidermis and prove that the keratinocytes are actively taking part in 
inflammatory response and are capable of producing a number of cytokines, chemokines, 
neuropeptides and DAMPs involved in immune responses to the stimuli (Barker et al., 
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1991, Steinhoff et al., 2001). Such stimuli include ultraviolet radiation, allergens/irritants, 
microbiological agents or trauma/wound repair.  
 
1.5.3.1  Keratinocytes as immune cells 
Keratinocytes can recognize DAMPs and PAMPs due to a set of cell surface and 
endosomal receptors, including Fc receptors (Tigalonowa et al., 1990), complement 
receptors, mannose receptors (Szolnoky et al., 2001), TLRs 1–6 and 9 (Baker et al., 2003, 
Pivarcsi et al., 2003, Lebre et al., 2007), as well as NLRs  (Harder and Nunez, 2009, 
Kobayashi et al., 2009) and RLRs (Kalali et al., 2008). Ligand binding to these receptors 
results in effective endocytosis and subsequent killing of microbiological agents (Kisich 
et al., 2007) and release of chemotactic mediators to recruit neutrophils, dendritic cells, 
monocytes and lymphocytes (Fig 1.14). 
Figure 1.14 Keratinocytes as sensors of exogenous and endogenous inducers of 
inflammation. (From Nestle et al. 2009) 
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Moreover, studies on keratinocytes exposed to Staphylococcus aureus suggest that 
keratinocytes are able to directly stimulate T-cells (Lebre et al., 2007, Strange et al., 
1994, Ardern-Jones et al., 2007) by acting as non-professional antigen presenting cells. 
They usually express low levels of co-stimulatory molecules CD80/86, and class-II–
mediated presentation of antigen by keratinocytes results in tolerance or anergy of T cells 
(Bal et al., 1990, Gaspari et al., 1988), rather than T cell activation. However, in multiple 
human skin diseases keratinocytes can up-regulate both major histocompatibility complex 
class I and II molecules (Banno et al., 2003, Bieber et al., 1989, Wittmann et al., 2005), 
and during inflammation keratinocytes may be able to stimulate CD4+ and CD8+ 
memory T cells (Black et al., 2007, Ardern-Jones et al., 2007, Mutis et al., 1993, 
Wittmann et al., 2005). IFN-γ was shown to up-regulate MHC class II expression on 
primary human keratinocytes and keratinocyte cell lines in vitro (Nickoloff and Naidu, 
1994). Moreover, it has been shown that apart from the classical presentation of peptides, 
keratinocytes can also use non-classical pathways for presentation of glycolipids via CD1 
molecules overexpressed in psoriatic skin or after mechanic trauma (Bonish et al., 2000).  
Keratinocytes can also indirectly influence immune responses, by releasing cytokines 
such as, IL-1, IL-6, IL-10, IL-18 and TNF (Albanesi et al., 2005). Particularly important, 
is the production of IL-1, a pleiotropic cytokine with a wide range of biological effects, 
including activation of T helper cells and DCs, and the promotion of maturation and 
clonal expansion of B cells (Arend et al., 2008). In healthy skin, keratinocytes 
constitutively synthesize IL-1α and IL-1β, which following keratinocyte activation, are 
released in biologically active form. Keratinocytes also promote differentiation of 
monocytes into DCs via release of GM-CSF (Pastore et al., 1997). Moreover, 
keratinocytes are an important source of chemokines modulating an immune response by 
attracting immune cells into the skin. Expression of CC-chemokine ligands (CCL): 
CCL20, CXCL9, CXCL10 and CXCL11 from activated keratinocytes selectively attracts 
effector T cells to the skin and was reported in several diseases, characterized by T cell 
infiltration, like psoriasis (Albanesi et al., 2005).  
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Furthermore, expression of CCL20 by keratinocytes regulates the trafficking of 
Langerhans cell precursors to the epithelium (Dieu-Nosjean et al., 2000). Upon 
activation, keratinocytes are also able to recruit neutrophils by releasing IL-8, as it was 
demonstrated in the inflamed epidermis of patients with psoriasis. Additionally, damaged 
keratinocytes are an important source of antimicrobial peptides (AMPs), in particular 
β‑defensins and cathelicidins. These peptides not only directly kill the pathogen, but also 
recruit immune cells and increase production of cytokines (Gilliet and Lande, 2008, Lai 
and Gallo, 2009). The production of AMPs by keratinocytes is regulated by T cell-
derived cytokines, mainly IL-17A and IL-22 (Kolls et al., 2008).  
Over the decades, keratinocytes have been shown to be pro-inflammatory effector cells 
that react to damaging insults by the coordinated production of a wide range of AMPs, 
pro-inflammatory cytokines and chemokines and their receptors (Table 1.4) (Grone, 
2002, Uchi et al., 2000). The release of these factors by keratinocytes factors has multiple 
consequences for the migration of inflammatory cells, systemic effects on the immune 
system, but also influences keratinocyte proliferation and differentiation processes, and 
affects the production of other cytokines by keratinocytes. What is more, release of 
cytokines from activated keratinocytes was shown to precede any inflammatory cell 
influx into the area and reflects changes intrinsic to the epidermis (Nickoloff and Naidu, 
1994), suggesting that epidermal keratinocytes could function as initiators of cutaneous 
inflammation. Moreover, mice with deletion of c-Jun and JunB in keratinocytes, 
spontaneously develop chronic inflammation in the skin and joints (Zenz et al., 2005). 
Similar cutaneous inflammation was observed in animals with deletion of IκB kinase-β 
(IKKβ), a regulatory kinase of NF-κB pathway in keratinocytes (Pasparakis et al., 2002). 
This demonstrates that genetic modification of key signalling pathways involved in 
inflammatory immune responses in keratinocytes can alter skin homeostasis and induce 
immunopathology, thus supporting a crucial role for keratinocytes in regulating systemic 
immune responses. 
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Table 1.4.  Keratinocytes as source and target of cytokines.  
Cytokine/ 
Chemokine 
Main functions in skin Receptor Receptor mediated effect 
IL-1a, b Pro-inflammatory IL-1R1/R2  Cytokine release 
IL-1Ra Competitive IL-1 inhibitor IL-1R1/R2  Prevents cytokine release 
IL-6 Pro-inflammatory, keratinocytes 
proliferation 
IL-6R  Growth induction 
IL-10 Immunomodulatory IL-10R  Th1 inhibition, B cell 
proliferation, antibody production 
IL-7, IL-15 T-cell trophic - - 
IL-8 Pro-inflammatory, neutrophil 
attraction  
CXCR2  Attract neutrophils 
IL-12, IL-18 Immunomodulatory IL-18R  
IL-20 Keratinocytes proliferation and 
differentiation 
- - 
TNF-a Pro-inflammatory, induce 
adhesion molecules 
TNF-a 
receptors 
Cytokine release, ICAM-1 
induction 
M-CSF Monocytes and macrophages 
proliferation, differentiation, 
and survival 
- - 
GM-CSF Hematopoietic growth factor 
and immune modulator 
- - 
TGF-a Enhance keratinocytes motility TGF-b  
receptors 
Differentiation control 
TGF-b1 Inhibit keratinocytes growth 
CCL2/MCP-1 Inflammatory attractant - - 
CCL20 B cell maturation, migration and 
recruitment of DC, LC and T 
cells 
CCR6 B cell maturation, migration and 
recruitment of DC, LC and T 
cells  
HB-EGF Keratinocytes growth factor EGF-R Growth induction 
FGF-2, FGF-
10 
Keratinocytes growth factor FGFR2  Growth induction 
IGF-1/IGF-2 Keratinocytes growth factor IGF-1R  Growth induction 
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NGF Keratinocytes and melanocyte 
growth factor 
NGF 
receptors  
Growth induction 
VEGF Endothelial cell growth factor - - 
PDGF Fibroblast and smooth muscle 
cell growth factor 
- - 
ET-1 Keratinocytes and melanocyte 
growth factor, vasoconstrictor 
ET-1 
receptors  
Growth induction 
IFN-b Defense against viral infections IFN-a/b 
receptor  
Growth inhibition 
IFN-g Th1 induction, IFN-g 
receptor  
Induce HLA-DR and ICAM-1 
CXCL9/ 
CXCL10/11 
Inflammatory mediator, T cell 
attractant 
- - 
CXC12 
 
T-lymphocytes, monocytes and 
LC attractant  
- - 
- - IL-2R Sensitize keratinocytes towards 
other growth inhibitory molecules 
- - IL-4R  Keratinocytes proliferation, IL-6 
production 
- - IL-13R  IL-6 production 
- - IL-17R Modulate effects of IL-4 and 
IFNg on keratinocytes activation 
- - IL-20R Keratinocytes proliferation 
- - LIF-R  Cellular differentiation, 
proliferation and survival 
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1.6  S100 calcium binding protein A9 (S100A9)  
S100A9 belongs to a family of 20 distinct calcium (Ca2+) binding protein and is one of 
DAMPs (Foell et al., 2007). This small protein with molecular weight of 14kDa is 
distinguished from other S100 proteins by its long and flexible C-terminal region (Itou et 
al., 2002). Crystal structure of each monomer consists of the hinge region that connects 
two EF-hand motifs. High affinity Ca2+ binding site is located at the C-terminus and a 
low-affinity Ca2+ binding site at the N-terminus. Upon Ca2+ binding there is a 
conformational change enabling macromolecular interactions. S100A9 can form homo-
dimers (e.g. cancer cell lines including breast MCF7 and hepatocellular SK-Hep-1), or 
hetero-dimers and tetramers with S100A8 (Korndorfer et al., 2007). Its activity is 
dependent on the extracellular Ca2+ and zinc (Zn2+) concentrations. Depending on the 
subunit composition, it can have different biological activity (Newton and Hogg, 1998).  
S100A9 was first discovered in 1987, in the infiltrating macrophages of rheumatoid 
arthritis (RA) patients (Odink et al., 1987). However, S100A9 protein was later re-
discovered in several contexts, which is reflected in its complex nomenclature:  
- NIF;  
- CGLB;  
- L1AG;  
- MAC387 
- Calgranulin B (CAGB) 
- p14 
- Myeloid related protein of molecular weight 14 kDa (MRP14) 
- Migration inhibitory factor-related protein of molecular weight 14 kDa (MIF) 
- CFAG 
- LIAG 
- 60B8AG 
S100A9 is expressed in neutrophils, activated monocytes and macrophages, but its up-
regulated expression was found in many inflammatory diseases at the site of 
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inflammation (Roth et al., 2003, Nacken et al., 2003) and in the serum of patients with 
RA (Liao et al., 2004), multiple sclerosis (Bogumil et al., 1998), Crohn’s disease 
(Lugering et al., 1995), and connective tissue diseases such as SLE, SSc and Sjogren's 
syndrome (Kuruto et al., 1990). The protein is also associated with many different cancer 
types (non-small cell lung carcinoma gastric cancer, prostate cancer, pulmonary 
adenocarcinoma, squamous cervical cancer, prostate cancer, breast cancer) (Cross et al., 
2005). Over expression of S100A9 in non-small cell lung carcinoma is associated with 
poor prognosis (Kawai et al., 2011). Moreover, S100A9 is also used as the marker of 
epithelial cells activation. 
 
1.6.1  S100A9 in keratinocytes 
Barely detectable in healthy epidermis, S100A9 expression was shown to be strongly 
induced during treatments simulating environmental stress situations such as mechanical 
stress (tape stripping), chemical stress (SDS and vaseline application), and UV light 
exposure (solar-simulated radiation) (Marionnet et al., 2003). Furthermore, S100A9 is 
up-regulated during wound healing (Thorey et al., 2001) and in hyper-proliferative 
psoriatic keratinocytes (Broome et al., 2003). 
Interestingly, evidence from activin-overexpressing mice, which develop a hyper-
proliferative and abnormally differentiated epidermis in the absence of inflammation, 
suggests that S100A9 overexpression in wound keratinocytes is most likely related to the 
activated state of the keratinocytes and not secondary to the inflammation of the skin 
(Munz et al., 1999, Thorey et al., 2001). There are several findings supporting the 
expression of S100A9 and S100A8 in keratinocytes being involved in epithelial 
differentiation and linked to the imbalance between proliferation and differentiation. 
The gene encoding S100A9 is located in the epidermal differentiation complex, within 
human chromosome 1q21 (Mischke et al., 1996), alongside genes encoding the cornified 
envelope precursors, involucrin, loricrin and several keratins. Such co-localization of 
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terminal differentiation genes with Ca2+ binding S100A9, points to importance of Ca2+ 
levels in control the differentiation of epithelial cells and the expression of genes 
encoding epidermal structural proteins, and suggests that expression of these genes is 
coordinately regulated (Hardas et al., 1996). 
Additionally, in vitro studies on HaCaT and HNEK cells showed close correlation of 
keratinocyte S100A9 expression with degree of differentiation, suggesting involvement 
in terminal differentiation pathway (Martinsson et al., 2005, Voss et al., 2011). Its 
overexpression in diseased epidermis is often linked to keratinocyte hyper-proliferation 
and abnormal keratinocyte differentiation (Broome et al., 2003, Benoit et al., 2006). 
Furthermore, injury-regulated induction of S100A8 and S100A9 genes was reported in 
differentiating suprabasal wound keratinocytes during the hyper-proliferative phase. 
Interestingly, S100A9 is not only located subcellular associated with the keratin 
cytoskeleton, but can be also released into the culture media (Thorey et al., 2001, Nukui 
et al., 2008). This indicates that S100A9 might have various roles in different processes. 
 
1.6.2  Pleiotrophy of S100A9 
S100A9 has diverse functions, including involvement in the reorganization of the keratin 
cytoskeleton in the wounded epidermis, chemoattraction of inflammatory cells. The table 
1.5 below contains more detailed information with key references.  Previous studies 
indicate that S100A9 activity can be regulated at post-translational level and these 
modifications result in decreased inflammatory activity, for example S-nitrosylation 
reduces NADPH oxidase activation (Cheng et al., 2010), while S-glutathionylation 
reduces its capacity to hetero-dimarise with S100A8 and bind fibronectin, but doesn’t 
affect arachidonic acid binding (Boyce and Ham, 1985). Also oxidation of S100A9 at 
methionine 63 and 83 was shown to regulate neutrophil migration (Sroussi et al., 2007). 
  
73 
 
Table 1.5. Pleiotrophic effects of S100A9. 
Function References 
Cell mobility 
• S100A8/A9 regulates polymerisation of microtubules 
(Aden et al., 2010) 
• In epithelial cells Ca-S100A8/A9 complexes bind to 
keratin intermediate filaments increasing cell mobility 
(Goebeler et al., 1995)  
Profibrotic 
• By sequestering zinc inhibits ECM degradation by 
MMPs (Rheinwald and Green, 1975) 
• Stimulates fibroblast growth as monomer and 
homodimer (Shibata et al., 2004), however as 
heterodimer inhibits fibroblast growth (Yui et al., 1997) 
• Activates human lung fibroblasts via RAGE mediated 
ERK1/2 MAP-kinase and NF-kB (Xu et al., 2013a) 
Proinflammatory 
• Activates NADPH oxidase (Kahan et al., 2009, Chen et 
al., 1985) 
• Induces expression and secretion of pro-inflammatory 
cytokines such as IL-6, IL-8, IL-10, IL-1b, TNF-a, 
MCP-1 in RA model (Sunahori et al., 2006, Nukui et 
al., 2008);  
• Important in development of autoreactive CD8+ T cells 
(Herfs et al., 2008) 
• Recruits inflammatory cells during inflammation 
(Burwinkel et al., 1994, Hessian et al., 1993, Guignard 
et al., 1996, McNeill et al., 2007, Walter and Ron, 2011)  
• Enhances trans-endothelial migration (Gerritsen et al., 
2003) 
• Regulates maturation of myeloid cells e.g. its 
production correlates with the surface expression of 
CD11b by monocytes and macrophages (Kerkhoff et al., 
2002)  
Regulation of differentiation and 
proliferation of keratinocytes 
• As heterodimer stimulates keratinocytes 
growth(Rammes et al., 1997) or inhibits proliferation 
and stimulates differentiation (Voss et al., 2011) 
Cancer promotion 
• Inhibits immune response to cancer by recruitment of 
myeloid derived suppressor cells (MDSCs) and 
inhibition of dendritic cells (Cheng et al., 2008),  
• S100A9 knockout improves rate of rejection of EL4 
lymphoma (Connelly et al., 2010) 
Other 
• Bound to CD36 promotes fatty acid uptake (Kerkhoff et 
al., 2001) 
• Activates NF-kB (Kahan et al., 2009), and the activation 
is TLR4 dependent (Averill et al., 2011); it also induces 
degradation of IkBa  
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1.6.3  S100A9 signalling 
As described above S100A9 has a whole array of functions. It is unsurprising, 
considering the various molecules it can bind. S100A9 bound to Ca2+ was reported as an 
agonist of a wide range of molecules including: 
-­‐ Arachidonic acid  
-­‐ Cytoskeletal elements (e.g. keratin filaments) 
-­‐ Receptor for Advanced Glycosylation Endproducts (RAGE)  
-­‐ Toll Like Receptor 4 (TLR4) 
-­‐ The major fatty acid transporter CD36 
-­‐ Matrix metallo-proteinases (MMPs) 
-­‐ Fibronectin 
-­‐ Heparin sulphate glycosaminoglycans 
The affinity of binding might depend on the subunits, as in vitro studies show that homo-
dimer has higher affinity than heterodimer S100A8/A9 to bind TLR4 and RAGE (Bjork 
et al., 2009). 
 
Enhanced production of S100A9 was found to be related not only to injury, but also 
stimulation with LPS (Henke et al., 2006), TNFα, IL-1α (Hayashi et al., 2007), IL-6 (Lee 
et al., 2012), IL-22 (Boniface et al., 2005) and IL-17 (Liang et al., 2006), VEGF 
(Hiratsuka et al., 2006), TPA (Schlingemann et al., 2003). However, reports on the TGF-
β effects on S100A9 are more conflicting. Hiratsuka after adding exogenous TGF-β 
observed increased levels of S100A9 in mice (Hiratsuka et al., 2006), while in vitro work 
of Hayashi showed suppression of mRNA upon stimulation of gingival keratinocytes 
with TGFβ (Hayashi et al., 2007). Furthermore, in mice lacking S100A9 and TLR4, 
down-regulation of TGFβ expression was reported (Kallberg et al., 2012). Suppression of 
S100A9 by and KGF was also described (Bando et al., 2010).  
 
The downstream signalling leads to activation of MAPK, JAK/STAT, IKK/ NF-κβ, PKC 
pathways, resulting in activation of several transcription factors, which bind to S100A9 
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promoter AP-1(Zenz et al., 2005), NF-κβ, STAT3 (Cheng et al., 2008), PU.1 (Henkel et 
al., 2002), C/EBP (Hayashi et al., 2007, Klempt et al., 1998, Kuruto-Niwa et al., 1998) 
and triggers different responses.  
 
A pharmacological compound quinoline-3-carboxamide (Q compound) was shown to 
bind the S100A9 homodimer limiting binding to TLR4-MD2, RAGE and arachidonic 
acid (Bjork et al., 2009). The drug is currently in phase II clinical trials for patients with 
metastatic prostate cancer (Pili et al., 2011, Dalrymple et al., 2012) and multiple sclerosis 
(Schulze-Topphoff et al., 2012). In February 2011, the oral version of Q compound called 
paquinimod (57-57, ABR-215757) was granted orphan medicinal product status, for the 
indication SSc and the phase I clinical trials started in 2012. 
1.6.4  S100A9 in SSc and other fibrotic diseases 
Several reports demonstrated pro-fibrotic potential of S100A9. S100A9 was shown to 
promote proliferation (Shibata et al., 2004) and activation of fibroblasts, as well as induce 
production of collagen type III and α-SMA in lung fibroblasts (Xu et al., 2013a). S100A9 
was also shown to inhibit degradation of ECM by MMPs, which might lead to further 
accumulation of ECM (Isaksen and Fagerhol, 2001).  Moreover, S100A9 can also 
perpetuate inflammation closely linked to fibrosis, by up-regulating expression of pro-
inflammatory cytokines IL-6, IL-8, IL-1β (Cesaro et al., 2012) and attracting immune 
cells. 
Although, the role of S100A9 in SSc is unknown recent publications suggest its 
importance in the development of disease. Overexpression of both S100A9 receptors, 
RAGE (Davies et al., 2009) and TLR4 (Bhattacharyya et al., 2013) was previously 
reported in SSc skin. Additionally, signalling via TLR4 was shown to augment TGF-β 
responses contributing to fibrosis in SSc (Bhattacharyya et al., 2013). Furthermore, 
increased levels of S100A9 were found in SSc skin and plasma, especially in patients 
with lung or kidney involvement (Xu et al., 2013b, van Bon et al., 2014). Interestingly, 
S100A9 correlates closely with disease severity auto-autoantibodies levels.  
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1.7  Aims 
Systemic sclerosis is a disease of complex pathophysiology, with interaction between 
many different cell types. In particular, fibroblasts are considered to be the major 
contributor to the disease pathogenesis. However, some the initiating events could occur 
within the most exposed part of the body, epidermis. Therefore the role of injured 
keratinocytes in SSc and their responses must be elucidated more clearly. Most SSc 
patients develop skin fibrosis and skin disease, which still accounts for significant 
morbidity in SSc despite the treatment improvements. An epidermal response to 
environmental triggers in SSc is likely to lead to activation of keratinocytes, which would 
affect they differentiation, and change in secreted growth factors and cytokines, causing 
abnormal cross talk with other cell types, especially fibroblasts. This thesis addresses the 
hypothesis that SSc epidermis plays an important role in propagation of skin fibrosis by 
releasing pro-inflammatory mediators and stimulating underlying fibroblasts 
 
1.8  Experimental approach  
To test this hypothesis analysis of epidermal blister sheets, dermal biopsies and immortal 
keratinocyte cell line has been employed:  
• To characterize SSc epidermis and determine whether SSc epidermal 
keratinocytes have altered differentiation program,  
• To examine evidence of SSc keratinocytes contribution to skin disease via process 
of epithelial to mesenchymal transition, 
• To evaluate the secretome of SSc skin, separate for epidermal and dermal 
component.  
• To investigate the effects of altered SSc keratinocyte derived mediators on 
underlying dermal fibroblast. 
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Chapter Two 
 
Materials and Methods 
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2.1    Clinical material 
All SSc patients used in this thesis fulfilled the American College of Rheumatology 
(ACR) preliminary criteria for disease and were classified into dcSSc and lcSSc 
according to internationally accepted criteria (LeRoy et al., 1988). Samples were 
classified as early SSc if within the first 2 years of disease onset, defined by the 
appearance of the first non-Raynaud’s symptom. Patients with disease duration above 2 
years were classified as established.   
The clinical and laboratory parameters used for assessment of disease included: duration 
of disease, skin score, internal organ involvement, and serology. The extend of skin 
involvement was classified using mRSS total skin thickness score (Clements et al., 1995). 
The internal organ classification was used as previously described (Shand et al., 2007). 
All patients and healthy volunteers have given written informed consent to participate in 
the study.  
 
2.1.1    Dermal punch biopsies 
Punch biopsies of 4mm diameter were taken from forearm skin of healthy controls and 
SSc patients at various stage of disease. Tissue was used in an explant experiment (see 
2.2.1) or fixed in formalin, embedded in wax and sectioned prior to staining. 
 
2.1.2    Epidermal suction blisters 
Suction blister cup (Ventipress, Uppsala, Sweden) was applied to the forearm as 
described previously (Rhodes et al., 1999). Under a pressure of 275–325 mmHg for 
approximately 2 hours, small blisters were raised (Fig 2.1), from which interstitial fluid 
was aspirated using an 18-gauge needle on a 2ml syringe (Kool et al., 2007), and frozen 
immediately at -70°C prior to analysis of S100A9 levels. The epidermal sheet (blister 
roof) was then carefully dissected with a scalpel and fine forceps, rinsed in phosphate-
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buffered saline (PBS) (Life Technologies, Glasgow, UK) and immediately placed in 
RNA stabilization reagent RNAlater (Life Technologies). Samples were then stored 
overnight at 4°C, followed by longer-term storage at -70°C prior to RNA extraction. 
 
Figure 2.1. Suction pump and raised suction blister. 
 
The controls were recruited among primary Raynaud's syndrome patients and healthy 
people. Clinical details of the patients and controls involved in the study are listed in a 
table 2.1.  
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Table 2.1.  Clinical details of patients and controls. 
 DcSSc 
patients 
LcSSc 
patients 
Controls 
N 24 8 9 
Age (mean ± SD) 54.4 ± 7.48 59.3 ± 10.19 38.6 ± 6.52 
Sex (Female/Male) 18/6 7/1 8/2 
Stage of disease  (early/established) 3/21 0/8 NA 
Skin score (mRSS) (mean ± SD) 21.4 ± 10.46 8 ± 5.13 NA 
Auto-antibodies 
Anti-topoisomerase-1 (ATA) 30.4% 12.5% NA 
Anti-nuclear (ANA) 82.6% 100% NA 
Anti-centromere (ACA) 4.3% 25% NA 
Anti-RNA polymerase (ARA) 17.4% 0% NA 
Anti-fibrillarin (U3RNP) 4.3% 0% NA 
Internal organ involvement 
Pulmonary a 47.8% 37.5% NA 
GI b 8.7% 62.5% NA 
Cardiac c 8.7% 0% NA 
None 8.7% 25% NA 
N - number of participants, SD – standard diviation, NA- non applicable; Skin score 
(mRSS) – assessment of skin thickening by palpation of the skin in 17 areas of the body 
(fingers, hands, forearms, arms, feet, legs and thighs, face, chest and abdomen) using a 0–
3 scale, where 0 = normal, 1 = mild thickness, 2 = moderate thickness and 3 = severe 
thickness. Total skin score can range from 0 (no thickening) to 51 (severe thickening in 
all 17 areas). a defined as predicted forced vital capacity (FVC) or carbon monoxide 
diffusing capacity (DLCO) of <55% or a 15% decline from baseline in FVC or DLCO, with 
fibrosis confirmed on high-resolution CT. b defined as at least 3 episodes of intestinal 
pseudo-obstruction requiring hospitalization or requiring ≥6 weeks of enteral or parental 
nutritional support. c defined as haemodynamically significant cardiac arrhythmias, 
pericardial effusion or congestive cardiac failure requiring specific treatment in the 
absence of other known cardiac causes. 
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2.2    Cell culture 
2.2.1   Skin explants culture for conditioned media 
Forearm punch biopsies of 4mm diameter were taken from 12 healthy controls and 12 
SSc patients. Their clinical details are listed in a table below. 
 
Table 2.2.  Clinical information of patients and controls used in the conditioned 
media study. 
 SSc patients  Control  
N 12 12 
Age (year, mean ± SD) 53 ± 12.16 35.7 ± 11.00 
Sex (female/male) 8/4 8/4 
Stage of disease (early/established) 6/6 NA 
Diffuse/ limited 9/3 NA 
Auto-antibodies 
Anti-topoisomerase-1 (ATA) 41.7% NA 
Anti-nuclear (ANA) 83.3% NA 
N - number of participants, SD – standard diviation, NA- non applicable 
Biopsies were washed in PBS and incubated with trypsin-EDTA (Life Technologies) for 
2hr at 37°C in 5% CO2. Following extensive washing with PBS, epidermis was separated 
from the dermis along the basement membrane using forceps. Explants were then 
incubated overnight with 1ml of serum free media supplemented with penicillin 
streptomycin (P/S); dermis in high glucose Dulbecco’s modified Eagle’s medium 
(DMEM) (Life Technologies) while epidermis in keratinocyte growth media (Life 
Technologies). Finally, conditioned media was aliquoted and stored at -80°C prior to 
analysis using Luminex or ELISA (Reiss et al., 2009, Beirne et al., 2009).  
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2.2.2    Human keratinocyte cell line (HaCaT)  
HaCaT is a spontaneously immortalized human keratinocyte cell line developed through 
long-term culture of normal human adult skin keratinocytes at reduced calcium 
concentration and elevated temperature (Boukamp et al., 1988). It was used in this thesis 
as in contrast to many virally transformed keratinocyte cell lines, HaCaT is capable of 
normal differentiation including, expressing of involucrin and filaggrin (Boukamp et al., 
1988). Moreover, although immortalized, HaCaT do not display invasive properties in 
vivo (Boukamp et al., 1988, Boukamp et al., 1985).  
HaCaT (ATCC, Teddington, UK) cell cultures were established from departmental liquid 
nitrogen stocks and expanded in growth in DMEM supplemented with 10% fetal calf 
serum (FBS) (Life Technologies). In short, vials containing frozen cells (passage 10-12) 
were warmed in water bath at 37°C. Thawed cells were transferred to a 15 ml tube with 9 
ml of warm media added, and centrifuged at 300 x g for 5 min. Supernatant was then 
removed and cells re-suspended in 10mls of growth media and seeded in to T75cm2 
flasks. The culture media was replaced every 2-3 days, and cells were passaged at 60-
70% confluence. Cultures were inspected using a phase-contrast microscope to confirm 
typical cobble shape like keratinocytes morphology (Fig.2.2). 
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Figure 2.2. Phase-contrast photomicrographs of HaCaT cells. 
 
 
2.2.3    Primary fibroblast strains 
Dermal fibroblasts were grown from explant cultures of human forearm skin biopsies 
(4mm) in DMEM supplemented with 10% FBS and 100U/ml penicillin and 100µg/ml 
streptomycin (P/S) (Life Technologies). Under aseptic conditions in a laminar flow 
cabinet, the tissue was washed, finely cut, adhered and cultured in 25cm2 tissue culture 
flasks in a humidified atmosphere of 5% CO2 in air at 37°C. The culture media was 
replaced every 3-4 days. Cells were passaged at confluence and used within 4 passages. 
Cultures were inspected using a phase-contrast microscope to confirm typical fibroblast 
morphology (Fig 2.3). 
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Figure 2.3. Phase-contrast photomicrographs of primary dermal fibroblast. 
 
2.2.4  Treatments with small molecules 
2.2.4.1    TGFβ treatment  
In order to clarify the time course of TGFβ1 responsiveness, HaCaT cells were grown in 
10% DMEM containing 10% FBS on 6 well plates. At approximately 80% confluence 
cells were washed twice in PBS, and serum-starved with 0.5% bovine serum albumin for 
24 hours, prior to agonist stimulation with recombinant TGF-β1 (R&D) at a 
concentration of 2ng/ml and 4ng/ml. Cells were monitored for change in morphology and 
phase-contrast photomicrographs were taken daily. Time points were taken at 0, 0.5, 1, 4, 
6, 24, 48 and 72 hours, after which cell monolayers were lysed for mRNA, to assess 
expression of Snail1 and Snail2.  
The immunofluorescent staining and Western blotting assays were performed with 
HaCaT cells stimulated with 2ng/ml of TGFβ1 for 72 hours.  
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2.2.4.2    LPS treatment 
HaCaT cells were cultured as previously described in 6 well and 12 well plates. At 80 % 
confluence cells were washed twice in PBS, and serum-starved with 0.5% FBS for 24 
hours, prior to treatment with 2ng/ml of LPS.  Cells were lysed at 6hr for RNA and at 
48hr for proteins.  
2.2.4.3   S100A9 treatment 
HaCaT cells and primary dermal fibroblasts (passage 3-4) were grown in DMEM 
supplemented with 10% FBS in 12-well and 96-well plates or chamber slides. At 80%-
90% of confluence media was removed, cells washed in PBS and replaced with DMEM 
containing 0.5% FBS and cultured for further 18-24hrs. Then media was removed and 
replaced with DMEM supplemented with 0.5% FBS and rhS100A9 (Sino Biological) at 
concentrations of 2µg/ml, 1.5µg/ml, 1µg/ml and 0.5µg/ml in volumes: 1ml/well of a 12 
well plate or per chamber and 120µl/well of a 96 well plate. Cells were maintained for a 
further 6-48 hours dependent on assay, and visually assessed for viability at 24 and 48hrs.  
2.2.4.4  TLR4 inhibitor treatment 
Primary dermal fibroblasts (passage 4, SSc n=3, control n=3,) were grown in DMEM 
supplemented with 10% FBS and P/S in 12-well plates. At around 80% of confluence 
cells were washed in PBS and cultured in 0.5% FBS P/S DMEM further 24hrs. Next 
fibroblasts were pre-treated for 1hr with 1µM of selective TLR4 inhibitor TAK-242 
(Calbiochem) (Matsunaga et al., 2011) prior to treatment with 1.5µg/ml of rhS100A9 
(Sino Biological) in 1ml/well of DMEM 0.5% FBS P/S. Cells were maintained for a 
further 6hr then lysed for RNA.  
 
2.2.5  Cell culture assays 
2.2.5.1   MTS assay 
Human dermal fibroblasts P4 from 3 healthy controls and 3 SSc patients were seeded in 
96 well plate at concentration of 5 000 cells/well and incubated in 10% serum DMEM. 
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After 24 hours the cells were washed 3x in PBS and switched to 1% serum containing 
rhS100A9 at concentrations 2µg/ml, 1µg/ml and 0.5µg/ml, TGFβ. The proliferation rate 
was assessed after 24hrs using CellTiter 96® Aqueous One Solution Cell Proliferation 
Assay (Promega). The cells were incubated with 20µl of the solution for 1.5hrs in the in a 
humidified atmosphere of 5% CO2 in air at 37°C.  
 
2.2.5.2  Crystal violet assay 
The effect of rhS100A9, TGFβ and LPS on proliferation of HaCaT cells and primary 
dermal fibroblasts was assessed by the crystal violet method (Karakecili et al., 2008). The 
incorporation of crystal violet dye into DNA allows for the sensitive estimation of cell 
numbers. Upon solubilisation with acetic acid, the amount of dye taken up by the cell 
monolayer is quantified by optical density (OD) and cell numbers estimated based upon 
OD at 570nM.  
 
In short, 10 000 cells/well were seeded on 96 well plates in 100µl of DMEM 
supplemented with 10% FBS and incubated at 37°C, 5% CO2. At 80% confluence cells 
were serum starved overnight. Then cells were treated with rhS100A9, TGFβ and LPS 
and 10% FCS was used as a positive control. After 48hrs of treatment cells were washed 
twice in PBS and excess liquid was carefully removed. Cells were incubated for 10 min 
at room temperature with 30ul of crystal violet solution (0.1mg of crystal violet, 10ml 
methanol, 40ml distilled water) per well. Plate was washed thoroughly in tap water and 
drained upside down on a paper towel to remove the water completely. Then 100ul/well 
of 33% acetic acid was added and the absorbance was read at 570nm on a plate reader. 
 
2.2.5.3  Viability assay 
Human dermal fibroblasts (P4) from 3 healthy controls and 3 SSc patients were seeded in 
96 well plate at concentration of 8 000 cells/well and incubated in 10% serum DMEM till 
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80% confluent. Then the cells were washed 3x in PBS and switched to 1% serum. After 
24 hours, proliferation was stopped using mitomycin C (10µg/ml) and cells incubated 
with serial dilution of rhS100A9 at concentrations 2µg/ml, 1µg/ml and 0.5µg/ml. The 
effect of rhS100A9 on cells viability was assessed after 72 hours using MTS assay.  
 
2.2.5.4    Scratch assay 
Human dermal fibroblasts (P4) from 3 healthy controls and 3 SSc patients were seeded in 
96 well plate at concentration of 8 000 cells/well and incubated in 10% serum DMEM till 
80% confluent. Then the cells were washed 3x in PBS and switched to 1% serum. After 
24 hours, proliferation was stopped using mitomycin C (10µg/ml) and cells incubated 
with serial dilution of rhS100A9 at concentrations 2µg/ml, 1µg/ml and 0.5µg/ml. The 
scratch was created and assessed at 24, 48 and 72 hours.  
 
2.3    Molecular biology techniques 
2.3.1    Tissue lysis for RNA 
Once equilibrated to room temperature blister epithelial sheets were transferred from 
RNA-later into a rounded bottom 2ml tubes containing 5mm metal bid, 500µl of RTL 
buffer and β-mercaptoethanol. The sheets were disrupted in a Tissue Lyser II (Qiagen) 
for 2 min at 20Hz/s performed twice. Lysates where then transferred to a fresh tube and 
spun for 3 min at 3000 x g. Supernatants were then used for the RNA extraction. 
 
2.3.2    Lysing and homogenisation of cell monolayers for RNA  
Media from monolayers of cells was removed and cells washed twice in PBS. Then 400µl 
of RTL buffer was added to each well and lysate collected using rubber policeman. 
Lysates were transferred to the 1.5ml Eppendorf tubes and homogenised by passing 5 
times through a 20-gauge needle.  
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2.3.3    RNA extraction  
Total RNA was extracted using RNeasy kit (Qiagen) according to manufactures 
instructions. In brief 400µl of 70% ethanol was added to each cell lysates and mixed by 
vortexing. The samples were then transferred to RNeasy spin columns and centrifuged for 
15s at 8000g. Flow-through was discarded; 700µl of RW1 buffer was added to the 
column and again centrifuged for 15s at 8000g. Next, spin columns were washed in 500µl 
of RPE buffer and centrifuged for 15s at 8000g, followed by another wash in 500µl of 
RPE buffer and 2min centrifugation at 8000g. The columns were then transferred to a 
fresh collection tubes and centrifuged at 1000g for 1min. RNA was eluted in 30µl of 
RNA/DNA free water.  
 
2.3.4    RNA quantification and quality control  
RNA was quantified using a Nanodrop ND-8000 spectrophotometer (Thermo-Scientific). 
Briefly, 1.2µl of samples were placed on the spectrophotometer and measured for 
quantity and purity estimated using 260/280 and 260/230 ratios. The minimum 260/280 
ratio accepted was 1.90 and minimum 260/230 ratio was 1.8. RNA quality was assessed 
using an Agilent 2100 Bioanalyzer (Agilent) using the Agilent RNA 6000 Nano kit and 
chips according to manufacturer’s instructions. The RNA integrity algorithm was used to 
determine integrity. For PCR purposes, minimum acceptable RIN values were >8.0.  
 
2.3.5    Reverse transcription 
Total RNA was reversely transcribed using QuantiTect Reverse Transcription kit 
(Qiagen) following standard protocol. In short, genomic DNA was removed by adding 
2µl of gDNA wipeout buffer to 1µg of RNA and incubated for 2 min at 42˚C. Then to 
each sample 1µl of reverse transcriptase and RT Primer Mix containing random and 
oligoDT primers was added, along with 5µl of RT buffer, and mixed. Samples were 
incubated for 15 min at 42˚C, followed by 3 min incubation at 95˚C. The cDNA template 
was then diluted 1 in 10 and stored at -80˚C. 
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2.3.6    Primer design  
Primers were designed using NCBI Primer-Blast software 
(www.ncbi.nlm.nih.gov/tools/primer-blast) and human accession numbers. Intron-
spanning amplicons placed towards the 3’ end of the gene of interest were preferred. 
Sequences were analysed for GC content and GC clamps and self-annealing using Vector 
NTI software. GC content of 40-60, and a difference in Tm ≤ 2°C were considered 
acceptable. Ideal primer length was 18-30 bases and amplicon length 80-200 bp. In order 
to ensure specificity, primer sequences were subjected to BLAST analysis 
(www.ncbi.nlm.nih.gov/blast). Specificity was confirmed using melt curve analysis. 
 
2.3.7    Assay standards  
For some of genes, complementary cDNA standards were amplified from human cDNA 
known to express the gene of interest. PCR amplification of the amplicon was performed, 
and the cDNA isolated by gel electrophoresis. Gel purification through the QiaQuick 
DNA purification columns (Qiagen) was performed. DNA was quantified using the 
Nanodrop, and these known quantities of amplicon were then diluted to provide eight 
standards diluted 10-fold in RNAse/DNase free water from 107 copies to 101 copies. 
These were used to construct standard curves and derive copy numbers and assay 
efficiencies. 
 
2.3.8    qPCR 
Diluted cDNA was used in qRT-PCR reactions performed in Rotor-Gene 2000 (Corbett). 
Each 10µl reaction contained 5µl of SensiMix (Bioline), 0.5µM of both forward and 
reverse primers, 2µl of nuclease free water and 2µl of cDNA template. The cycling 
conditions were as follows: initial denaturation at 95°C for 5 min followed by 40 cycles 
of amplification (denaturation at 95°C for 10s, annealing at 57°C for 20s, and extension 
for 10 s at 95°C). Samples were run in duplicates and each run included no cDNA 
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template control. Primers sequences for gene of interest and housekeeping are listed in an 
Appendix 1. 
Target transcript expression was normalised to the expression of the most stable 
housekeeping gene (TUBB for epidermal blisters, TBP for fibroblasts and HaCaT cells 
incubated with S100A9) using previously described the ΔΔCT method (Livak and 
Schmittgen, 2001). The relative gene expression of a specific gene was calculated 
according to the equation: 
Relative gene expression = 2(CtREF – CtGOI), 
Where Ct (cycle threshold) is a number of cycles required for the fluorescent signal to 
cross the threshold of background fluorescence signal; REF- most stable housekeeping 
gene; GOI is a gene of interest. 
To ensure accuracy of the ΔΔCT method serial dilutions of cDNA were amplified using a 
range of primers and the efficiency of primers was assessed for each GOI and REF gene. 
Only primers with efficiency 98% - 100% were used. Normalisation factors for qPCR 
assays presented in the chapter investigating EMT in SSc skin were calculated for each 
gene using GeNorm analysis software based on most stable housekeeping gene out of 
five (Vandesompele et al., 2002). TUBB and B2M were found to be most stable genes in 
blister sheets and therefore used for the analysis of SNAI1 and SNAI2 in the epidermal 
sheets; while TBP and B2M was used in HaCaT cells stimulated with TGFβ. 
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2.4    Immunological assays 
2.4.1    Measurement of secreted proteins 
In order to profile growth factors cytokines and chemokines released by SSc and control 
epidermis and dermis, media conditioned by the explants was assayed using multiplex 
platform and ELISAs. Assays sensitivity is listed in the Table 2.3. 
 
Table 2.3. Luminex and ELISA assays sensitivity. 
Analyte 
Mean assay 
sensitivity (pg/ml) Type of assay 
Total number 
of samples 
FGF-2 0.9 Luminex 24 
G-CSF 0.2 Luminex 24 
GM-CSF 0.4 Luminex 12 
IL-1a 1.1 Luminex 24 
IL-1b 0.1 Luminex 24 
IL-1ra 0.6 Luminex 24 
IL-8 0.4 Luminex 24 
MCP-1 1.4 Luminex 24 
VEGF-A 1.4 Luminex 24 
PDGF-AA 0.3 Luminex 12 
PDGF-BB 0.7 Luminex 12 
IL-6 1.8 Luminex 12 
S100A9 6.55 ELISA 12 
HGF 40 ELISA/Luminex 12/12 
CCL20 0.47 ELISA 12 
CTGF 63 ELISA 16 
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2.4.1.1    Luminex based multiplex assay 
The Luminex assay uses xMAP® technology, which enables simultaneous quantitation of 
multiple proteins in a sample. Polystyrene color-coded beads, coated with target specific 
antibodies are mixed together and incubated with the samples. Captured analytes are 
subsequently detected using biotinylated detection antibodies and a reporter dye 
streptavidin-phycoerythrin conjugates. In the Luminex analyzer, a red light laser excites 
the internal dyes that identify each bead, while green light source excites reporter dye 
bound to the surface of the beads and digital signal processing to effectively allow 
multiplexing of samples using. 
Conditioned media from epidermal and dermal explant experiment were send to 
Biolegend, where they were analysed for presence of FGF-2, G-CSF, GM-CSF, IL-1a, 
IL-1b, IL-1ra, IL-8, MCP-1, VEGF-A, PDGF-AA and PDGF-BB, HGF using multiplex 
platform, Luminex (Biolegend, San Diego, US). Unfortunately, not all assays that I was 
interested in were available for multiplex analysis at the time. Therefore, samples had to 
be analysed by separate sandwich ELISAs for the remaining targets: S100A9, CCL20 and 
CTGF. 
2.4.1.2    CCL20 and S100A9 ELISAs  
Commercial ELISA kits was used to assess levels of CCL20 (R&D Systems, 
Minneapolis, US), and S100A9 (MBL International, Woburn, US). Standard 
recommended protocols were followed. In brief, conditioned media from epidermal and 
dermal explant experiment and appropriate standards was loaded in duplicates on a 96 
well plate pre-coated with monoclonal antibodies specific to CCL20/S100A9 and 
incubated for 2hr/1hr on a plate shaker. Wells were washed and incubated with HRP-
conjugated antibody for 2hr/1hr on a plate shaker. Then ELISA plates were washed and 
TMB substrate solution was added to all wells. The reactions were then stopped using the 
stop solution (sulphuric acid) once sufficient color development was observed. The 
absorbance of each well was then analysed by reading the absorbance at wavelengths 450 
nm and 540 nm. After subtracting background absorbance, mean value was subjected to 
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semi-logarithmic analysis and expressed as a concentration in pg/ml. The readings were 
further analysed in Prism GraphPad.  
 
2.4.1.3    CTGF ELISA  
Human CTGF development ELISA kit, which detects free CTGF was purchased from 
Peprotech. An ELISA protocol provided by the manufacture was followed. In brief, Nunc 
MaxiSorb plates were coated with 1µg/ml of monoclonal human CTGF coating antibody 
(100µl per well) over night at room temperature.  The plates were then washed 4 times in 
0.05% PBST and blocked for 1hr with 300µl per well of blocking solution (sterile filtered 
1% BSA in PBS) and washed 4 times with PBST. Next, 100µl of sample/ CTGF standard 
(serial dilution from 4000pg/ml to 62.5pg/ml) was loaded on a plate and incubated for 
2hrs.  
Afterwards, plate was washed 4 times and 100µl of biotinylated anti-CTGF detection 
antibody at concentration of 0.5µg/ml was added. After 2hrs incubation and subsequent 
series of washing, 100µl of avidin-HRP conjugate was added to wells and incubated for 
30min at room temperature. The plate was washed and 100µl of pre-incubated Glo 
Substrate Reagent A and B mixture (R&D Systems) was added and incubated in the dark 
for additional 10 minutes. The luminescence of each well was then recorded using 0.1-
0.5s readings. After subtracting background luminescence, mean value was subjected to 
semi-logarithmic analysis and expressed as a concentration in pg/ml. The readings were 
further analysed in Prism GraphPad.  
 
2.4.2    Immunohistochemical analysis of paraffin embedded sections 
For formalin-fixed paraffin-embedded (FFPE) specimens, samples were stored overnight 
in 4% formaldehyde (CellPath, Newtown, UK). Fixed tissues were processed and 
dehydrated overnight and embedded in molten paraffin wax. 3µm sections were cut on a 
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Leica UK microtome and mounted onto poly-L-lysine-coated slides (VWR, Lutterworth, 
UK). After drying at 42°C overnight, sections were stored for staining.  
 
2.4.2.1    Immunohistochemical staining 
FFPE sections were de-waxed in xylene (Genta Medical, York, UK) for 10 minutes, 
rehydrated in gradient concentrations of ethanol and washed in water. Then endogenous 
peroxidase activity was blocked for 10 min with methanol containing 1% hydrogenpp 
peroxide. Standard protocols for heat mediated antigen retrieval in citrate buffer (pH 6) or 
Tris-EDTA (pH 9) for 5-15 minutes were followed in all but pro-collagen staining, where 
proteinase K digestion was used. Antigen retrieval protocols were optimised for each 
antibody used. 
After cooling down sections were washed in water and unspecific binding was blocked 
with 10% normal serum (Vector Labs, Peterborough, UK) for 30 minutes. Endogenous 
biotin activity was then blocked using a commercial avidin/biotin blocking kit (Vector 
Labs) according to manufacturer’s instructions. Diluted in 0.05% PBST antibodies were 
then applied onto tissue sections and after overnight incubation at 4°C or 1 hour at room 
temperature sections were washed in PBS. Appropriate IgG controls were included for all 
immunohistochemical stains. List of primary antibodies used, their dilutions and 
incubation time was collected in Table2.4. 
Optimisation of antibody dilution, length and ambient temperature during treatment was 
performed for each antibody used. Binding of primary antibodies was detected using an 
appropriate biotin-conjugated secondary antibody at 1:200 dilution for 30 minutes, 
followed by 30 min incubation with peroxidise or alkaline-phosphatase substrate (Vector 
Labs). Sections were developed using 3,3’ diaminobenzidine tetrachloride (DAB) as a 
chromagen or alkaline phosphatase (both from Vector Labs). Sections were 
counterstained in Mayers’ haematoxylin for 30s, dehydrated with alcohol, cleared in 
xylene, and mounted with a permanent mountant (DPX) (VWR). Where necessary 
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commercial ImmPress kit was used with rabbit antibodies to aid specificity of staining 
(Vector Labs).  
Table 2.4. List of primary antibodies used in immunochistochemistry and 
immunofluorescence. 
Antibody 
target Purchased from Species Dilution 
Incubation 
time 
E-cadherin BD Biosciences (Oxford, UK) Mouse monoclonal 1:100 Overnight 
Vimentin Santa Cruz (Heidelberg, Germany) Mouse monoclonal 1:50 Overnight 
Cytokeratin 14 
(K14) 
Vector Labs 
(Peterborough, UK) Mouse monoclonal 1:20 1hr 
Loricrin Abcam (Cambridge, UK) Rabbit monoclonal 1:500 1hr 
Filaggrin Abcam Mouse monoclonal 1:200 Overnight 
Involucrin Abcam Rabbit polyclonal 1:500 1hr 
P-smad2/3 Santa Cruz Rabbit polyclonal 1:100 1hr 
FSP-1 Abcam Rabbit polyclonal 1:50 1hr 
Collagen IV Southern Biotech (Cambridge, UK) Goat polyclonal 1:20 1hr 
Ki-67 Dako (Ely, UK) Mouse monoclonal 1:75 30 minutes 
α-SMA Dako Mouse monoclonal 1:75 30 minutes 
S100A9 Abcam Rabbit monoclonal 1:250 1hr 
S100A8 Abcam Mouse monoclonal 1:50 1hr 
Langerin Abcam Mouse monoclonal 1:100 Overnight 
Pro-collagen 
type I Abcam Rat monoclonal 1:800 30 minutes 
Pan-cytokeratin Santa Cruz Mouse monoclonal 1:100 1hr 
HGF Abcam Mouse monoclonal 1:200 Overnight 
CTGF Abcam Mouse monoclonal 1:500 Overnight 
p-Hspb1 (S78) Abcam Mouse monoclonal 1:500 Overnight 
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Sections were viewed with a Zeiss Axioskop Mot Plus microscope, an Axiocam digital 
camera using Axiovision software (Zeiss, Cambridge, UK). Figures shown are 
representative of all sections. 
2.4.2.2    Immunofluorescent staining of cells 
Cells were grown in 8 well chamber slides (BD Bioscience, Bedford, MA) and after 
serum starvation treated for 48-72hrs, then washed with PBS and fixed in ice-cold 
methanol-acetone for 5 min at 4°C. After subsequent PBS wash, unspecific binding was 
blocked with 10% normal serum (Vector Labs) for 30 minutes. Diluted antibodies to Pan-
cytokeratin and FSP-1 (Table 1) were then applied, and after appropriate incubation time 
cells were washed in 0.05% PBST. Then an suitable fluorophore-conjugated secondary 
antibody (Life Technologies) at 1:2000 dilution was applied and incubated for 30min in 
protected from light conditions. Finally, cells were washed and mounted with Vectashield 
media (Vector Labs) containing 4',6-Diamidino-2-Phenylindole (DAPI) and examined 
with a Zeiss Axioskop Mot Plus microscope using fluorescence detecting camera (Zeiss). 
 
2.4.2.3    Histological analysis 
Sections were viewed with a Zeiss Axioskop Mot Plus microscope, an Axiocam digital 
camera using Axiovision 4.8 software (Zeiss). Between 6 and 12 sections of both healthy 
controls and SSc patients were used for the analysis. Microscope measurements, for 
instance, of epidermal thickness, were performed on 10 high power fields per sample by 
observers blinded to sample category. Figures shown are representative of all sections. 
2.4.2.3.1  Epidermal thickness 
In order to determine thickness of the epidermis, an area from the basement membrane to 
the most inner part of stratum corneum was measured. Mean thickness for each section 
was calculated and included in statistical analysis. Then from each section an area of 10 
cells from basal and spinous layers was measured on 6 fields of view using Axiovision. 
97 
 
The mean was calculated for each section and included in comparison between healthy 
control and SSc.    
2.4.2.3.2   Measurement of loricrin, involucrin and filaggrin bands 
For analysis of terminal differentiation skin sections were stained for classical markers: 
loricrin, involucrin and filaggrin. The expression band thickness for each marker was 
measured based on 10 measurements taken from each section, and the calculated mean 
was used to test the difference between healthy and SSc skin.  
2.4.2.3.3   Number of proliferating cells  
Number of cells positive for proliferation marker – ki67 in the epidermis was counted, 
averaged for each sample and divided by total number of cells in the basal layer. The 
result was then expressed as a percentage of the basal cell number and used for analysis. 
2.4.2.3.4   Phoshorylated - Smad2/3 in epidermal keratinocytes and papillary dermis 
Number of keratinocytes with nuclear phospho-Smad2/3 staining was calculated. 
Moreover, cells positive for phospho-Smad2/3 in 50µm area in papillary dermis adjacent 
to basal membrane were examined. The measurements were based on an average from 10 
high power fields of view for each section and the numbers compared between controls 
and SSc in order to assess TGFβ signalling in this area. 
2.4.2.3.5   E-cadherin intensity scoring 
E-cadherin staining intensity scoring was performed on 6 fields of view for each sample 
and scored between 1 (the least intense staining) and 3 (the most intense staining). The 
scores were then averaged for each sample and the mean was used for comparison 
between control and SSc.  
2.4.3    Western blot analysis 
Western blots of the fibroblast and HaCaT cells were performed to detect levels of E-
cadherin, αSMA, FSP-1, type I collagen and CTGF.	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2.4.3.1    Preparation of protein cell lysates 
Media from dermal fibroblast and HaCaT cells monolayers were aspirated and cells 
washed three times in PBS. Cells were lysed in 200µl RIPA buffer (Sigma) containing 
complete protease inhibitor cocktail (Roche, London, UK) and phosphatase inhibitor 
(Sigma, St. Louis, US). Cells were incubated on ice for 5 min and scraped using rubber 
policeman. The lysates were then transferred to the Eppendorf tubes and centrifuged at 
3000 x g for 10 min to remove cell debris. Total protein was assessed using BCA protein 
assay (Thermo Fisher, Waltham, US) and aliquots of the lysate were stored at -80°C.  
 
2.4.3.2    Electrophoresis and protein transfer 
Samples were prepared by addition of 2µl of a reducing agent and 5µl of a sample buffer 
(both Life Technologies) to 13µl of cell lysates and heated for 10 min at 70°C. Samples 
were then loaded on 4-12% Bis-Tris polyacrylamide gels (Life Technologies) at 16µl per 
well, alongside protein marker (Life Technologies) and electrophoresed in MOPS SDS 
buffer (Life Technologies) for 50min at 200V. Afterwards, proteins were blotted on 
nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK) for 1.5hr at 30V and 
the membranes incubated for 1hr in blocking buffer (5% milk 0.05% PBST) on the 
rocking platform. The blots were subsequently probed overnight/1hr with primary 
antibodies diluted in the blocking buffer, followed by washing in 0.05% PBST and 1hr 
incubation with appropriate biotinylated species-specific secondary antibodies diluted 
1:1000. After subsequent washing the blots were visualised using chemiluminescent 
detection system (GE Healthcare) and developed against photographic film (GE 
Healthcare). Finally, optical density of bands was calculated and presented in graphs. List 
of primary antibodies including dilution factors are available in Table 2.5. 
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Table 2.5. List of primary antibodies used in Western blotting. 
Antibody target Purchased from Species Dilution Incubation time 
E-cadherin BD Biosciences Mouse monoclonal 1:1000 Overnight 
FSP-1 Abcam Rabbit polyclonal 1:750 Overnight 
Collagen type I Millipore (Nottingham, UK) Goat monoclonal 1:1000 Overnight 
CTGF Abcam Mouse monoclonal 1:500 Overnight 
α-SMA Dako Mouse monoclonal 1:1000 Overnight 
β-tubulin Abcam Rabbit polyclonal 1:10000 2hr 
GAPDH Abcam  Goat monoclonal 1:20000 1hr 
 
2.4.4    Phosphorylation microarray  
Forearm skin biopsy samples from SSc (n=4) and control (n=4) subjects were 
immediately frozen in liquid nitrogen in order to prevent the decay of phosphorylation 
events. Epidermis was separated surgically and samples were shipped to Kinexus 
Bioinformatics (Vancouver, Canada), where they were lysed and processed using 
phospho-site specific antibodies. This service uses the KAM-1.2 chip with two samples 
analyzed at a time utilising 500 pan-specific antibodies (for protein expression) and 300 
phospho-site-specific antibodies (for phosphorylation) in duplicate for at least 248 
different phospho-sites, 193 protein kinases, 24 protein phosphatises and 150 regulatory 
subunits of these enzymes and other cell signalling proteins that regulate cell 
proliferation, stress and apoptosis. 
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2.5    Statistical analysis 
For quantitative variables, the mean ± standard deviation or, where appropriate, standard 
error of the mean from replicate samples, or from independent experiments were 
calculated. Summary data are presented as mean ±SD/SEM of n observations. Statistical 
analysis was assessed as indicated in the text with means compared using either the 
Student's t-test (in vitro experiments with primary fibroblasts and HaCaT cells) included 
in the Microsoft Excell package (Redmond, US), one-way ANOVA with post hoc 
analysis using Tukey’s multiple comparison test (mRNA analysis of blister sheets), or 
nonparametric Mann-Whitney U test (proteome and phosphor-smad2/3 analysis) using 
the GraphPad Prism 5 software (La Jolla, US). A p value ≤ 0.05 was considered as 
statistically significant. 
Permutation testing for phosphorylation array data was performed using an Excel add-in, 
Significance Analysis of Microarray Data (Tusher et al., 2001) and followed by 
calculation of the false discovery rate (Hochberg and Benjamini, 1990).   
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Chapter Three 
 
Results: Morphological Characteristics of SSc Epidermis 
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3.1  Introduction 
SSc is a complex rheumatic connective tissue disease with wide spectrum of symptoms. 
However, skin involvement is one of the most common features and its severity is often 
used as a marker of disease severity and prognosis. Some of the cardinal features of the 
SSc skin include fibrosis, thickening, abnormal pigmentation and alopecia. Over the 
years a lot of efforts have been put into better understanding of processes associated with 
skin fibrosis, but the vast majority of studies have concentrated on the dermal component 
of the skin. Therefore, data regarding SSc epidermis and characteristics of its 
keratinocytes are very limited. Even reports on basic morphological features of the SSc 
epidermis are sporadic and often inconsistent. For example epidermal thickness in SSc 
vary between publications, from hypertrophic (Van Praet et al., 2011, Rossi et al., 2010, 
Sauermann et al., 2002, Aden et al., 2008), through normal (Morley et al., 1985a), to 
atrophic (Cooper et al., 1979). Likewise, previous reports cannot agree on proliferation 
status of the keratinocytes in SSc skin, and include hyperplasia (increase in cell number) 
(Milano et al., 2008), as well as a non- significant increase in number of proliferating 
cells (Pablos et al., 1999).  
Histological studies performed in our lab have shown changes in the SSc epidermis in the 
pattern of K14 and K1/K10 expression. Moreover, proteomic analysis revealed altered 
levels of proteins involved in epidermal differentiation, such as increase in caspase 14 
precursor, K1 and K14, but decrease in K5, when compared with control (Aden et al., 
2008). The presence of nuclei in the SSc stratum corneum (parakeratosis) was also 
previously reported (Van Praet et al., 2011, Maeda et al., 1993). However, those changes 
consistent with altered differentiation of SSc keratinocytes were never fully investigated.  
Following on from these findings I started systematically analyse the epidermis in SSc. 
As discussed in the introduction section of this thesis, normal human epidermis comprises 
of proliferating basal keratinocytes and suprabasal keratinocytes, which stop dividing and 
undergo terminal differentiation. These two types of keratinocytes can be distinguished 
by the pattern of cytokeratins, and expression of structural proteins of the cornified-
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envelope (Watt et al., 1993, Candi et al., 2005). The mitotically active basal progenitor 
cells, express K5 and K14 but do not synthesise proteins associated with the cornified-
envelope. Upon migration to suprabasal position the expression of cytokeratins switch to 
K1 and K10, and they start synthesis of structural envelope proteins such as involucrin, 
loricrin, and filaggrin, which later become cross linked by Ca2+ dependent 
transglutaminase. During the process, keratinocytes become gradually flattened and loose 
their intracellular organelles, including nuclei. This journey ends in stratum corneum, 
from where the cornified envelopes are finally removed from the skin surface.  
The differentiation process is closely regulated, so that the number of proliferating and 
differentiating keratinocytes at any given time is closely coupled, giving the epidermis of 
the same thickness and mechanical strength. However, this process is altered following 
injury to the skin. Keratinocytes at the wound edge can withdraw from the terminal 
differentiation process to enable sufficient number of cells for wound re-epithelialisation. 
An activated phenotype of keratinocytes around the site of injury is associated with a 
change in the pattern of cytokeratins expression. Synthesis of normally absent K6, K16 
and K17 is induced, while cytokeratin 14 continues to be expressed in suprabasal layers 
(Usui et al., 2005). These changes are also mirrored in the expression of cornified 
envelope proteins, with markers of terminally differentiating keratinocytes expressed 
closer to the basal layer than normally (Li et al., 2000).  
Protein phosphorylation is one of the forms of post-translational modifications that affect 
protein activity. Upon introduction of a phosphate group some proteins become activated 
while others, become inhibited. Therefore, unsurprisingly reversible phosphorylation of 
proteins controls almost all aspects of cell life, while abnormal action of protein kinases 
and phosphatases responsible for phosphorylation and de-phosphorylation disrupts intra- 
and extracellular processes leading to pathology. Therefore, distinguishing 
phosphorylation status of proteins in SSc epidermis would allow a better understanding 
of changes in the diseased epidermis. 
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The aim of this chapter is to further characterize the SSc epidermal keratinocytes. 
Differences in morphology such as, epidermal thickness and number of keratinocytes, 
between normal and SSc epidermis are examined. In addition, comparison of 
proliferation rate between the SSc epidermis and control epidermis is made, and 
expression of standard differentiation markers is investigated in cutaneous sections. 
Furthermore, differences in phosphorylation of epidermal proteins reported by Aden 
(Aden et al., 2010) are further evaluated. 
 
3.2  Results 
Figures 3.1 to 3.7 were adapted from the paper (Nikitorowicz-Buniak et al., 2014). 
3.2.1  Epidermal thickness 
Although dermal thickness is increased in SSc, reports on epidermal thickness are not 
consistent (Morley et al., 1985b, Van Praet et al., 2011, Rossi et al., 2010). Therefore, to 
assess the extent of epidermal thickness, histological studies were performed on full 
thickness skin biopsies stained with hematoxylin. This assessment revealed that the 
epidermis in the majority of SSc sections contained more layers of cells, when compared 
with control tissue (Fig.3.1a). The mean thickness ± SEM of control epidermis was 
51.3µm ± 7.58 and 88.9µm ± 4.20 for SSc (Fig.3.1b). The observed thickening of SSc 
epidermis was statistically significant (p<0.05).  
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Figure 3.1 Comparison of epidermal thickness between control and SSc.  
(a) Control and SSc skin sections were stained with hematoxylin. Parakeratosis in SSc stratum 
corneum (SC) was marked using arrows. Representative images chosen to analyse (b) thickness 
of epidermis was measured from the basal to the cornified layer (HC n=6, SSc n=6). For each 
section 5 images were taken at 20X magnification and 10 measurements were taken from each 
image to calculate the mean thickness for each section. The results are presented as mean ± SEM. 
Statistical significance was determined using the Mann-Whitney U test **p<0.05.  
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3.2.2  Keratinocyte hypertrophy 
To find out whether the thickened epidermis contained more and/or larger cells, the cells 
were counted (Fig.3.2a) The mean cell number 307.1±71.37 observed in SSc epidermis 
was significantly higher when compared to healthy subjects 209.6±47.81 (p<0.005). 
Moreover, during counting of keratinocytes, it has been noticed that the cells in the SSc 
epidermis seemed to be larger. The link between the size of epidermal cells and its 
differentiation status has been established in 70s’ (Sun and Green, 1976). As discussed in 
the introduction chapter of this thesis, bigger cell size is characteristic to differentiating 
cells. As the cell increases in size, it loses ability to divide, but starts expressing 
differentiation markers, such as involucrin. Thus, to investigate if the SSc keratinocytes 
are indeed larger than those in control epidermis, the area of basal (dividing) and spinous 
(differentiating) cells was measured. Basal cells of healthy controls had mean area of 
74.76µm ±8.03, while SSc were significantly bigger 111.71µm ±16.71 (p<0.05) 
(Fig.3.2b). Cell area of spinous layer keratinocytes (Fig.3.2c) was also significantly 
increased, with 91.97µm ±14.17 in healthy epidermis and 165.09µm ±43.90 in SSc 
(p<0.05). 
Since the epidermal layer has significantly more keratinocytes, the proliferation rate may 
be enhanced in SSc. However, the hypertrophy of SSc keratinocytes would point to 
higher number of cells that are undergoing terminal differentiation. Therefore both of 
those processes were investigated in more depth.  
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Figure 3.2 Activated keratinocytes in SSc epidermis.  
(a) The mean number of epidermal keratinocytes was established based on 6 images at 20X 
magnification for each section (HC n=5, SSc n=6). The area of 10 cells in basal and spinous 
layers was measured at 5 separate 20X images for each section (HC n=5, SSc n=6) and the mean 
area of the cells in (b) basal and (c) spinous epidermal layers was calculated for SSc and control 
epidermis. The results are presented as mean ± SEM. Statistical significance was determined 
using the Mann-Whitney U test *p<0.05, ** p<0.005.  
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3.2.3  Keratinocytes proliferation 
In order to determine, if the increase in cell number in SSc epidermis is due to over 
proliferation, normal and SSc sections were stained with a proliferation marker, ki-67 
(Fig.3.3a). Positively stained cells in both normal and SSc epidermis were located within 
1-3 layers from the basal membrane. The mean percentage of keratinocytes expressing ki-
67 in the SSc epidermis was 8.4±2.19 and healthy subjects 3.3±3.66 (Fig.3.3b). 
Although, the difference between control and SSc was relatively large, the variation 
between the samples meant that only a trend towards increased (p=0.235) was observed. 
 
Figure 3.3 Keratinocytes proliferation in SSc epidermis.  
(a) The expression of proliferating cells in the epidermis of SSc patients and controls was 
detected using anti-ki-67 antibody. (b) The mean percentage of proliferating cells was calculated 
from an average of 6 measurements of ki67 positive cells taken from each section, divided by 
total number of cells in the basal layer (HC n=5, SSc n=6). The results are presented as mean ± 
SEM. Statistical significance was determined using the Mann-Whitney U test. P value was non-
significant.  
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3.2.4  Keratinocytes terminal differentiation 
As shown in Figure 3.1a, in some SSc sections nucleated cells were still present within 
stratum corneum, indicating parakeratosis. Moreover, the cornified layers of these 
biopsies had tightly packed corneocytes whereas, in healthy epidermis corneocytes were 
spaced, and individual ones could be recognised. The findings were consistent across 
early and established dcSSc, and suggest that terminal differentiation may be either 
delayed or incomplete. Furthermore, the hypertrophy of SSc keratinocytes indicates that 
the differentiation process in the SSc epidermis is altered. Also as already mentioned, 
reports from our lab showed altered expression of marker of basal keratinocytes K14, that 
is not confined to basal layer in SSc, but also expressed in suprabasal layers, suggesting 
altered differentiation in SSc keratinocytes. Therefore, to assess if expression of other 
markers of keratinocyte differentiation process was also changed in SSc, sections were 
stained with antibodies against classical terminal differentiation markers, involucrin, 
loricrin and filaggrin.  
The cells positive for involucrin in control samples were present only in the granular 
layer of the epidermis (Fig.3.4). However, in SSc epidermis the staining was extended 
downwards to the spinous layer keratinocytes, with all but basal cells positive for 
involucrin.   
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Figure 3.4 Abnormal expression of involucrin in SSc epidermis.  
The expression of differentiation marker involucrin in the epidermis of SSc patients and controls 
was detected by immunohistochemical staining using anti-involucrin antibody. Sections were 
counterstained with hematoxylin. 
Similar results were observed with loricrin, which stained positive just 1 layer below 
stratum corneum in controls, but in SSc epidermis strong staining was also seen few 
layers down, and weak staining in all but basal keratinocytes (Fig.3.5).  
 
Figure 3.5 Abnormal expression of loricrin in SSc epidermis.  
The expression of differentiation marker loricrin in the epidermis of SSc patients and controls 
was detected by immunohistochemical staining using anti-loricrin antibody. Sections were 
counterstained with hematoxylin. 
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Finally, filaggrin in controls stained single layer of cells below stratum corneum, but in 
SSc the staining was observed in more layers of cells (Fig.3.6). Moreover, loricrin along 
with involucrin and filaggrin seem to appear in relatively lower epidermal layers during 
differentiation of SSc epidermal keratinocytes, closer to the basal layer. One possible 
explanation is that although, cells enter a differentiation process, they travel towards the 
stratum corneum at a slower rate and the process of their removal from cell surface is 
delayed in SSc.  
 
Figure 3.6 Abnormal expression of filaggrin in SSc epidermis.  
The expression of differentiation marker filaggrin in the epidermis of SSc patients and controls 
was detected by immunohistochemical staining using anti-filaggrin antibody. Sections were 
counterstained with hematoxylin. 
Moreover, when quantified, the mean depth of involucrin, loricrin, and filaggrin staining 
was increased over 2 fold in SSc epidermis compared to controls (Fig.3.7). The mean 
depth of involucrin staining in SSc epidermis was 22.5µm ±22.85 compared to 15.15µm 
±0.97 in controls (p<0.05). Similarly, loricrin depth in SSc was 8.80µm ±7.21 compared 
to 4.83µm ±1.20 in controls (p=0.05), and filaggrin depth in SSc was 6.03µm ±1.72 and 
2.24µm ±0.22 in controls (p<0.0005). The expansion in number of layers expressing 
terminal differentiation markers indicates that the cornification process is delayed. This 
could partially explain increase in epidermal thickness seen in SSc. Additionally, such 
abnormal differentiation and increased cell number could impact on signalling and 
Control"" SSc""
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protein secretion from the epidermis and therefore alter epidermal-dermal cross talk. 
 
Figure 3.7 Quantitative analysis of involucrin, loricrin and filaggrin staining. 
Representative images such as the one in the previous figures 3.4 - 3.6 were chosen to analyse 
expression bands of (a) involucrin (HC n=5 SSc n=7) (b) loricrin (HC n=6 SSc n=9) and (c) 
thickness of filaggrin (HC n=5 SSc n=7). The mean thickness for each band was calculated from 
10 measurements taken from each section. The results are presented as mean ± SEM. Statistical 
significance was determined using the Mann-Whitney U test *p<0.05.   
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Heat shock protein 27 (HSBP1), a member of small heat shock protein is also involved in 
keratinocytes differentiation (Hell-Pourmojib et al., 2002), and its expression in normal 
keratinocytes correlates with differentiation status. HSBP1 undergoes phosphorylation 
and redistribution to the cytoskeleton during the late phase of epidermal keratinocyte 
differentiation (Robitaille et al., 2010, Jonak et al., 2011, Gandour-Edwards et al., 1994).  
The abnormal expression pattern of HSBP1 in SSc epidermis was earlier reported (Aden 
et al., 2008), with the protein stained not only suprabasal but also basal layers of 
keratinocytes. However, the phosphorylation status of HSBP1 in the SSc epidermis was 
never previously investigated. As demonstrated in this chapter the differentiation process 
of SSc keratinocytes is altered and delayed. Therefore, I anticipated differential 
expression of phosphorylated HSBP1 between control and SSc sections. Indeed the 
staining revealed changes to the location of the protein between control, early and late 
SSc (Fig.3.8).  
As expected control sections showed strong cytoplasm staining of phospho-HSBP1 in the 
granular layer. However, sections of early SSc showed also staining in the lower 
suprabasal layers of the epidermis. Although basal cells of control and early SSc 
epidermis were negative for phospho-HSBP1, the late disease sections staining was less 
heterogeneous with positive cells also in the basal layer. Further demonstrating 
differences in keratinocyte differentiation associated proteins between control and SSc 
epidermis, as well as changes with disease progression.  
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Figure 3.8 Enhanced phosphorylation of heat shock protein 27 (HSBP1) in SSc 
epidermis.  
The expression of phosphorylated HSBP1 in the epidermis of SSc patients and controls was 
detected by immunohistochemistry. Sections were counterstained with hematoxylin. 
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3.2.5  Phosphorylation of proteins in SSc epidermis 
KinexTM antibody microarray was previously performed on epidermal tissue in my 
department to detect of phosphorylation of more than 240 protein kinases, 28 
phosphatases, and 90 other cell signalling proteins implicated in cell proliferation, stress 
and apoptosis (Aden et al., 2010). The results showed an altered pattern of 
phosphorylation in SSc epidermis. Among those differentially phosphorylated were 
proteins involved in signal transduction pathways, cell cycling and cell metabolism 
participants. However, only proteins with 2 fold difference and above were included in 
the analysis. The remaining data still contains proteins with significantly altered 
expression and phosphorylation. As small difference in phosphorylation level may have a 
large impact on cellular processes I decided to perform analysis of interactions between 
all proteins with significantly upregulated or downregulated phosphorylation in SSc. In 
order to better understand processes important in disease pathogenesis I investigated 
using String software (von Mering et al., 2003, von Mering et al., 2005, Jensen et al., 
2009, Franceschini et al., 2013) in which biological processes these proteins are involved. 
 
3.2.5.1 Proteins with upregulated phosphorylation or aboundance in SSc epidermis 
detected by Kinexus 
Kinexus assay results revealed 20 proteins with increased phosphorylation levels in SSc 
compared with controls. Some proteins were phosphorylated at just one site others at a 
few. These proteins amongst others included phosphatases and kinases, as well as 
proteins with well-established links with SSc, such as Smad2 and PDGF receptor.  The 
whole list of proteins with increased phosphorylation along with their phosphorylation 
sites, and fold difference is presented in a table 3.1.  
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Table 3.1. Increased proteins phosphorylation in SSc epidermis.  
Protein Phospho site  Fold increase p-value 
40S ribosomal protein S6 (RPS6) S235 1.47 0.0072 
p38 alpha (MAPK14) T180+Y182 1.20 0.0086 
Protein kinase D (PRKD1) S738+S742 1.63 0.0092 
p70/p85 ribosomal protein-serine S6 
kinase alpha (RPS6KB1) 
T229 and 
S221/S227 1.52 and 1.43 
0.0109 and 
0.0319 
Platelet-derived growth factor receptor 
kinase alpha (PDGFRA) 
Y754 and 
Y572+Y574/
Y579+Y581 
1.75 and 1.63 
0.0174 
and 
0.0363 
Protein-serine kinase C gamma 
(PRKCG) T655 and 
T514 
1.22 and 1.86 
0.0182 
and 
0.0394 
Tyrosine hydroxylase isoform a (TK) S18 1.94 0.0218 
Integrin alpha 4 (INTGR4) S988 1.15 0.0224 
Microtubule-associated protein tau 
(MAPT) S518 1.42 0.0241 
Phosphoprotein-enriched in 
diabetes/astrocytes 15 (PEA15) S116 1.58 0.0256 
SMA- and mothers against 
decapentaplegic homolog 2 (Smad2) S465+S467 1.64 0.0293 
p70/p85 ribosomal protein-serine S6 
kinase alpha (RPS6KA1) T389 1.35 0.0294 
Protein-serine kinase C delta (PRKCD) S645 1.53 0.0321 
N-methyl-D-aspartate glutamate 
receptor 1 subunit zeta (GRIN1) S896 1.19 0.0335 
G protein-coupled receptor-serine 
kinase 2 (GRK2) S670 1.27 0.0389 
MAPK/ERK protein-serine kinase 1 
(MAP2K1) T291 1.48 0.0389 
Synapsin 1 isoform Ia (SYN1) S9 1.32 0.0398 
Protein-serine kinase C beta (PRKCB) T641 1.30 0.0467 
Myosin regulatory light chain 2, smooth 
muscle isoform (MYLK2) S20 1.33 0.0473 
Protein-tyrosine phosphatase 1D 
(PTPN11) S576 1.83 0.0478 
 
To better visualize the interactions between those proteins String analysis was performed 
(Fig.3.9) 
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Figure 3.9 Model of predicted interactions between proteins with significantly 
higher phosphorylation status in SSc epidermis. 
Interactions between proteins with increased phosphorylation in SSc epidermis biopsies 
compared to controls (as identified by phospho-protein microarray assay performed on 
control epidermis n=4 and SSc epidermis n=4) were modeled using String 9.1 software. 
The lines between nodes represent protein associations, with stronger associations 
represented by thicker lines.  
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According to algorithms used by the String software majority of the proteins with higher 
phosphorylation interact together; however PEA15, INTGR4, PRKD1 and MYLK2 did 
not seem to link with other proteins from the list. Then the biological processes involving 
the proteins with upregulated phosphorylation were identified using enrichment GO 
Biological Processes available within the software. The processes after adjustment for 
false discovery rate included: response to growth factor (9 proteins), cell surface receptor 
signaling (13 proteins), protein phosphorylation (8 proteins), response to wounding (9 
proteins), blood coagulation (7 proteins), hemostasis (7 proteins), positive regulation of 
biosynthetic process (9 proteins), platelet activation (5 proteins), regulation of response to 
stress (7 proteins), cell death (8 proteins), innate immune response (6 proteins), cell-cell 
signaling (7 proteins), and positive regulation of cell migration (4 proteins). The wide 
range of different pathways in which the upregulated proteins take part, is mainly due to 
the fact that most of those proteins are enzymes with multiple substrates.  
Some of the proteins had not only increased phosphorylation, but were also more 
abundant, namely PTPN11, MAPK14, PPP1CB, PRKCG, RPS6, RPS6KB1. According 
to PhosphoSite database (www.phosphsite.org) PTPN11, PPP1CB and calcium-activated 
PRKCG are involved in cell motility, polarity and chemotaxis. However, there is no data 
available on the phosphorylation of the particular sites indicated by Kinexus assay, 
similar with RPS6KB. RPS6 participates in regulation of molecular association. 
MAPK14 phosphorylation at T180 and Y182 induces its enzymatic activity and is 
implicated in altered apoptosis, cell adhesion, cell cycle regulation, cell motility, as well 
as cytoskeletal reorganization. Alterations in those activities are possibly able to 
contribute to fibrosis and inflammatory changes seen in SSc.  
In order to gain a more comprehensive view of the protein interactions in the SSc 
epidermis, significantly increased proteins detected with Pan-specific antibodies of the 
Kinexus array were also included in the analysis. The model of interactions between the 
52 proteins of SSc epidermis, generated by String software showed interlinked pathways 
involved in many different biological processes (Fig.3.10). Again most of the proteins 
formed a complex network of interconnected interactions.  
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 Figure 3.10 Model of interactions between proteins with significantly abundance 
and higher phosphorylation status in SSc epidermis. 
Interactions between proteins with increased phosphorylation and abundance in SSc epidermis 
biopsies compared to controls were modeled using String 9.1 software. The lines between nodes 
represent protein associations.  
Then proteins were subdivided by involvement in biological processes and their p values 
adjusted for false discovery rate. As presented in table 3.2, results indicate that SSc 
epidermal cells have phenotype similar to that seen during wound healing, and have 
activated response to stress. Additionally, when compared to controls, the SSc epidermis 
has increased activation of innate and adaptive immune system, signal transduction, 
pathways implicated in platelet activation and blood coagulation. 
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Table 3.2.  Biological processes with increased proteins phosphorylation and/or 
abundance in SSc epidermis.  
Biological process p-value Number of proteins 
Protein phosphorylation 2.24e-16 23 
Immune response-activating signal transduction 7.10e-11 13 
TRIF-dependent toll-like receptor signaling 3.86e-10 9 
Response to growth factors 4.04e-10 13 
TLR4 signalling 1.41e-9 9 
Intracellular signal transduction 1.44e-9 22 
Cell surface receptor signaling 3.06e-9 26 
Pattern recognition receptor signaling 8.66e-9 9 
Innate immune response activation  1.09e-8 9 
Response to wounding 9.04e-8 18 
Platelet activation 2. 94e-7 10 
Blood coagulation 4.91e-7 13 
Hemostasis 5.07e-7 13 
Regulation of response to stress 2.29e-6 14 
Cell activation 7.58e-6 12 
Fibroblast growth factor receptor signaling 1.55e-5 7 
Epidermal growth factor receptor signaling 3.69e-5 7 
Negative regulation of cell death 3.69e-6 12 
T cell receptor signaling 6.69e-5 6 
Regulation of cell differentiation 8.74e-4 12 
Leukocyte migration 2.98e-3 6 
Signal transduction 3.23e-3 23 
Cellular response to stimulus 3.38e-3 26 
Cell-cell signalling 4.02e-3 11 
Posttranscriptional regulation of gene expression 4.54e-3 7 
Regulation of gene expression 6.97e-3 21 
Regulation of cell mobility 1.08e-2 7 
Chemotaxis 1.23e-2 8 
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p value after correction for false discovery rate. 
3.2.5.2  Proteins with downregulated phosphorylation levels or abundance in SSc 
epidermis 
Kinexus had also identified 17 proteins with decreased phosphorylation levels in SSc 
epidermis compared to control. The table 3.3 shows the details, including 
phosphorylation site and fold decrease. Interestingly, MAPT phosphorylation in SSc 
epidermis was reduced at one site while increased at the other when compared to control. 
Similar was true for phosphorylated HSBP1, for which immunostaining of skin sections 
revealed increased abundance and in the phospho-array was decreased, however the 
antibodies used in these techniques were designed to bind to different phosphorylation 
sites. Unfortunately, PhosphoSite database does not contain details on the effects of 
phosphorylation of particular locations for MAPT and HSBP1. MAPKAPK2 
phosphorylation activates its enzymatic activity, and HSP27 is one of its substrates. The 
induction of MAPKAPK2 signaling was shown to be a response to cytokines, stress and 
chemotactic factors, which is consistent with the hypothesis of activated epidermis in 
SSc. 
Increased phosphorylation at S78 is responsible for cell cycle regulation as is 
phosphorylation of H3.3 and INSR at that specific site according to PhosphoSite 
database. This along with previous results in this chapter showing abnormal 
differentiation of keratinocytes further indicates that SSc epidermal keratinocytes have an 
altered cell cycle. PTK phosphorylation at these particular sites activates the enzyme 
responsible for: cell adhesion, differentiation, stimulation of cell motility, cytoskeletal 
reorganization and transcription regulation. Cytoskeletal reorganization is also linked to 
phosphorylation of ADD1. CAV2 actions induced by phosphorylation include signal 
transduction, control of cellular growth control and apoptosis. While SAPK 
phosphorylation induces apoptosis and alters cell adhesion and transcription. Binding of 
phosphor into CTNNB1 at S45 leads to alteration of cell adhesion and motility, as well as 
protein degradation. In contrast phosphorylation of B23 at T199 inhibits its activity.  
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While phosphorylation of FOXO3 at position T32 also inhibits its activity, as well as 
alters genes transcription. 
Table 3.3. Decreased proteins phosphorylation in SSc epidermis. 
Protein Phospho site  Fold decrease p-value 
Heat shock 27 kDa protein beta 1 
(HSPB1) S15 0.64 0.0007 
Acetyl coenzyme A carboxylase 
(ACACB) S80 0.53 0.0008 
Histone (H3.3) S11 0.63 0.0016 
Lymphocyte-specific protein-tyrosine 
kinase (LCK) S157 0.72 0.0164 
Mitogen-activated protein kinase-
activated protein kinase 2 
(MAPKAPK2) 
T222 0.76 0.0178 
Focal adhesion protein-tyrosine kinase 
(PTK2) 
Y576 and 
S722 0.77 and 0.57 
0.0226 and 
0.0466 
Adducin alpha/gamma (ADD1/3)* S726/S693 0.78 0.0235 
Microtubule-associated protein tau 
(MAPT) S530 0.53 0.0270 
Nucleophosmin (B23) T199 0.61 0.0337 
Stress-activated protein kinase 1/2/3 
(MAPK8/11/12) T183+Y185 0.53 0.0354 
Caveolin 2 (CAV2) S36 0.44 0.0447 
Insulin receptor (INSR) Y999 0.57 0.0448 
Catenin (cadherin-associated protein) 
beta 1 (CTNNB1) S45 0.51 0.0474 
Forkhead-like transcription factor 1 
(FOXO3) T32 0.80 0.0502 
p value after correction for false discovery rate; * not included in the String analysis 
 
When modeled the interactions using String software majority showed close connections 
(Fig.3.11), similar to the results of upregulated phosphorylation. Those interactions 
indicated involvement of these proteins into several biological processes, including cell 
signaling and phosphorylation, as well as responses to growth factors.  
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Figure 3.11 Model of predicted interactions between proteins with significantly 
lower phosphorylation status in SSc epidermis. 
Interactions between proteins with decreased phosphorylation in SSc epidermis biopsies 
compared to controls (as identified by phosphoprotein microarray assay performed on 
control epidermis n=4 and SSc epidermis n=4) were modeled using String 9.1 software.  
 
 
 
The model of interactions between 40 proteins, which showed decreased phosphorylation 
levels or reduced expression in SSc epidermis (Pan-specific results), was then generated 
by String software. Its outcome showed interlinked pathways involved in many different 
biological processes (Fig.3.12).  
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Figure 3.12 Model of predicted interactions between proteins with significantly 
lower phosphorylation status or reduced abundance in SSc epidermis. 
Interactions between proteins with decreased phosphorylation in SSc epidermis biopsies 
compared to controls (as identified by phosphoprotein microarray assay performed on control 
epidermis n=4 and SSc epidermis n=4) were modeled using String 9.1 software. The lines 
between nodes represent protein associations, with stronger associations represented by thicker 
lines.  
 
The proteins characterized by reduced phosphorylation in SSc epidermis were then 
analysed using the String enrichment option for biological processes with false discovery 
rate correction. Those processes that reached significant p-value had a wide range and 
besides protein phosphorylation included, response to stress, DNA damage and growth 
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factors, as well as cell cycle regulation, immune response, and protein biosynthesis 
(Table 3.4). Although, proteins present associated with wound healing and keratinocyte 
differentiation were also identified amongst these with reduced abundance in SSc, the 
overall change in phosphorylation of proteins from these processes did not reach 
significance. 
  
Table 3.4.  Biological processes with decreased proteins phosphorylation or 
abundance in SSc epidermis.  
Biological process p-value Number of proteins 
Protein phosphorylation 7.029e-7 14 
Protein kinase activity 0.0002 11 
Response to stress 0.0018 12 
Regulation of protein metabolism 0.0013 13 
Cellular protein modification 0.0012 16 
Pattern recognition receptor signalling 0.0019 5 
Activation of innate immune response  0.0019 5 
Regulation of cell cycle 0.0024 10 
Response to DNA damage 0.00604 8 
Response to growth factors 0.0064 6 
Regulation of defense response 0.0073 7 
TLR4 signalling pathway 0.0076 4 
Positive regulation of apoptosis 0.01 8 
MAPK cascade 0.016 5 
Protein complex biogenesis and assembly 0.016 8 
Cell death 0.023 10 
Response to hormone stimulus 0.032 8 
Positive regulation of cell proliferation  0.052 7 
Homeostasis 0.053 9 
p value after correction for false discovery rate. 
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The figure 3.13 illustrates that many of the SSc epidermal proteins with lower 
phosphorylation are implicated in more than one biological function.  
 
 
Figure 3.13 Clautering of proteins with decreased phosphorylation in SSc epidermis 
into major groups controling cellular proliferation, differentiation and response to 
wounding and stress. 
Proteins with decreased phosphorylation in SSc epidermis biopsies compared to controls and 
were analysed for biological functions using String 9.1 software. The schematic representation 
demonstrates proteins belonging to three main identified clusters relevant to disease process and 
function of the epidermis.  
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In order to determine, if the SSc keratinocytes phenotype characterized by the changes 
described above will remain present during cell culture, I have tried to establish primary 
keratinocyte cultures. However, despite all the efforts I did not managed to optimize the 
protocol (see Appendix 2) to get enough cells from patients and controls to carry out 
these experiments. The main reason seems to be a limited number of actively 
proliferating keratinocytes that was isolated from 4mm forearm biopsy. The cells 
attached to the matrix produced by pre-seeded 3T3 fibroblasts divided slowly and most of 
the time started to differentiate before reaching a level of confluence required to passage 
or cryopreserve (Fig 3.14). Even though, some strains grew better after passaging them 
for just one time, they either did not attach to the dish or quickly started to differentiate.  
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Figure 3.14 Culture of primary human keratinocytes using 3T3 feeder cells. 
Images of keratinocytes were taken during different stages of cell culture. 
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3.3  Discussion 
In this chapter analysis of morphological characteristics of SSc epidermis was performed, 
in order to increase the limited existing knowledge of this part of the skin in the disease. 
The main emphasis was on comparing phosphorylation of proteins, and expression levels 
of proteins involved in differentiation and proliferation between control and SSc 
epidermis. Due to large differences between diffuse and limited SSc subsets, and to avoid 
additional variability between samples, and simplify interpretation of the results in my 
work I have focused on the dcSSc subset. As demonstrated above, SSc epidermis differs 
from control epidermis in many important aspects of morphology, protein expression and 
phosphorylation. 
 
The observed significant increase in epidermal thickness between basal layer and stratum 
corneum confirms some of the previous reports (Van Praet et al., 2011, Rossi et al., 
2010). This points to unbalance between epithelial cell proliferation and rate of terminal 
differentiation, which in normal conditions contributes to the overall epidermal thickness. 
In the healthy epidermis, proliferation at the basal layer is precisely balanced with 
desquamation in the cornified layer. Given the increased thickness in SSc skin, I sought 
to assess these two processes to determine whether increased proliferation, altered 
differentiation, or a combination of both was occurring.  
 
The analysis of the stratification process revealed presence of nuclei in the SSc stratum 
corneum (parakeratosis) in some of the SSc sections. This was consistent with previous 
reports (Van Praet et al., 2011, Maeda et al., 1993). Additionally, in SSc epidermis key 
structural cornified-envelope proteins: involucrin, loricrin and filaggrin were found much 
closer to the basal layer of keratinocytes than in healthy subjects, where the expression 
was limited to top granular layers. This indicates similarities between SSc epidermis and 
epidermis during wound re-epithelialisation (Mansbridge and Knapp, 1987). Such 
premature expression of differentiation markers was also reported to be associated with 
hyperproliferative keratinocytes of wounds and psoriasis skin (Hertle et al., 1992, Li et 
al., 2000). Moreover, the significantly thicker bands of expression of those cornified 
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envelope precursors, along with parakaretosis and atypical tightly packed stratum 
corneum, further points to an abnormal terminal differentiation process in SSc skin. Such 
partial differentiation could provide the basis to the thickening of epidermis seen in the 
disease. 
Another contributor to the SSc epidermal hypertrophy could be the observed increase in 
number of keratinocytes with a trend towards increase in proliferation marker ki-67. 
Previous reports concerning SSc keratinocytes proliferation were inconsistent and 
included hyperplasia (Milano et al., 2008), non- significant increase in number of 
proliferating cells (Pablos et al., 1999) as well as epidermal atrophy (Cooper et al., 1979). 
There may be several reasons of discrepancies between these results, including 
differences in patients cohorts of these studies, such as disease duration, mRSS, age of 
participants, and subset of SSc patients used in the study (Milano et al., 2008).  
The significant hypertrophy of basal and spinous keratinocytes may also be a factor 
contributing to the increased thickness of SSc epidermis. Keratinocyte size is known to 
be linked to its differentiation status; smaller size is associated with DNA synthesis and 
inhibition of differentiation, while larger size with stimulation of differentiation and 
inhibition of cell division (Watt and Green, 1981). The presented evidence is consistent 
with other results of keratinocyte differentiation analysis in SSc epidermis, described in 
this chapter. Thus further strengthen evidence of disrupted terminal differentiation of SSc 
keratinocytes, and supports previous report of abnormal expression of K14 and K1/K10 
in SSc epidermis (Aden et al., 2008).  
Heat shock protein 27 (HSBP1) is a member of small heat shock protein family, which 
acts as molecular chaperone able to sequester damaged proteins and prevent their 
aggregation. This property is regulated via reversible phosphorylation in response to 
variety of stimuli including mitogens, and inflammatory cytokines such as IL-1β and 
TNFα. The phosphorylation of HSBP1 by mitogen-activated protein kinase-activated 
kinases 2   and 3 (MK2/3) or PCK delta is Akt or ERK-dependent (Gandour-Edwards et 
al., 1994, Maizels et al., 1998). Phosphorylation of HSBP1 results in dissociation of large 
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multi-meric complex and loss of chaperoning activity (Rogalla et al., 1999). Other 
functions of HSBP1 include control of apoptosis (Arrigo, 2000), differentiation (Hell-
Pourmojib et al., 2002) and cell migration through regulation of actin remodeling. 
The non-phosphorylated form of HSBP1 inhibits actin polymerization while its 
phosphorylation promotes actin polymerization and cell migration (Benndorf et al., 
1994). In addition to its role in actin remodeling, HSBP1 contributes to the expression of 
pro-inflammatory mediators including IL-6 and IL-8 (Alford et al., 2007). Moreover, 
HSBP1 expression and phosphorylation was demonstrated to regulate fibroblast 
adhesion, and wound contraction (Hirano et al., 2004, Hirano et al., 2002). HSBP1-
deficient mice show a significant impairment in wound healing associated with collagen 
deposition, increased inflammation and enhanced neutrophil infiltration (Crowe et al., 
2013). Therefore, discovery of increased phosphorylation at S82, with simultaneous 
reduction of phosphorylation at S15 in the SSc epidermis might be important. However, 
due to the limited knowledge as to the effect of these phospho sites on the HSBP1 
functions, it is difficult to discuss the implications beyond keratinocyte differentiation.  
Unfortunately, the observations of altered differentiation and proliferation of SSc 
keratinocytes could not be modeled in vitro due to issues with primary keratinocytes cell 
culture. However, the experiments with primary keratinocytes and fibroblasts are 
essential to confirm the effect of SSc epidermis on dermal fibroblasts (see chapter 4), thus 
it is a key issue to establish successful cell culture of this cells. To achieve this aim a 
bigger size of biopsy could be attempted or else optimally growing strains of SSc 
keratinocytes could be immortalized. The last option is not ideal due to the fact that a 
strain with enhanced proliferation is selected, which does not have to represent the 
majority of keratinocytes. Moreover, during the immortalization process itself some 
changes could be introduced, that could lead to further differences between immortal and 
typical SSc keratinocytes. Nevertheless, overall this could be outweighed by benefits of 
almost unlimited number of SSc keratinocytes.  
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All the results presented in this chapter indicate abnormal differentiation of SSc 
keratinocytes, which could be an effect of contact with stiff and fibrotic ECM of the SSc 
dermis, or differential expression of soluble factors by different skin components. Such 
alteration in keratinocytes differentiation combined with abnormal phosphorylation could 
be linked to cell activation, and impact on cell signalling and protein secretion form the 
epidermis, and therefore modify epidermal-dermal cross talk, as well as interactions with 
other cell types. Alterations of protein phosphorylation affecting a variety of different 
biological processes suggest, that they may be associated in SSc skin pathogenesis, either 
by generating pathological changes or as a compensatory mechanism to those changes. 
Thus highlighting the idea that not one single pathway could be responsible for SSc skin 
disease, but many are involved in creation of the SSc phenotype. 
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Chapter Four 
 
Results: SSc Epidermis Contribution to Fibrosis and Inflammation 
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4.1  Introduction 
SSc is a rheumatic connective tissue disorder of unknown etiology, and its common 
features include autoimmunity, inflammation, and vasculopathy, leading to fibrosis 
(Kahaleh and LeRoy, 1999). Central to SSc pathogenesis is fibroblast activation (Jimenez 
and Bashey, 1977, Abraham et al., 2007), which in SSc lesions persist as myofibroblast, 
with enhanced ability to produce collagens, adhere, and contract extracellular matrix 
(ECM) (Jimenez et al., 1986). Although, the majority of studies were performed on the 
dermis, there is increasing evidence supporting a key role for the epidermis in promoting 
dermal fibrosis (Bellemare et al., 2005, Simon et al., 2011, Niessen et al., 2001, Meyer et 
al., 2011, Funayama et al., 2003, Mustoe and Gurjala, 2011).  
Epithelial cells during tissue repair can stimulate fibroblasts via interleukin 1 (IL-1) 
(Maas-Szabowski and Fusenig, 1996) to secrete growth factors and cytokines essential 
for epithelial cells growth (Smola et al., 1993). The keratinocytes can also regulate 
fibroblast expression of ECM modulating genes such as CTGF and type I collagen 
(Koskela et al., 2010, Ghaffari et al., 2009). In organotypic co-cultures with epithelial 
cells, fibroblasts contract more readily than in monolayers (Shephard et al., 2004a). The 
correct epithelial-mesenchymal interactions are essential for skin homeostasis 
(Szabowski et al., 2000, Maas-Szabowski et al., 2000) and repair (Werner et al., 2007, El 
Ghalbzouri and Ponec, 2004). These interactions are based on the production of soluble 
factors (Smola et al., 1993, Denton et al., 2009, Ghahary et al., 2004) and cell-matrix 
interactions (Gailit and Clark, 1994, Watt and Fujiwara, 2011).  
A previous report from our lab has demonstrated that SSc keratinocytes are activated and 
resemble those seen in wound healing (Aden et al., 2008). Injured epidermal cells are 
known to secrete pro-inflammatory cytokines and chemokines (Luger and Schwarz, 
1990), as well as growth factors affecting the phenotype and proliferation of dermal 
fibroblasts (Werner et al., 2007). Considering abnormal differentiation and increased cell 
number in SSc, which were presented in the previous results chapter of this thesis, it is 
possible that such anomalies can be associated with changes in soluble factors released by 
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epidermis and dermis.  
In order to establish if that is the case I have used profiling of key growth factors and 
cytokines implicated in SSc pathogeneis and in keratinocyte-fibroblast cross talk, 
including IL-6, IL-8, CCL20, MCP-1 and S100A9 which were used as markers of 
inflammation, as well as IL-1α, IL-β, and their inhibitor IL1-ra. In keeping with this idea 
I selected targets which were previously reported to be elevated in the skin of SSc 
patients, including inmunostaining showing increased expression of IL-6 (Khan et al., 
2012), CCL20 (Tao et al., 2011), and MCP-1 (Karrer et al., 2005) by SSc keratinocytes 
and fibroblasts. Also during the timecourse of the work on this thesis data showing 
increased S100A9 in SSc was reported (Xu et al., 2013b). However, there is no 
information on SSc epidermal expression of other targets, including IL-1α as researchers 
have focused on dermal part of the skin (Kawaguchi 2004*). 
CTGF and PDGF were used as fibrotic markers, while HGF as anti-fibrotic marker 
implicated in epithelial repair. All of these were previously reported to be increased in the 
SSc skin (Igarashi et al., 1996, Frost et al., 2012, Yamakage et al., 1992), but without 
specific analysis of their role in the disease epidermis. VEGF was used as indicator of 
angiogenesis and it has been previously described to be elevated in SSc keratinocytes 
(Davies et al., 2006). FGF-2, a major growth factor released by keratinocytes to stimulate 
growth of fibroblasts also known to be overexpressed in the SSc skin (Lawrence et al., 
2006) was use as indicator of epidermal- dermal cross talk. 
This chapter focuses on assessment of differences in concentrations of these key soluble 
factors. Their release by epidermal and dermal explants into conditioned media was 
measured using Luminex or ELISA, and the results were validated by 
immunohistochemistry analysis of skin sections, as well as evaluation of mRNA levels in 
the epidermal blister sheets. 
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4.2  Specific methods 
4.2.1    Lactate dehydrogenase (LDH) assay 
Aliquots of 50µl of the media conditioned overnight with SSc or control dermis, and 
epidermis were transferred to 96-well flat bottom plate in duplicate wells and assayed 
using LDH Cytotoxicity Assay Kit (Thermo Scientific). In brief to each sample 50µl of 
the Reaction Mixture was added and mixed. The plate was then incubated at room 
temperature for 30 minutes protected from light. After that time, the Stop Solution was 
added and mixed, and absorbance was measured at 490nm and 680nm on microplate 
reader (Mithras LB940). After correcting for blank sample absorbance (serum free media 
without cells), cytotoxicity was calculated for each sample by subtracting the absorbance 
at 490nm from the absorbance at 680nm. 
 
4.3  Results 
Figures 4.1 to 4.8, 4.10, 4.13 to 4.17, 4.20 and 4.21 were adapted from the paper 
(Nikitorowicz-Buniak et al., 2014). 
4.3.1 Secrotome assay analysis 
4.3.1.1 LDH assay 
LDH is an enzyme present in the cytoplasm, often used in cell viability and cytotoxicity 
assays. Upon damage to plasma membrane, the membrane integrity is lost and LDH is 
released into cell culture media, where it can be quantified by a coupled enzymatic 
reaction. LDH catalyzes the conversion of lactate to pyruvate via reduction of NAD+ to 
NADH. NADH is then used to reduce a tetrazolium salt to a red formazan product, which 
is then measured spectrophotometrically.  
Therefore, this assay was used to evaluate viability of the cells in the epidermal and 
dermal explants after overnight incubation in serum free media (Fig.4.1). The mean level 
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of LDH in the media conditioned with SSc epidermis was 0.17±0.05, control epidermis 
0.13±0.05, SSc dermis 0.10±0.01, and control dermis 0.18±0.03 while LDH positive 
control was 1.1±0.02. The values for samples were between 6 and 10 fold lower than the 
positive control. As expected, there were no significant differences in LDH release 
between SSc and control samples or between epidermal and dermal explants. This 
indicates that majority of cells within epidermal and dermal explants were viable, and the 
concentration of growth factors and cytokines measured in the conditioned media was 
due to active release process, rather than presence due to release during cell death. 
 
 
 
Figure 4.1. LDH in the conditioned media.  
Skin biopsies were taken from healthy controls (n=17) and patients (n=7). The epidermis was 
separated from the dermis using trypsin-EDTA and explants were then incubated overnight with 
serum free media. The graph shows distribution with mean ± SEM concentration of LDH in the 
conditioned media. Statistical significance was assessed by Mann-Whitney U test. P value was 
non-significant. 
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4.3.1.2  Secretion of selected cytokines, chemokines and growth factors into 
conditioned media by SSc epidermal and dermal explants 
After confirming that viability of cells was not significantly afected during overnight 
incubation, media was subjected to analysis by Luminex or ELISA. In order to establish 
potential differences in release of inflammatory cytokines and chemokines, angiogenic 
and profibrotic growth factors, as well as proteins associated with wound healing, 
conditioned media samples were assayed for classical markers of these processes 
involved in SSc pathogenesis. 
No differences in CCL20 levels in media conditioned were detected in SSc epidermis and 
dermis samples when compared to control (Fig.4.2a). Similar, MCP-1 epidermal samples 
were at the same level (Fig.4.2b); however, a 1.4 higher release from control dermis was 
observed when compared with SSc dermis and showed a trend towards significance 
(p=0.2136). The results of IL-8, another major mediator of inflammatory response, also 
showed only a trend towards higher release from SSc epidermis than controls with 2.2 
fold increase (p=0.0881) but, no differences were observed between control and SSc 
dermal levels (Fig.4.2c). 
Unexpectedly, an important cytokine IL-6, previously reported to be overexpressed in 
SSc skin, revealed only a trend towards significance (p=0.3889), although with 4 fold 
higher release from SSc epidermis than from control; while levels released by control and 
SSc dermis were similar (Fig.4.2d). However, a few samples classified as outliers (over 
200 fold deference from the average) were removed from analysis, reducing statistical 
power.  
Out of all inflammatory mediators tested, the only significant overproduction was 
observed with S100A9 from SSc epidermis, which showed 2.7 fold increase when 
compared to control samples (p<0.05) (Fig.4.2e). Moreover, this pleiotropic modulator of 
inflammation in SSc also showed a trend towards enhanced release form SSc dermis 
compared to controls (321.5±48.79 and 258.6±83.45, p=0.1797).  
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Figure 4.2. Cytokines and chemokines in the conditioned media.  
Skin biopsies were taken from healthy controls (n=12 for all but IL-6 and S100A9, where n=6) 
and patients (n=12 for all but IL-6 and S100A9, where n=6). The epidermis was separated from 
the dermis and explants were incubated overnight with serum free media. The graphs show 
distribution with mean ± SEM concentration of (a) CCL20; (b) MCP-1; (c) IL-6; (d) IL-8; (e) 
S100A9. Statistical significance was assessed by Mann-Whitney test; *p<0.05. 
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Also contradicting previous report (Kawaguchi et al., 2006) showing overexpression of 
IL-1α by SSc dermal fibroblast, this pro-inflammatory cytokine was undetected in many 
dermal samples, especially SSc conditioned media. Where the concentration was 
measured (Fig 4.3a), a trend towards higher release from control dermis with 5 fold 
increase was observed, (p<0.05), while no differences were noted in the levels in the 
control and SSc epidermal samples.  
Levels of another IL-1 family member, IL-1β were in all but 2 SSc epidermal conditioned 
media below level of detection (Fig.4.3b). More successfully measured was concentration 
of the IL-1 receptor antagonist, IL-1ra although no significant differences were detected 
between samples (Fig.4.3c).  Interestingly, epidermis seem to be primarily responsible for 
release of this antagonist with levels in control conditioned epidermis 906.3±431.3 and 
1219±537.2 in SSc epidermis compared to much lower in control and SSc dermis 
(164.2±63.02 and 134.6±70.70).  
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Figure 4.3. IL-1 family members in the conditioned media.  
Skin biopsies were taken from healthy controls (n=12) and patients (n=12). The epidermis was 
separated from the dermis using trypsin-EDTA and explants were then incubated overnight with 
serum free media. The graphs show distribution with mean ± SEM concentration of  (a) IL-­‐1α;	   
(b) IL-­‐1β;	   (c) IL-1ra. Statistical significance was assessed by Mann-Whitney U test. P value was 
non-significant. 
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One of the key pro-fibrotic growth factors, CTGF was released in 4.2 higher 
concentrations from SSc epidermis than from control epidermis (p<0.05). Surprisingly, 
concentrations in samples incubated with SSc dermal explants were below levels of 
detection, while the mean level in control dermal samples was also low (Fig.4.4a). 
Whereas, anti-fibrotic HGF release into the media was found to be increased by 4.2 fold 
in SSc epidermis (p<0.005) and 1.6 fold in SSc dermis (p<0.05) compared to levels in 
healthy control subjects (Fig.4.4b). Although, results for the dermal samples were 
predicted, the significantly increased levels in epidermal samples were unforeseen.  
Angiogenic and mitogenic towards fibroblasts, FGF-2 showed a trend towards higher 
levels in media conditioned by SSc epidermis compared to controls (148.7±26.42 and 
117.2±14.76, p=0.2981), while no differences were observed between control and SSc 
dermal samples (Fig.4.4c). No significant differences in levels of secreted VEGF-A, 
PDGF-AA or G-CSF were observed, when evaluated against levels released by control 
dermal tissue (Fig.4.4d-f). Though, 1.8 times raised concentrations of VEGF-A (p=0.14) 
and 2.7 times higher PDGF-AA levels (p=0.2) found in SSc epidermis conditioned media 
trended towards significance. GM-CSF in the conditioned media could not be measured 
as it was below assay detection level. 
Since, SSc epidermis demonstrated significantly increased levels of S100A9, CTGF and 
HGF, those molecules were selected for further investigation. 
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Figure 4.4. Growth factors in epidermis and dermis conditioned media.  
Skin biopsies were taken from healthy controls (n=12 for all but PDGF-AA where n=6) and 
patients (n=12 for all but PDGF-AA where n=6). The epidermis was separated from the dermis 
using trypsin-EDTA and explants were then incubated overnight with serum free media. The 
graphs show distribution and mean ± SEM for media concentration of  (a) CTGF;  (b) HGF; (c) 
FGF-2; (d) VEGF;  (e) PDGF-AA; (f) G-CSF. Statistical significance was assessed by Mann-
Whitney U test; * p< 0.05, **p<0.005. 
CCN2
C
on
ce
nt
ra
tio
n 
(p
g/
ul
)
 C
on
tr 
ep
i
SS
c e
pi
Co
ntr
 de
rm
SS
c d
erm
0
200
400
600
800
FGF-2
C
on
ce
nt
ra
tio
n 
(n
g/
ul
)
 C
on
tr 
ep
i
SS
c e
pi
Co
ntr
 de
rm
SS
c d
erm
0
100
200
300
400
PDGF-AA
C
on
ce
nt
ra
tio
n 
(n
g/
ul
)
 C
on
tr 
ep
i
SS
c e
pi
Co
ntr
 de
rm
SS
c d
erm
0
5
10
15
HGF
C
on
ce
nt
ra
tio
n 
(n
g/
ul
)
 C
on
tr 
ep
i
SS
c e
pi
Co
ntr
 de
rm
SS
c d
erm
0
500
1000
1500
VEGF-A
C
on
ce
nt
ra
tio
n 
(n
g/
ul
)
 C
on
tr 
ep
i
SS
c e
pi
Co
ntr
 de
rm
SS
c d
erm
0
100
200
300
400
500
G-CSF
C
on
ce
nt
ra
tio
n 
(n
g/
ul
)
 C
on
tr 
ep
i
SS
c e
pi
Co
ntr
 de
rm
SS
c d
erm
0
20
40
60
a" b"
c" d"
e" f"
**"
*"
*"
145 
 
4.3.2 Detection of CTGF, HGF and S100A9 in the SSc skin using 
immunohistochemistry 
In order to confirm or refute the results of enhanced CTGF, HGF, and S100A9 release 
into the conditioned media by SSc epidermis, immunohistochemistry was performed on 
human tissue sections . In healthy controls, positive staining for CTGF (Fig.4.5) was 
mainly limited to the epidermis, while blood vessels and basal membrane showed only 
weak staining. In contrast, SSc sections showed pronounced staining in the epidermis, the 
epithelial/dermal junction (Fig.4.5i) and around blood vessels (Fig.4.5ii). Interestingly, 
more CTGF was present at epidermal-dermal junction in early stages of disease than 
established, where it was present in the reticular dermis, especially around vasculature, as 
well as in the epidermis. This suggests that the epithelial cells express CTGF that 
accumulates at the epithelial /dermal junction possibly stimulating dermal fibrosis. 
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Figure 4.5. Elevated levels of CTGF in SSc epidermis and at the epidermal-dermal 
junction.  
Representative images of CTGF staining performed on forearm skin sections taken from early 
and late SSc patients and controls counterstained with hematoxylin. (i) Epidermal-dermal 
junction, (ii) blood vessel. Ctrl-control 
 
The immunohistochemical staining of HGF maintained a very different pattern than 
CTGF, with stronger staining (Fig.4.6) in healthy epidermis compared to SSc and no 
changes at the epidermal-dermal junction (Fig.4.6i). However, more HGF positive cells 
were present in SSc dermis (Fig.4.6ii) than in controls. There was no staining in or 
around the vasculature. No differences in staining pattern were observed between early 
and established disease.  
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Figure 4.6. HGF staining in SSc and control skin.  
Representative images of HGF staining performed on forearm skin sections of SSc patients and 
controls counterstained with hematoxylin. (i) Epidermal-dermal junction, (ii) dermis. Ctrl-control 
 
The last of the significantly increased molecules in the media conditioned with SSc 
epidermis was S100A9, a calcium binding protein usually found as a dimer with S100A8. 
Therefore, immunofluorescent staining was used to determine the location of S100A9 
and its heterodimer partner, S100A8 in skin sections. Staining confirmed striking 
elevated expression of S100A9 in SSc epidermis when compared with control subjects 
(Fig.4.7). The S100A9 signal was observed throughout SSc epidermis, while in the 
healthy skin it was present only in some epidermal appendages. S100A8 staining was 
observed only in the most upper parts of SSc epidermis. Only single cells were double 
labeled in the dermis in control and disease tissue.  
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Figure 4.7. Increased levels of S100A9 staining in the epidermis of SSc patients.  
Representative images of double immunofluorescent staining for S100A8 and S100A9 performed 
on forearm skin sections of SSc patients and controls. 
 
 
4.3.3 mRNA levels of selected growth factors and cytokines in epidermal blister 
sheets 
Since increase in CTGF and S100A9, but not S100A8, in the SSc epidermis as judged by 
immunohistochemistry, the levels of the mRNA for these proteins were also investigated. 
RNA was extracted from epidermal blisters sheets taken from controls (HC n=9) and SSc 
patients (dcSSc n=24, lcSSc n=8) in order to measure relative expression of CTGF, HGF, 
S100A9 and proteins closely associated with them mRNA using qPCR. The values were 
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normalized relative to TUBB mRNA expression using the ΔΔCT method and the results 
presented as mean ± SEM. The one-way Anova test was used to calculate statistical 
significance, * p<0.05.  
Results of blister epidermal sheets analysis were consistent with the staining, showing 
significantly increased in CTGF mRNA levels in dcSSc epidermis compared to controls 
and lcSSc (both p<0.05) (Fig.4.8). The mean levels in control samples (0.2±0.067) and 
lcSSc (0.17±0.049) were similar, and around 2.5 fold lower than in dcSSc (0.5±0.102). 
 
 
Figure 4.8. Increased CTGF mRNA in the epidermal blister sheets of dSSc patients.  
Levels of CTGF mRNA were measured in the epidermal blister sheets of SSc patients and 
controls. The results are presented as mean ± SEM. The one-way ANOVA followed by Tukey’s 
multiple comparisons test was used to calculate statistical significance, * p<0.05. HC- control 
(n=9), dcSSc – diffuse SSc (n=24), and lcSSc- limited SSc (n=8). 
 
To establish if another CCN family member, NOV mRNA is also altered in the SSc 
epidermis its levels were measured in epidermal blister sheets (Fig.4.9a). Relative mRNA 
level of control (0.04±0.007) was significantly lower than those from dcSSc patients 
(0.08±0.009) p<0.05). Post hoc analysis did not show any changes between and lcSSc 
samples (0.05±0.01) and controls or dcSSc samples. 
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PAI-1 along with CTGF and NOV is often implicated in fibrotic disease, including SSc. 
However, there are no reports about its levels in SSc epidermis, thus they were measured 
in the blisters sheets. Results of the qPCR analysis showed that no differences were 
detected in PAI-1 mRNA level between control, lcSSc and dcSSc samples (Fig.4.9b). 
 
 
Figure 4.9. Increased NOV mRNA in the epidermal blister sheets of dSSc patients.  
Levels of (a) NOV and (b) PAI-1 mRNA were measured in the epidermal blister sheets of SSc 
patients and controls. The results are presented as mean ± SEM. The one-way ANOVA followed 
by Tukey’s multiple comparisons test was used to calculate statistical significance, * p<0.05. HC- 
control (n=9), dcSSc – diffuse SSc (n=24), and lcSSc- localized SSc (n=8). 
 
 
In contrast to strong S100A9 staining of SSc epidermis no difference was observed in the 
levels of S100A9 mRNA in the blister sheets. Equally, no difference was observed in the 
levels of its heterodimer partner S100A8 mRNA (Fig.4.10). Collectively, these results 
may indicate that S100A9 protein expression is regulated at post-transcriptional level. 
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Figure 4.10. S100A8 and S100A9 mRNA in the epidermal blister sheets of dSSc.  
Levels of (a) S100A8 and (b) S100A9 mRNA were measured in the epidermal blister sheets of 
SSc patients and controls. The results are presented as mean ± SEM. The one-way ANOVA test 
was used to calculate statistical significance. P value was non-significant. HC- control (n=9), 
dcSSc – diffuse SSc (n=24), and lcSSc- localized SSc (n=8). 
 
TLR4, which transduce signals from bacterial lipopolysaccharide (LPS), as well as 
endogenous DAMPs including S100A9, was recently shown to be overexpressed in SSc 
skin and make fibroblasts more responsive to pro-fibrotic stimulation by TGF-β1 
(Bhattacharyya et al., 2013). However, analysis of TLR4 mRNA in epithelial blister 
sheets showed it to be present at similar levels in control and both subsets of SSc 
(Fig.4.11). 
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Figure 4.11 TLR4 mRNA in the epidermal blister sheets of dSSc patients.  
Levels of (a) S100A8 and (b) S100A9 mRNA were measured in the epidermal blister sheets of 
SSc patients and controls. The results are presented as mean ± SEM. The one-way ANOVA test 
was used to calculate statistical significance. P value was non-significant. HC- control (n=9), 
dcSSc – diffuse SSc (n=24), and lcSSc - localized SSc (n=8). 
 
Although, increase in the IL-6 mRNA levels in SSc dermal fibroblast was reported (Khan 
2012), there is no data available on IL-6 mRNA levels in the epidermis or epidermal 
keratinocytes of SSc patients. Previous report from our group showed extensive IL-6 
staining in SSc epidermis and to determine if its production is also increased on the 
mRNA level its quantities were assessed in the epithelial sheets. The results indicated that 
IL-6 relative mRNA levels in dcSSc were trending towards lower (p=0.2) when 
compared with levels in control blister sheets, or even lcSSc (Fig.4.12). However, the 
quantity of mRNA does not have to be parallel to the protein levels. Due to 
posttranslational events even despite the normal levels of gene copies the protein may be 
significantly elevated.  
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Figure 4.12. IL-6 and IL-8 mRNA in the epidermal blister sheets of SSc patients.  
Levels of (a) IL-6 and (b) IL-8 mRNA were measured in the epidermal blister sheets of SSc 
patients and controls. The results are presented as mean ± SEM. The one-way ANOVA test was 
used to calculate statistical significance. P value was non-significant. HC- control (n=9), dcSSc – 
diffuse SSc (n=24), and lcSSc - localized SSc (n=8). 
 
Finally, HGF the last soluble factor identified by conditioned media study to be released 
at higher concentrations from SSc epidermis. Its mRNA was undetectable in the 
epidermal sheets of both patients and controls (data not shown), suggesting that the 
increased HGF protein released from epidermal explants is not being transcribed locally 
but most likely is produced by dermal fibroblasts.  
 
4.3.4  Effect of S100A9 on dermal fibroblasts. 
As ELISA on explant conditioned media and histology on skin sections have shown 
S100A9 to be upregulated in the epidermis of SSc patients, the next step was to establish 
S100A9 effects on dermal fibroblasts. In particular, I was interested in possible changes 
to fibroblast migration, proliferation and viability, as well as CTGF expression, as these 
could impact on pro-fibrotic phenotype of fibroblasts. Therefore, serum starved (DMEM 
containing 1% FBS) dermal fibroblasts from controls (n=4) and SSc patients (n=4) were 
incubated with recombinant human S100A9 (rhS100A9) (Sino Biological).  
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In order to assess impact of S100A9 on viability of fibroblasts, prior to addition of 
rhS100A9 cells were incubated with mitomycin C (10µg/ml) to stop cell proliferation. 
After 72hrs the crystal violet method was used to compare differences in cell numbers 
between control and SSc fibroblasts treated with different concentrations of S100A9. The 
results revealed that S100A9 did not have any significant effect on control and SSc 
fibroblast viability when compared with untreated cells (Fig.4.13a).  
 
 
Figure 4.13. Effect of S100A9 on viability and proliferation of dermal fibroblasts.  
Dermal fibroblasts were incubated with rhS100A9. (a) Viability and (b) proliferation were 
measured in dermal fibroblasts of SSc patients and controls, and normalised against untreated 
samples. The results are presented as mean ± SEM of three independent experiments. The 
student’s t- test was used to calculate statistical significance, * p<0.05. 
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The proliferation rate was assessed 48hrs after the treatment with rhS100A9 using 
Proliferation Assay (Promega), and revealed differences in response between control and 
SSc fibroblasts (Fig.4.13b). The percentage change in proliferation as compared to 
untreated samples showed that, addition of S100A9 at concentrations 1µg/ml and 2µg/ml 
induced increased proliferation in SSc fibroblast (p<0.05), while in control fibroblast it 
had an opposite effect and decreased proliferation. That difference in response of SSc and 
control fibroblasts was significant at 1µg/ml and 2µg/ml of S100A9 (p<0.05).  
For in-vitro scratch assay fibroblasts from healthy controls (n=3) and SSc patients (n=3) 
were pretreated with mitomycin C (10µg/ml), to assure that the scratch closure is due to 
migration rather that proliferation, and incubated with rhS100A9. The scratch was 
assessed after 48 hours and presented as percentage of scratch closure (Fig.4.14). S100A9 
at 0.5µg/ml enhanced migration of the fibroblasts from both control and SSc patients 
(p<0.05, p<0.005) compared to unstimulated cells. Moreover, this increased migration 
was also observed in SSc fibroblasts stimulated with 2µg/ml (p<0.005), but not the 
control fibroblasts. 
 
Figure 4.14. Effect of S100A9 on migration of dermal fibroblasts.  
Dermal fibroblasts were incubated with rhS100A9 migration was measured in dermal fibroblasts 
of SSc patients and controls. The results are presented as mean ± SEM of three independent 
experiments. The student’s t- test was used to calculate statistical significance, *p<0.05, 
**p<0.005. 
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By stimulation of fibroblast proliferation and migration, S100A9 may take an active role 
in propagation of fibrotic changes in the SSc skin. To further investigate consequences of 
increased concentrations of S100A9 in SSc skin on fibroblast, the effect on production of 
fibrotic markers by dermal fibroblasts was evaluated. Monolayers of dermal fibroblasts 
from controls (n=3) and SSc patients (n=3) treated with S100A9 for 24hrs were lysed for 
mRNA, and those treated for 48hrs were lysed for proteins. Western blots revealed that 
production of CTGF, after incubation with S100A9, was increased in SSc fibroblasts 
(p=0.05) but not in controls, when normalised against GAPDH (Fig.4.15). 
 
Figure 4.15. CTGF production by dermal fibroblasts in response to S100A9.  
Dermal fibroblasts were incubated with rhS100A9. (a) Membranes were probed with anti- CCN2 
antibodies to detect CCN2 levels in cell lysates after 48hour treatment. Anti-GAPDH antibody 
was used as a loading control. (b) Densitometry of the western blot was measured and normalised 
against GAPDH. Each panel represents the results of two independent experiments. Data was 
presented as mean ± SD. Statistical significance was assessed by student’s t-test; *p≤0.05. 
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However, the results of type I collagen and α-SMA expression after incubation with 
S100A9 were not consistent between different primary cell strains (Fig.4.15). Type I 
collagen was detected only in a few strains, and in those strains it was upregulated by 
S100A9. α-SMA expression either increased after treatment with S100A9 or did not 
change. Interestingly, in the group where there were no differences in α-SMA expression 
after S100A9 treatment, the basal levels of α-SMA were high. This may suggest that 
those cells might have been already activated despite serum starvation, and could not be 
further stimulated by addition of S100A9. 
 
Figure 4.16. Collagen and α-SMA production in response to S100A9. 
Dermal fibroblasts were incubated with rhS100A9. Membranes were probed with anti- collagen 
type I and α-SMA antibodies to detect their levels in cell lysates after 48hour treatment. β-tubulin 
was used as a loading control. Images represent the results of two independent experiments.  
 
As CTGF expression is mainly regulated at the transcription levels, to confirm that 
S100A9 induces increase in CTGF protein, the mRNA levels were measured after 24hr 
incubation with S100A9. Due to large inter run variability between experiments the fold 
change from basal levels was calculated. The results of the analysis confirmed S100A9 
enhancing effect on CTGF production (Fig.4.17). A significant increase was observed in 
response of both control and SSc fibroblasts. The stimulating effect of S100A9 in SSc 
cells was seen at 0.5µg/ml and 1.5µg/ml (p=0.01 and p= 0.04 respectively), while control 
cells required higher concentration	   (p<0.05). This may be due to the higher levels of 
TGF-β in the SSc skin that could sensitise cells to release CTGF in response to S100A9 
so lower levels of S100A9 are required in comparison to control fibroblasts. 
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Figure 4.17. Effect of S100A9 on CTGF mRNA levels in dermal fibroblasts.  
Dermal fibroblasts were incubated with rhS100A9. Relative expression of CTGF mRNA after 
24hr treatment was measured with qPCR. The values were normalized relative to TBP mRNA 
expression using the ΔΔCT method. The results are presented as mean ± SEM of fold change 
form basal expression. The student’s t-test was used to calculate statistical significance, * p≤0.05. 
Increased levels of collagen type I are also often seen in fibrosis; therefore its mRNA 
levels were assessed in dermal fibroblast after stimulation with S100A9. However, in 
contrast to CTGF, no significant differences were seen between treated and untreated 
fibroblasts (Fig.4.18). 
 
Figure 4.18. Effect of S100A9 on type I collagen mRNA levels in dermal fibroblasts.  
Dermal fibroblasts were incubated with rhS100A9. Relative expression of collagen type I mRNA 
after 24hr treatment was measured with qPCR. The values were normalized relative to TBP 
mRNA expression using the ΔΔCT method. The results are presented as mean ± SEM of fold 
change form basal expression. The student’s t- test was used to calculate statistical significance. P 
value was non-significant. 
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As described in the introductory chapter of this thesis, IL-6 and IL-1α are key pro-
inflammatory cytokines. In addition IL-1α plays critical role in maintaining cross talk 
between keratinocytes and fibroblasts. Therefore, it was important to establish if S100A9 
influences mRNA levels of these cytokines. Considerable differences were observed in 
the response to the recombinant S100A9 between different strains of primary dermal 
fibroblasts, especially controls. However, even despite this variability a clear trend 
towards increased IL-6 was noted in SSc fibroblasts incubated with 0.5µg/ml of S100A9 
(p=0.07) (Fig.4.19a). However, no changes were seen in IL-1α mRNA levels (Fig.4.19b). 
 
Figure 4.19. Effect of S100A9 on IL-6 and IL-1α mRNA levels in dermal fibroblasts.  
Dermal fibroblasts were incubated with rhS100A9. Relative expression of IL-6 and IL-1α mRNA 
after 24hr treatment was measured with qPCR. The values were normalized relative to TBP 
mRNA expression using the ΔΔCT method. The results are presented as mean ± SEM of fold 
change form basal expression. The student’s t- test was used to calculate statistical significance. P 
value was non-significant. 
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After studying the response of fibroblasts to stimulation of S100A9 it was important to 
find out which receptor is responsible for the downstream signaling. I hypothesized that 
the TLR4 pathway is involved in the process. Therefore an experiment was set up to 
establish if inhibition of TLR4 would block S100A9 mediated CTGF release. Indeed a 
selective TLR4 inhibitor TAK-242 TLR4 significantly reduced CTGF mRNA levels in 
cells stimulated with S100A9 (p<0.05) (Fig. 4.20) 
 
Figure 4.20. Effect of TLR4 inhibition on S100A9 mediated CTGF mRNA levels in 
dermal fibroblasts.  
Dermal fibroblasts were incubated with TAK-242 (1µM) prior to stimulation with rhS100A9 
(1.5ug/ml). Relative expression of CTGF mRNA after 6hr treatment was measured with qPCR. 
The values were normalized relative to TBP mRNA expression using the ΔΔCT method. The 
results are presented as mean ± SEM of fold change form basal expression. The student’s t- test 
was used to calculate statistical significance (* p≤0.05). 
 
Similar effect of the TLR4 inhibitor on CTGF secretion upon stimulation with S100A9 
was also observed on the protein level (Fig. 4.21).  
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Figure 4.21. Effect of TLR4 inhibition on S100A9 mediated CTGF levels in dermal 
fibroblasts.  
Dermal fibroblasts were incubated with TAK-242 (1µM) prior to 48hrs stimulation with 
rhS100A9 (1.5ug/ml). (a) CTGF in cell lysates (HC n=3, SSc n=3). (b) Quantitative analysis of 
the Western blot normalized against GAPDH. The results are presented as mean ± SEM. The 
student’s t- test was used to calculate statistical significance, * p≤0.05. 
 
4.3.5  Effect of S100A9 on keratinocytes. 
Although, the hypothesis was that dermal fibroblasts are the main target of S100A9 
released by SSc keratinocytes, its autocrine effect is also possible. In order to establish if 
S100A9 affects proliferation or differentiation of keratinocytes, or their CTGF and IL-6 
release, these processes were assessed in HaCaT cells (due to difficulties with access to 
primary keratinocytes) stimulated with the recombinant protein.  
Crystal violet method was used to establish differences in proliferation in response to 
incubation with S100A9. However, no differences were observed in cell number between 
treated and untreated cells after 48hrs incubation (Fig.4.22). 
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Figure 4.22. Effect of S100A9 on proliferation of HaCaT cells.  
HaCaT cells incubated with rhS100A9 for 48hr and proliferation was measured using crystal 
violet method. The results are presented as mean ± SEM of three independent experiments. The t- 
test was used to calculate statistical significance. P value was non-significant. 
 
The proliferation investigation was followed by an examination of effect S100A9 on 
keratinocytes differentiation, which could explain changes in the differentiation program 
of SSc keratinocytes. However, despite previous reports on S100A9 affecting 
differentiation of keratinocytes (Thorey et al., 2001, Voss et al., 2011), staining of HaCaT 
cells treated with 1µg/ml of S100A9 for 48hrs, did not reveal any changes in the 
expression of involucrin and loricrin when compared to untreated cells (data not shown). 
Though, for that effect a prolonged exposure to S100A9 might be required. Additionally, 
primary cell strains could behave differently to an immortal HaCaT line, and organotypic 
3D cultures of the epidermis might be a better model than monolayer.  
Next, I wanted to establish if stimulation of HaCaT cells with S100A9 is able to induce 
transcription of CTGF gene. Although, TGF-β used as positive control as expected 
induced increase in CTGF mRNA levels (p<0.05), no differences were observed with 
HaCaT cells stimulated with S100A9, when compared with untreated cells (Fig.4.23).  
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Figure 4.23. Effect of S100A9 on CTGF mRNA levels in HaCaT cells.  
HaCaT cells were incubated with rhS100A9. Relative expression of CTGF mRNA after 24hr 
treatment was measured with qPCR. The values were normalized relative to TBP mRNA 
expression using the ΔΔCT method. The results are presented as mean ± SEM of two independent 
experiments. The student’s t- test was used to calculate statistical significance, * p<0.05. 
 
Then, I decided to look if S100A9 can induce expression of pro-inflammatory cytokines 
such as IL-6. The results of ELISA performed on the media taken from HaCaT cells 
treated with S100A9 showed a trend (p=0.06) towards increased release of IL-6 by cells 
treated with S100A9. As expected incubation of HaCaT cells with LPS, which was used 
as a positive control, induced over 2 fold increase (p<0.05) in released IL-6 compared to 
both untreated cells and cells treated with S100A9 (Fig. 4.24). 
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Figure 4.24. Effect of S100A9 on IL-6 release from HaCaT cells.  
HaCaT cells were incubated with rhS100A9 for 24hr. IL-6 was measured in conditioned media 
using ELISA. The results of two independent experiments are presented as mean ± SEM. The 
student’s t- test was used to calculate statistical significance, * p<0.05. 
 
Therefore, the data presented above supports the initial hypothesis, that in the context of 
SSc and fibrosis in general, S100A9 has mainly paracrine effect on fibroblast rather than 
autocrine. 
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4.4  Discussion 
One of cardinal features of SSc is skin fibrosis, which is linked to severity and prognosis 
of the disease. Significant research has focused on the role of the dermis in SSc 
pathogenesis. Despite the fact that epidermal–dermal interactions are essential for healthy 
skin, only a limited number of studies have explored the SSc epidermis. Studies from 
other fibrotic skin diseases have reported the importance of the epidermis in promoting 
dermal fibrosis (Bellemare et al., 2005, Niessen et al., 2001, Simon et al., 2011), and a 
report from our group has implicated keratinocytes derived IL-1α as an activator of SSc 
dermal fibroblasts (Aden et al., 2010). Moreover, data in my previous chapter has 
demonstrated morphological changes in SSc keratinocytes, which could impact on 
epidermal interactions in the disease. Therefore, the focus of this chapter was to build 
upon these observations and explore further the changes in SSc epidermis and identify 
factors that are most likely to affect the underlying dermal fibroblasts and contribute to 
disease. 
In particular the impact of SSc epidermis on skin inflammation and fibrosis was 
investigated. Differences in concentrations of secreted molecules, namely FGF-2, CTGF, 
HGF, G-CSF, VEGF-A, PDGF-AA, IL-1α, IL-1β, IL-1ra, IL6, IL8, CCL20, MCP-1, and 
S100A9, between normal and SSc epidermis were examined; histological studies with a 
selected panel of proteins were performed, which were then followed by analysis of the 
expression of genes encoding these proteins. 
One of the explanations for the abnormal differentiation in SSc epidermis, demonstrated 
in the previous chapter, could be a change in the epidermal-dermal interactions caused by 
differential expression of growth factors and cytokines. The secretome analysis results 
revealed that SSc epidermis released significantly higher amounts of CTGF, HGF and 
S100A9 compared to healthy epidermis, while SSc dermis released significantly higher 
levels of HGF than healthy dermis (Nikitorowicz-Buniak et al., 2014). The data presented 
above illustrates the ability of SSc epidermis to produce soluble factors relevant to SSc 
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pathogenesis and thus the possible importance of SSc epidermis in generation and 
maintenance of the disease.  
CTGF, responsible for stimulation of fibroblasts growth, myofibroblast differentiation 
(Grotendorst et al., 2004), matrix production and granulation tissue formation, is 
considered a key factor driving fibrosis in SSc (Frazier et al., 1996). CTGF is 
overexpressed in the majority of fibrotic diseases including SSc, where its increased 
serum, plasma and dermal interstitial fluid levels are associated with severity of skin 
disease and disease duration (Sato et al., 2000). Furthermore, the CTGF gene, primarily 
regulated by TGFβ at transcriptional level, is overexpressed in SSc skin and lung 
fibroblasts (de Winter et al., 2008, Shi-Wen et al., 2008). Here I demonstrate that this 
critical factor for maintenance of fibrosis is also upregulated in SSc epidermis and bound 
to the ECM at the dermal epidermal junction in early disease. 
CTGF levels in SSc epidermal explants conditioned media were significantly higher than 
healthy controls. Enhanced staining in SSc epidermis, at epidermal-dermal junction and 
around blood vessels, further strengthened the evidence of increased CTGF production by 
SSc epidermis and epidermal contribution to the disease. The findings were also 
confirmed by epidermal blister sheets analysis, which showed a significant increase in 
CTGF mRNA in SSc. Interestingly, mRNA of another member of CCN family often 
linked to fibrosis, NOV (CCN3) was also found to be increased in the epidermal blister 
sheets, suggesting important role of CCN family members in the diseased epidermis. 
HGF, produced by mesenchymal cells upon injury becomes cleaved to a mature 
biologically active form, which binds to the c-Met receptor on epithelial cells and 
enhances their proliferation and migration to enable wound closure. However, HGF can 
also act in an autocrine manner, when released by epithelial cells themselves, as in certain 
types of cancer and extensive skin injury (Nayeri et al., 2006). Keratinocytes 
overexpressing HGF are hyperproliferative and form thickened epidermis (Hamoen and 
Morgan, 2002). HGF can be regarded as anti-fibrotic agent due to its ability to suppress 
collagen synthesis and CTGF in SSc fibroblasts (Bogatkevich et al., 2007, Jinnin et al., 
2005, Sherriff-Tadano et al., 2006). Previous works showed enhanced HGF levels in SSc 
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patients serum (Beirne et al., 2009), increased mRNA levels in SSc skin (Frost et al., 
2012), and amplified expression in SSc fibroblasts along with its receptor c-Met 
(Kawaguchi et al., 2002). Results from our group have demonstrated increased 
phosphorylation of c-Met in SSc epidermis (Aden et al., 2010).  
Data in this report show significantly raised HGF in the conditioned media from SSc 
epidermis when compared with healthy controls. However, immunostaining and mRNA 
assay results suggests that keratinocytes might not be an important source of HGF in SSc 
skin. They indicate that the local fibroblasts might be responsible for the overproduction 
and keratinocytes are a target. Therefore, it would be useful to compare levels in the 
media with the levels bound to c-met receptor. Increased presence of this anti-
differentiation factor could explain delayed differentiation of SSc keratinocytes.  
The results of ELISA performed on conditioned media by epidermal cells also showed 
that S100A9 is released in higher concentrations by SSc epidermis and suggested 
keratinocytes as the main sources of the protein in the SSc skin. This was further 
confirmed by immunofluorescent staining, which revealed S100A9 expression in basal 
and SSc epidermis, in contrast to just weak basal expression in control epidermis. Only 
weak staining and no changes in S100A8 expression pattern were found between SSc and 
control sections. Results of the epidermal blisters sheets analysis further confirmed 
increase S100A9 mRNA in SSc and no differences in S100A8 mRNA levels, suggesting 
that in SSc skin S100A9 does not heterodimerise with S100A8. 
S100A9 belongs to a family of calcium-binding S100 proteins and was reported to reduce 
keratinocyte proliferation and increase differentiation (Voss et al., 2011). Its 
overexpression is seen in suprabasal keratinocytes of inflamed hyperproliferative, 
abnormally differentiated epidermis like in psoriasis (Benoit et al., 2006); certain types of 
cancers and inflammatory skin diseases such as lupus erythematosus. Therefore, its high 
levels might be also responsible for the abnormal differentiation of SSc keratinocytes. 
Moreover, S100A9 is one of the damage associated molecular pattern (DAMPs) 
molecules, a danger signal recognised by immune cells and known to be induced in 
168 
 
keratinocytes during epidermal stress (Thorey et al., 2001, Marionnet et al., 2003, Dazard 
et al., 2003). S100A9 secretion stimulates expression of IL-8, IL-6 and other pro-
inflammatory cytokines which then stimulate release of S100A9 (Nukui et al., 2008). 
Such positive feedback loop further perpetuates pathological changes. These pro-
inflammatory properties of S100A9 were investigated in this thesis using the HaCaT cell 
line, and dermal fibroblasts as targets.  
Although, the role of S100A9 in SSc is unknown, recent publications suggest its 
importance in the development of the disease, and show increased levels of S100A9 in 
SSc skin and plasma (Xu et al., 2013b), serum, feces and saliva of SSc patients 
(Andreasson et al., 2011, Giusti et al., 2007). S100A9 has been shown to signal via TLR4 
and RAGE, and both pathways contribute to CTGF production. Moreover, 
overexpression of both RAGE (Davies et al., 2009) and TLR4 (Bhattacharyya et al., 
2013) was previously reported in SSc skin. Although, the results presented in this chapter 
did not show differences in TLR4 mRNA between control and SSc sections, this does not 
rule out active TLR4 signalling and might be caused by anti-inflammatory therapy, that 
patients undergo in order to control symptoms of SSc, or the effects of statins, which are 
widely prescribed to chronic disease patients. Recently, S100A9 was reported to promote 
lung fibroblast activation via RAGE pathway (Xu et al., 2013a) while  enhanced TLR4 
signalling seem to sensitize fibroblasts to pro-fibrotic stimulation by TGF-β1, a widely 
accepted factor in SSc pathogenesis (Bhattacharyya et al., 2013).  
Recently S100A8/S100A9 was also reported to be produced by activated keratinocytes of 
FGF receptor knockout mouse and identified as a key player in development of dermal 
fibrosis in these mice (Meyer et al., 2011). Moreover, increased S100A8/S100A9 
circulatory levels were also shown to associate with SSc lung fibrosis (van Bon et al., 
2014). However the exact form of the S100A8 protein was not investigated, thus it is 
difficult to comment if the SSc pulmonary disease link is related to homo- or 
heterodimer. Therefore, the direct effect of S100A9 on fibroblasts and keratinocytes in a 
context relevant to fibrosis was established. The results have shown that HaCaT cells 
stimulated with S100A9 have increased IL-6 levels. Moreover, S100A9 stimulates 
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proliferation and migration of SSc dermal fibroblasts, and induces CTGF protein and 
mRNA in cultured dermal fibroblasts from both SSc and control. This is an important 
finding suggesting a link between pro-inflammatory and pro-fibrotic pathways that may 
play role in SSc pathogenesis. It emphasizes the potential for epithelial damage or 
activation to modulate dermal fibroblast properties by induction of key growth factors, 
and demonstrates the importance of interactions of epidermal keratinocytes with dermal 
fibroblasts. However, this mechanism might be responsible for changes in other organs 
too. Implication of TLR4 depended pathway provides a link between damage signal and 
involvement of innate immune system profoundly linked to fibrosis.  
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Chapter Five 
 
Results: TGFβ signalling – EMT in SSc skin 
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5.1  Introduction 
Presence of active TGFβ signalling in SSc skin and its crucial role in SSc pathogenesis 
are well documented (Xu et al., 1991, Leask et al., 2002, Rudnicka et al., 1994, Holmes et 
al., 2001). Enhanced TGFβ1 and TGFβ receptors expression was observed in the skin, 
including the epidermis of patients with active SSc disease (Higley et al., 1994). TGFβ 
not only promotes fibrosis on its own, but also induces expression of other pro-fibrotic 
factors such as ET-1 (Shi-wen et al., 2007), PDGF (Bonner, 2004) and CTGF, all of 
which are also implicated in SSc disease. CTGF, which is often used as a downstream 
marker of TGF-β signalling, was shown in previous chapter of this thesis to be 
overexpressed in SSc epidermis. Its induction is known to be mediated by the TGF-
β/Smad pathway (de Winter et al., 2008), which can also stimulate epithelial cells to 
undergo EMT and acquire the properties of mesenchymal cells (Hoot et al., 2008). 
 
Another process associated with EMT is persistent inflammation, which leads to the 
release of cytokines into the microenvironment of epithelial cells, triggering their 
activation, which can then result in their transition into fibroblasts. Originated this way 
fibroblasts become activated by inflammatory signals and start to produce ECM, which 
accumulates leading to tissue fibrosis. A link between EMT and lung fibrosis is well 
established (Kim et al., 2006, Yasukawa et al., 2013), but in case of fibrosis of other 
organs, such as kidney it is disputable (Iwano et al., 2002). In a previous chapter of this 
thesis I have demonstrated increased levels of pro-inflammatory S100A9 and IL-6 in the 
SSc epidermis. Reports of enhanced expression of other inflammatory markers in SSc 
skin were also published (Koch et al., 1993, Tao et al., 2011).  
 
Therefore, such a pro-inflammatory environment combined with active TGFβ signalling 
in the SSc epidermis could potentially trigger the EMT process in SSc keratinocytes. 
Recently, two groups reported evidence for EMT associated changes in SSc skin 
(Nakamura and Tokura, 2011, Gillespie et al., 2011); however, these reports were not 
followed by more extensive studies. EMT could link the changes found in the SSc 
epidermis, with the persistent myofibroblast phenotype seen in the underlying dermis. 
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Thus in this chapter I have explored whether there is any evidence of SSc epidermal 
keratinocytes undergoing an EMT process using immunohistochemistry and RT-qPCR 
techniques. 
 
 
5.2  Results 
Studies were performed to determine whether complete or partial EMT might be a feature 
of abnormal epidermis of SSc patients and contribute to the increased population of 
myofibroblasts seen in the SSc skin. 
 
5.2.1 Expression of phosphorylated Smad2/3  and K14 in SSc skin 
Smad dependent TGFβ1 signalling has been implicated in wound healing and fibrosis. Its 
ability to stimulate production of pro-inflammatory cytokines, ECM synthesis, but also 
stimulate proliferation and differentiation of fibroblasts, as well as regulation of 
keratinocytes makes Smad/TGFβ1 an important player in SSc pathogenesis. Previous 
studies have demonstrated increased TGFβ1 in the skin, but they were mainly focused on 
the dermis. In order to examine for the presence of Smad signalling in the SSc epidermis, 
immunohistology was performed on skin sections.  
Analysis of sections stained with anti-phospho-Smad2/3 antibodies (red) revealed its co-
localisation with nuclear stain DAPI (blue) in SSc skin (Fig.5.1). This nuclear expression 
was observed throughout the SSc epidermis, apart from the last granular layer, where the 
protein was stained in the cytoplasm. In contrast, in healthy epidermis no staining was 
observed in the basal cells, while the supra-basal cells showed cytoplasmic localisation. 
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Figure 5.1. Phosphorylation of Smad2/3 in SSc epidermis.  
Representative images of double immunofluorescent staining performed to detect phosphorylated 
Smad2/3 (red) and K14 (green) in the epidermis of SSc patients and controls forearm skin 
sections. DAPI (blue) was used to stain nuclei.  
SSc#Control#
Smad2/3# Smad2/3#
K14# K14#
IgG#
Merge# Merge#
174 
 
In order to investigate possible cross talk between the SSc epidermis and local dermal 
fibroblasts, p-Smad2/3 positive cells within the immediately adjacent dermis (Fig.5.2a) 
and in the epidermis (Fig.5.2b) were examined. A significant increase was noted in the 
number of p-Smad2/3 positive cells in the SSc papillary dermis from 41.6±7.55 in 
controls to 69.2±10.94 in SSc (p<0.05). However, even more pronounced difference was 
observed in the number of positive keratinocytes from 31.4±5.12 in controls to 
123.6±16.58 in SSc (p<0.005). 
 
Figure 5.2. Quantitative analysis of phospho-Smad2/3 staining in SSc skin.  
Cells showing nuclear phospho-Smad2/3 staining were counted and mean was calculated for each 
section based on average of 5 high magnification fields of view. The graphs show mean± SEM of 
phospho-Smad2/3 positive cells in (a) papillary dermis and (b) epidermis of controls (n=6 and 7 
respectively) and SSc patients (n=6 and 7 respectively). The Mann-Whitney test was used to 
calculate statistical significance, * p<0.05, ** p=0.005.  
 
Such augmented activation of Smad2/3 in the SSc keratinocytes and fibroblasts at the 
epidermal-dermal junction, suggests that in this area cross- talk between these 2 cell types 
takes place, but also confirms previous findings of active Smad dependent TGFβ 
signalling in the SSc skin, including epidermis. Moreover, increased TGFβ signalling in 
the papillary dermis is consistent with the increased CTGF staining in this area of the 
early SSc samples, showed in the previous chapter.  
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5.2.2 Modeling EMT in HaCaT cells stimulated with TGFβ 
As already mentioned, Smad dependent TGFβ signalling described in the SSc skin 
(Honda et al., 2012, Gruschwitz et al., 1990, Falanga et al., 1992) can also stimulate 
keratinocytes to undergo EMT. The origin of myofibroblasts present in the fibrotic tissue 
seen in SSc is unclear, and the EMT process is given as one of the possibilities of 
generation of these cells. Therefore, it had to be determined, whether SSc epidermal 
keratinocytes loose their epithelial phenotype and gain characteristics of mesenchymal 
cells, thus contributing to increased population of local fibroblasts. In order to validate 
qPCR assays and protein markers relevant to the process, before moving into experiments 
with patients’ samples, an EMT model was established. Cells of the immortal 
keratinocyte line, HaCaT were incubated with TGFβ1, a known EMT inducer. The cells 
were then either used for immunofluorescent staining, or lysed for protein/ mRNA 
assays. The sections below present the results of these assays. 
In order to look at the ability of detection of EMT changes by immunofluorescent 
staining with in house antibodies, HaCaT cells were incubated with TGFβ1 for 72hr 
(Rasanen and Vaheri, 2010). As anticipated, morphology assessment by bright field 
microscopy, revealed altered cell morphology from the typical for keratinocytes cobble 
shape, into more elongated fibroblast-like phenotype in treated cells (Fig.5.3 BF). 
Furthermore, cells incubated with TGFβ1 had lower density than the controls, suggesting 
inhibition of proliferation, as previously described (Munger et al., 1992, Kretschmer et 
al., 2003).  
In addition, immunofluorescent staining with epithelial specific marker Pan-cytokeratin 
and the mesenchymal cell marker FSP-1 was performed to assess the effect of the 
treatment on the expression of epithelial and mesenchymal markers. Consistent with 
changes in shape, TGFβ1 treatment caused decreased expression of Pan-cytokeratin with 
simultaneous increase in FSP-1 (Fig.5.3). Those results indicate, that as expected, HaCaT 
cells treated with TGFβ1 started to acquire a mesenchymal phenotype, which is 
consistent with EMT changes. 
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Figure 5.3. EMT changes in HaCaT cells treated with TGFβ1.  
HaCaT cells were incubated with TGFβ1 for 72hr. Cells morphology was assessed by bright field 
microscopy (BF), and double immunofluorescent staining was performed to assess effect of the 
treatment on the expression of epithelial and mesenchymal markers. Pan-cytokeratin (Pan-CK) 
was used as an epithelial marker (red), FSP-1 was used as mesenchymal marker (green), and 
DAPI (blue) was used to stain nuclei. The figure shows representative images of 3 independent 
experiments. Scale bars = 20µm. 
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However, to confirm these results, Western blotting was performed on lysates of HaCaT 
cells incubated with 2ng/ml and 4ng/ml of TGFβ1 for 24, 48 and 72hrs. Membranes were 
probed with α-SMA, E-cadherin, and GAPDH was used as a loading control (Fig 5.4). 
No differences in α-SMA levels were observed at 24hrs. The highest level of α-SMA was 
seen in samples incubated with 2ng/ml of TGFβ1 for 48hrs, followed by 4ng/ml of 
TGFβ1 for 48hrs and 4ng/ml of TGFβ1 for 72hrs. E-cadherin levels did not show any 
alteration at 24hr, between untreated and samples treated with 2ng/ml of TGFβ1. 
However, TGFβ1 at 4ng/ml after 24hr started to reduce E-cadherin levels. As expected, 
incubation with TGFβ for 48 and 72hr lead to decrease in E-cadherin compared to 
untreated controls. 
 
 
Figure 5.4. Changes in levels of α-SMA and E-cadherin in HaCaT cells lysates after 
treatement with TGFβ1.  
HaCaT cells were incubated with TGFβ1 (2ng/ml or 4ng/ml) for 24, 48 and 72hr and lysates used 
for Western blotting detection of E-cadherin and α-SMA. The image is representative of 3 
independent experiments. 
 
Since negative controls samples showed relatively high levels of α-SMA, further studies 
were performed using FSP-1 as an additional marker of the EMT process, which proved 
to be more discriminatory as a marker of the mesenchymal phenotype. Consistent with 
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immunofluorescent results Western blotting analysis of cell lysates showed induction of 
mesenchymal marker FSP-1 in cells treated with TGFβ1, but not in controls (Fig 5.5). 
 
Figure 5.5. Changes in levels of E-cadherin and FSP-1 in HaCaT cells lysates after 
treatement with TGFβ1.  
HaCaT cells were incubated with TGFβ1 for 72hr and lysates used for Western blotting detection 
of E-cadherin, and FSP-1. The image is representative of 3 independent experiments. 
 
 
Finally, to ensure that the EMT changes can be also detected on the transcriptional level, 
and to optimize the qPCR assays, RNA was extracted and after RT-qPCR copy numbers 
of transcription factors involved in EMT were measured. As expected, after 24hrs 
incubation a 6.9 fold increase in SNAI1 was observed in cells treated with 2ng/ml of 
TGFβ1 and a 4.3 fold increase in cells treated with 4ng/ml compared to controls 
(Fig.5.6a). After 48hrs the increase was 6.8 and 2.5 respectively, while after 72hrs the 
fold increase reduced to 3.6 for 2ng/ml and 3.4 for 4ng/ml treatments.  
SNAI2 copy number also increased after TGFβ1 treatment, and after 24hrs incubation 
was 3.9 times higher in samples where 2ng/ml was used, and 3.4 times higher with 
4ng/ml of TGFβ1 when compared to untreated control. However, after 48hrs incubation 
the fold difference between treated and untreated samples was even higher, 6.7 for 
2ng/ml and 4.3 for 4ng/ml. Furthermore, increasing incubation to 72hrs reduced the 
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difference and samples treated with 2ng/ml exhibited 3.9 fold increase in SNAI2 when 
compared to untreated, while for 4ng/ml treatment the 2.9 fold increase was recorded. 
The results suggest that the optimal concentration of TGFβ1 for EMT induction in 
HaCaT cells is 2ng/ml for 24-48hrs, and the best time point for SNAI1 mRNA detection 
is 24-48hrs but for SNAI2 it is 48hrs.  
 
Figure 5.6. Changes in mRNA levels of Snail1 and Snail2 in HaCaT cells lysates 
after treatement with TGFβ1.  
HaCaT cells were incubated with TGFβ1 for 24- 72hr and cell lysates used for RT-qPCR 
detection of SNAI1 and SNAI2.  The image is representative of 3 independent experiments. The 
graphs show mean ± SEM. 
 
5.2.3  Continuity of the basement membrane in SSc skin 
Once assured that potential EMT changes will be detected by the optimized assays, 
analysis of patient’s samples was initiated. Paraffin embedded sections of forearm skin of 
healthy controls and SSc patients were stained using antibodies against mesenchymal 
marker FSP-1 and the basement membrane protein – collagen IV. The double 
immunofluorescent staining results showed FSP-1 staining in control tissue around blood 
vessels and single positive cells in the basal epidermal layers and dermis (Fig.5.7).  
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Figure 5.7. Immunofluorescent staining of collagen IV and FSP-1 in SSc skin.  
Representative images of double immunofluorescent staining performed to detect basement 
membrane protein collagen IV (red) and mesenchymal cell marker FSP-1 (green) in the epidermis 
of SSc patients and controls forearm skin sections. DAPI (blue) was used to stain nuclei. 
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FSP-1 staining was increased in SSc, where not only more positive cells were observed in 
the epidermis, but in contrast to basal location in controls they were present also in the 
suprabasal layers. In the SSc dermis FSP-1 signal was detected around blood vessels, as 
well as bound to ECM. However, collagen IV in the basement membrane of SSc patients 
did not appear compromised and the thickness of the basement membrane did not show 
any changes. As expected, staining was restricted to the epidermal-dermal junction and 
areas around blood vessels. There were also no indications of cells that were migrating 
through the membrane from the epidermis into the dermis. 
 
 
5.2.4  Double immunofluorescence for vimentin and E-cadherin  
Despite lack of evidence for compromise to or migration of cells through the basement 
membrane we decided to investigate further if any signs of EMT are present in the SSc 
skin. Unfortunately, there is no single specific marker available that would allow 
distinctive recognition of fibroblasts from other types of cells of mesenchymal origin. 
Therefore, I have chosen on this occasion to use vimentin, as a mesenchymal marker and 
looked for cells that would co-express it with E-cadherin to indicate EMT.  
 
Analysis of double staining of vimentin with E-cadherin, did not reveal any differences in 
pattern or level of E-cadherin expression, between control and SSc skin sections 
(Fig.5.8). Vimentin staining was very intense in the dermis of control and SSc. 
Interestingly, similar to FSP-1 staining results; positive cells were detected in the 
epidermis, with basal location in the controls and suprabasal in the SSc. Moreover, those 
cells were positive for both vimentin and E-cadherin. As already mentioned in the 
introduction chapter such co-expression of epithelial and mesenchymal markers could 
indicate EMT process or else be due to local dendritic cells, which can express both 
markers. 
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Figure 5.8. Immunofluorescent staining of E-cadherin and vimentin in SSc skin.  
Representative images of double immunofluorescent staining performed to detect epithelial cell 
marker E-cadherin (green) and mesenchymal marker vimentin (red) in the epidermis of SSc 
patients and controls forearm skin sections. DAPI (blue) was used to stain nuclei.  
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5.2.5  Langerin and FSP-1 co-staining 
An epidermal population of dendritic cells called Langerhans cells (LCs) contributes 3-
5% of nucleated cells in the epidermis (Merad et al., 2008). LCs express E-cadherin to 
attach to keratinocytes (Valladeau and Saeland, 2005), and due to their hematopoietic 
origin (Stingl et al., 1980) also express vimentin (de Waal et al., 1984) and FSP-1 (Boni 
et al., 1997). To establish if LCs are the source of vimentin and FSP-1 positive cells in 
the epidermis and therefore confounding the results above, langerin (CD207) a type II 
trans-membrane lectin receptor on LCs was used along with FSP-1. 
 
The results of immunofluorescent staining of skin sections revealed that all cells positive 
for FSP-1 were also positive for langerin. This suggests, that those cells belong to a 
subset of dendritic cells expressing langerin (most likely LCs), rather than cells 
undergoing EMT. 
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Figure 5.9. Co-staining of langerin and FSP-1 in control and SSc epidermis.  
Representative images of double immunofluorescent staining performed to detect Langerhans cell 
using langerin (red) and mesenchymal cells using FSP-1 (green) in the epidermis of SSc patients 
and controls forearm skin sections. DAPI (blue) was used to stain nuclei. 
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5.2.6  Fibrotic markers in the SSc skin 
As demonstrated in previous sections of this chapter the SSc skin shows an increased 
staining of mesenchymal markers, vimentin and FSP-1. Although, fibrotic markers such 
as α-SMA and pro-collagen I were extensively studied in the dermis, the epidermal 
compartment of the skin was often omitted in the published reports as irrelevant to the 
disease process. In order to examine the expression of these markers in the SSc 
epidermis, α-SMA and pro-collagen type I immunohistochemistry was performed on 
paraffin embedded skin sections.  
 
Consistent with a previous study (Farina et al., 2009), staining with α-SMA antibody 
(Fig. 5.10) revealed a higher number of positive cells, especially in the SSc upper dermis 
in the proximity of the epidermis when compared to healthy skin. Moreover, 43% of SSc 
sections (3 out of 7) had positive α-SMA staining in cytoplasm of epidermal 
keratinocytes of basal and suprabasal layers compared to 0 of 6 controls. All of the 
sections with the epidermis positive for α-SMA came from late stage dcSSc patients.  
 
Cells positive for pro-collagen type I were found in both healthy and SSc dermis 
(Fig.5.11A). However, in contrast to control and early SSc sections, the extracellular 
staining present especially in the upper dermis was absent in 2/3 of late SSc samples. At 
the same time, the number of dermal cells expressing pro-collagen in the late SSc 
increased from 18.5±3.9 in controls and 19.3±5.7 in early stage disease to 40.3±4.3 (both 
control vs. late stage disease and early vs. late stage disease p<0.05), illustrating the 
amplified number of myofibroblasts with disease progression (Fig.5.11.B). The different 
pattern of pro-collagen expression between different stages of disease suggests that, as 
SSc advances there might be a change in the epidermal-dermal cross talk, as the 
extracellular pro-collagen was mainly detected in the papillary dermis in early stages of 
the disease. Such loss of extracellular pro-collagen type I points also at the alteration in 
components of the ECM in the SSc. 
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Figure 5.10. Elevated levels of α-SMA in epidermis of late SSc patients.  
Representative images of forearm skin sections of patients with early and late SSc, and controls 
stained with α-SMA.  
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Figure 5.11. Increased levels of intracellular type I with decrease in extracellular 
levels in the papillary dermis of late SSc patients.  
(a)Representative images of forearm skin sections of patients with early and late SSc, and 
controls stained with pro-collagen type I. Cells showing positive staining were counted and mean 
was calculated for each section based on average of 3 high magnification fields of view. (b) 
Mean± SEM of type I pro-collagen positive cells in the dermis of control subjects, early and late 
SSc patients (n=4, n=3 and n=3 respectively). The one-way ANOVA followed by Tukey’s 
multiple comparison test was used to calculate statistical significance, * p< 0.05.  
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The interesting results of diminished extracellular bound type I pro-collagen at the 
epidermal dermal junction in late SSc was followed by assessment of pro-collagen 
mRNA in the epidermal blisters. The gene encoding alpha1 chain of type 1 pro-collagen 
(COL1A1) was measured in extracts from epidermal tissue samples and showed a 
significant reduction in type I collagen mRNA levels with disease progression in the 
epidermis of SSc patients (p<0.05). The late SSc patients’ epidermis contained 2.2 times 
less pro-collagen mRNA (56.5±7.98) when compared with control (122.2±26.54) and 1.7 
fold reduction than in early samples (96±19.56) (Fig.5.12). There was no significant 
difference in the relative copy number of this gene between controls and early SSc 
patients. Such correlation between epidermal mRNA and extracellular levels of pro-
collagen at the epidermal-dermal interface further strengthen the interplay between these 
two skin components. 
 
Figure 5.12. Decreased pro-collagen type I mRNA in the epidermis of late SSc 
patients.  
Levels of COL1A1 mRNA in epidermal blister sheets were compared between control, early and 
late dcSSc disease. HC - control (n=6), early SSc – early diffuse SSc (n=3), late SSc – late diffuse 
SSc (n=8). The one-way ANOVA followed by Tukey’s multiple comparison test was used to 
calculate statistical significance, * p< 0.05. 
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5.2.7 mRNA assays for EMT markers in epidermal blister sheets  
To ensure that the investigation of possible EMT evidence in SSc epidermis is carried out 
also at the mRNA level, qPCR assays were included for key markers of EMT, Snail1 and 
Snail2. Samples were normalised using normalisation factor calculated by GeNorm 
software based on expression of most stable genes TUBB and B2M.  
Analysis of blister epithelial sheets revealed a 2.4 fold increase in number of SNAI1 
copies (p<0.05) in SSc compared to controls, which among healthy subjects included 
patients with primary Raynaud’s syndrome. However, no significant differences were 
observed with SNAI2 between control and SSc samples. 
 
 
Figure 5.13. SNAI1 and SNAI2 mRNA in epidermal blister sheets. 
Copy numbers of (a) SNAI1 and (b) SNAI2 mRNA were measured in the epidermal blister sheets 
of SSc patients and controls. The results are presented as mean ± SEM. The Mann-Whitney U test 
was used to calculate statistical significance, * p<0.05. HC- control (n=9), dcSSc – diffuse SSc 
(n=14). 
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5.3  Discussion 
Chapter 4 has demonstrated elevated levels of pro-inflammatory S100A9 and pro-fibrotic 
CTGF in SSc epidermis. Both proteins have been recently shown to be associated with 
the EMT process (Sonnylal et al., 2013, Cormier et al., 2014). Therefore in this chapter, 
the effect of the inflammatory microenvironment and active TGFβ signalling on potential 
EMT changes in SSc skin has been examined. The presence of active Smad signalling in 
the SSc epidermis and papillary dermis has been clearly demonstrated. In addition 
possible expression of markers of the EMT process, has been investigated it the SSc 
epidermis. Although, an in vitro model of EMT in HaCaT positively identified changes 
consistent with the transition of keratinocytes, no definite answers were found in SSc 
skin. This work complements work carried out on EMT in SSc skin by Gillespie and 
Nakamura (Gillespie et al., 2011, Nakamura and Tokura, 2011).   
 
As described in previous reports (Rasanen and Vaheri, 2010, Lamouille and Derynck, 
2007), I found that TGFβ1 treated cells begin to change morphology to more elongated, 
as seen under bright field microscope. Immunohistochemistry of HaCaT cells incubated 
with TGF-β showed an increase in FSP-1 expression coupled with decreased Pan-
cytokeratin when compared with controls, which was expected and indicates a switch 
from epithelial to mesenchymal markers. The result was confirmed by Western blotting, 
where TGFβ1 treatment led to down-regulation of E-cadherin, consistent with Wang’s 
data (Wang et al., 2012), and upregulation of FSP-1 protein. Moreover, cells incubated 
with TGF-β had significantly raised levels of SNAIL1 and SNAIL2 mRNA when 
compared with untreated, consistent with previous report (Herfs et al., 2008). The time 
course confirmed that both SNAIL1 and SNAIL2 are induced early on during the EMT, 
and precede any changes to protein markers. All these observed changes suggest that the 
cells treated with TGFβ were undergoing EMT. The finding is consistent with previous 
reports of TGFβ stimulation of epithelial cells to undergo EMT reviewed by Zavadil 
(Zavadil and Bottinger, 2005). 
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Hypothetically, a portion of fibroblasts observed in SSc skin could originate from 
proliferation of local fibroblasts, bone marrow derived fibroblasts progenitors or 
epithelial/endothelial derived fibroblasts via EMT and EndMT. Studies on other organs 
have indicated the potential importance of EMT in SSc. Moreover, I had found that 
upregulated TGF-β signalling via Smad2/3, known to promote EMT, and activated 
keratinocytes, are both features of SSc skin. Thus, this work is an attempt to address a 
question: is there any evidence for EMT in SSc skin?  
 
During the course of my study reports suggesting EMT in SSc skin started to appear. 
Gillespie (Gillespie et al., 2011) described basal cells of the SSc epidermis with increased 
SFRP4, lack of Caveolin-1 and decreased E-cadherin expression along with the 
expression of vimentin. These findings suggest that due to inhibition of WNT signalling 
basal cells undergo EMT and thus are directly involved in SSc pathogenesis but was 
reported only in a conference abstract form, making the results are more difficult to 
scrutinize. Another association between EMT and SSc skin was brought by Nakamura, 
who reported that Twist and Snail1 positive cells were found within eccrine glands of 
SSc patients (Nakamura and Tokura, 2011). Although interesting, the report was based on 
a limited number of SSc samples, and therefore might not be truly representative to the 
wider cohort of SSc patients. 
 
To obtain more evidence of the occurrence of EMT in SSc skin, and gain more insight 
into its role in SSc skin pathogenesis a series of experiments were set up to detect EMT 
changes in SSc skin sections and epidermal blisters. As anticipated, immunostaining 
revealed activated canonical TGF-β signalling in SSc epidermis illustrated by nuclear 
staining for phosphorylated Smad2/3. Additionally a rise in Smad2/3 phosphorylation 
was observed in the dermis adjusted to the epidermis, confirming cross talk between the 
activated epidermis and dermis. However, despite enhanced TGF-β signalling no loss of 
E-cadherin was observed in epidermal keratinocytes of SSc patients. In both healthy 
control and diseased epidermis some cells positive for vimentin and FSP-1 were 
observed, although, they co-stained for langerin, indicating that these cells are 
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Langerhan’s cells rather than epidermal keratinocytes undergoing EMT. In SSc skin 
sections enhanced expression of the FSP-1 marker in the dermis was observed which was 
expected due to the higher number of myofibroblasts in the fibrotic dermis.  
 
Likewise, no decrease of collagen IV was observed in SSc sections that would suggest 
degradation of the basement membrane, which would enable cells undergoing EMT to 
migrate into the dermis. Interestingly, some of the sections stained with α-SMA antibody 
gave positive results in the late SSc epidermis. Detection of this mesenchymal marker 
often induced during EMT in SSc epidermis was unexpected, but repeated a number of 
times the staining looks specific and gave consistent results. However, to definitely 
confirm the specificity of the staining blocking peptide should be used. The presence of 
α-SMA positive cells in SSc epidermis may suggest some partially evolved EMT process, 
or at least an altered program of differentiation in the SSc skin.  
 
Production of collagen type I have been shown to be upregulated in dermal fibroblast in 
SSc by a number of studies (LeRoy, 1974, Krieg et al., 1978). The protein is synthesized 
in a precursor form as a pro-collagen, which is converted into collagen by enzymatic 
cleavage of amino-and carboxyterminal peptides. These pro-collagen peptides are used as 
markers of collagen biosynthesis, but are also involved in a regulatory process of 
collagen production (Krieg et al., 1978, Fouser et al., 1991, Paglia et al., 1979, Horlein et 
al., 1981). Especially, the amino-terminal pro-collagen peptides were demonstrated to 
significantly reduce collagen production by fibroblasts via negative feedback loop, and 
decreased levels of these peptides in SSc were shown to contribute to disregulated 
collagen production by SSc fibroblasts (Krieg et al., 1978).  
 
In this chapter pro-collagen type I expression pattern was observed to change with 
disease duration. In SSc patients with early stage of disease pro-collagen type I was 
mainly located bound to the ECM at the epidermal dermal junction, comparable to 
controls. However, with disease progression the extracellular expression in the papillary 
dermis decreased, while the number of cells in the papillary dermis expressing pro-
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collagen type I increased. This is in contrast with a reported 3 fold increase in 
concentration of C-terminal peptide in serum of dcSSc patients when compared to control 
(Kikuchi et al., 1994). These opposite results may be due to the fact that the antibody I 
have used for detection of type I pro-collagen in skin sections binds to the N terminal of 
pro-collagen, which is degraded more easily than the C-terminal peptide which circulates 
in blood. However, this does not explain the differences in pro-collagen expression in 
different stages of the disease. 
 
This change in pro-collagen expression suggests altered collagen type I processing in 
established SSc. Perhaps pro-collagen cleavage in established SSc is as some suggest 
intracellular (Bienkowski et al., 1978, Kadler et al., 2007) while in controls and early 
disease the cleavage is at the membrane in fibropositors. Moreover it is possible that 
generation of collagen fibrils occurs faster in the patients with late SSc, therefore the N-
terminal peptide in late SSc is seen only inside the cells and not in the ECM. However, 
described in this chapter reduction in N-terminal pro-peptide at the epidermal-dermal 
junction, could also be linked to the overexpression of collagen in the SSc, due to lack of 
negative feedback loop (Krieg et al., 1978).    
Although the pro-collagen mRNA was previously shown to be raised in SSc skin 
fibroblasts (Graves et al., 1983), the results of mRNA analysis of gene encoding pro-
α2(I) chain of type 1 collagen performed on epidermal tissue shows lower levels in late 
SSc than in controls. Detection of this procollagen in the epidermal sheets rises questions 
regarding specificity of the primers used, as type I collagen is not normally present in the 
epidermal cells. Indeed COL1A1 shows some degree of homology with other procollagens.  
However, presence of pro-α2(I) chain of type 1 collagen in the mRNA derived from 
epidermal sheets but may also indicate dermal contamination of the samples. However, if 
the finding was real this would further point to altered collagen processing with the 
disease progression.  
To gain a more definite answer regarding the possible EMT in SSc, staining for Snail1 
and Snail2 was performed on skin sections, but despite trying different antibodies and 
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optimizing protocols the staining was very unspecific (not shown). Therefore, the levels 
were analysed in RNA extracted from epidermal blister sheets, showing doubling of 
SNAI1 mRNA copy number in SSc compared to controls. Such an increase in gene 
expression, encoding an EMT-inducing transcription factor may suggest an active EMT 
process in the SSc epidermis. Although no significant change in SNAI2 was observed, 
this gene is usually expressed later on during transition process. Thus absence of SNAI2 
induction in SSc epidermis does not have to indicate absence of EMT but may imply 
early stage of these changes. 
Although, active Smad/TGF-β signaling, presence of αSMA in epidermis and enhanced 
CTGF expression, along with enhanced levels of SNAI1 mRNA in SSc suggest EMT 
changes, other results obtained so far do not indicate EMT changes in SSc skin. 
Therefore, SSc epidermis might be a scene of partial EMT that has already been reported 
during wound re-epithelialisation (Arnoux et al., 2008, Yan et al., 2010, Savagner et al., 
2005) Considering that the SSc keratinocytes phenotype is similar to that seen in wound 
healing this explanation might be probable. However, substantially more work should be 
done to get a definitive answer, preferably lineage tracking of labeled epidermal cells and 
therefore would require an animal model. 
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Chapter Six 
 
Summary Discussion and Future Work 
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This thesis was set out to explore the concept of the SSc epidermis playing an important 
role in propagation of skin fibrosis by releasing pro-inflammatory and profibrotic 
mediators stimulating underlying fibroblasts. In this thesis proteins involved in SSc 
dermal fibroblast stimulation have been identified, as well as pathways and biological 
processes that are altered in the SSc epidermis, which can contribute to the disease. Also I 
have confirmed that keratinocytes are activated in SSc skin, and have altered 
differentiation and proliferation processes. In addition I have sought to investigate 
evidence of EMT changes in epidermal keratinocytes of SSc patients. Although no signs 
of the complete EMT process was found, I showed changes consistent with a partially 
evoked EMT.  
The background knowledge available on this subject has been limited and inconclusive. 
My findings however clarify the importance of the epidermis in the context of 
understanding SSc pathogenesis. This chapter aims to summarise my novel findings, 
which have been presented in the results chapters addressing the main research questions 
asked in the thesis, but also discusses the contribution to the field, limitations of the 
studies, as well as future works that could further explore the areas studied in this thesis. 
 
6.1  Epidermal hypertrophy and premature expression of differentiation markers in 
SSc 
I was able to demonstrate significant increase in the epidermal thickness in SSc skin, 
which was consistent with more recent reports (Van Praet et al., 2011, Rossi et al., 2010), 
but contradicted older observation describing SSc epidermal atrophy (Cooper et al., 
1979). This dissimilarity between results from older and recent publications could be 
caused by different classification of SSc disease, which has changed considerably over 
the years and was not clearly defined till the 80s (LeRoy et al., 1988). I have also shown 
that this thickening of the SSc epidermis could be linked to abnormal differentiation of 
SSc keratinocytes, as well as hypertrophy of SSc keratinocytes, and increased 
proliferation of epidermal cells in the disease. The parakeratosis, which I found to be 
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present in some of the SSc sections, was consistent with previous reports (Van Praet et 
al., 2011, Maeda et al., 1993). Changes in the SSc epidermal keratinocyte differentiation 
program based on the expression pattern of keratins K14, K1/10 were also previously 
reported (Aden et al., 2008), however the markers of differentiation used in this thesis 
were never studied previously in the SSc skin.  
Premature expression of involucrin, loricrin and filaggrin described in this thesis is 
characteristic to hyper-proliferative keratinocytes of wounds and psoriasis skin (Hertle et 
al., 1992, Li et al., 2000, Mansbridge and Knapp, 1987), and further strengthens evidence 
of similarities between SSc epidermis and wound re-epithelialisation. This is in line with 
results described in this thesis revealing a trend towards increased proliferation of SSc 
keratinocytes and consistent with previous findings (Pablos et al., 1999). However, my 
proliferation analysis had included only limited number of samples studied. Increasing 
the number of samples, closer age matching of controls and patients and stratifying 
patients with early and established disease, plus taking into consideration mRSS of 
patients, would strengthen the resolving power of this analysis. It would also be 
interesting to look at the behavior of SSc keratinocytes in culture, to find out if they 
would retain their phenotype. Also studying their behavior during calcium switching 
experiments could provide some detail on the triggers and mechanisms of such abnormal 
differentiation.  
 
6.2  Protein phosphorylation in the SSc epidermis 
This thesis demonstrates that not only the morphology of the SSc epidermis is affected 
but also phosphorylation and abundance of the epidermal proteins. Proteins with altered 
levels of phosphorylation in the SSc epidermis include phosphatases, kinases, and 
proteins associated with the SSc pathogenesis, such as Smad2 and PDGFR. Overall I 
report extensive changes in phosphorylation status in diverse proteins involved in cell 
motility, polarity and chemotaxis, apoptosis, cell adhesion, cell cycle regulation, as well 
as cytoskeletal reorganization, differentiation, and regulation of transcription. The results 
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presented in this thesis indicate that SSc epidermal cells have an activated response to 
stress and wound healing, increased activation of innate and adaptive immune system, 
signal transduction, pathways implicated in platelet activation and blood coagulation. 
Therefore my findings are consistent with the general knowledge and current model of 
processes contributing to fibrosis and inflammatory changes seen in SSc. 
The main limitation of this study was the small number of samples used in the assay. 
Moreover the epidermis was separated from the dermis using a scalpel after snap 
freezing, which could result in dermal contamination. Therefore if repeated in the future 
it would be useful to consider other rapid but more accurate methods of separation.  It 
would also be interesting to see if the altered phosphorylation is linked to alternative 
splicing or mutation, for example the reduction of phosphorylation at a particular site 
might be due to the splice variant/mutated gene that results in the protein that lacks that 
phosphor site. Also selecting a protein with a changed phosphorylation status, and 
studying in detail the functional effect of the change in vitro in the context of fibrosis and 
inflammation could complement work presented in this thesis. 
 
6.3  Epidermal secretome  
As shown by my work, SSc epidermal biopsies release a wide range of cytokines, 
chemokines, and growth factors into the media, thus demonstrating the potential 
importance of the epidermis as a secretory organ able to influence behavior of cells 
including underlying fibroblasts and endothelial cells, as well as cells of the immune 
system.  
The main limitations of the skin explant proteome analysis were wide variations in the 
normal control and disease concentration values. This could be limited in the future by 
recruitment of more closely matched controls, as well as obtaining larger numbers of skin 
biopsies, although this is challenging in an uncommon condition and using a relatively 
invasive sampling method. Moreover, including more acute untreated cases, and 
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stratification of patients into early and late SSc would help to reduce variability between 
samples, and reduce standard deviation of the mean. In addition, if the experiment could 
be repeated in the future, the volume of the media should be reduced to increase 
concentration of the soluble factors and therefore avoid problems with detection. 
Moreover, performing Western blot analysis of the explants after collecting the media to 
compare levels of proteins released into the media with levels of ECM or cell-bound, 
would help in better understanding of the abnormalities seen, including signaling 
pathways and their downstream targets.  
 
6.3.1 S100A9 
Immunofluorescent staining of skin sections, as well as epidermal and dermal explant 
secretome analysis presented in this thesis have demonstrated that S100A9 is 
overexpressed by SSc keratinocytes, and released in higher concentrations by SSc 
epidermis than controls. Results of the epidermal blisters sheet analysis also show a trend 
towards an increase in S100A9 mRNA. Although S100A9 was previously reported to be 
increased in SSc serum, feces and saliva of SSc patients (Andreasson et al., 2011, Giusti 
et al., 2007), only recently and synchronous to work on this thesis upregulated levels have 
been reported in the SSc skin (Xu et al., 2013b).  Nonetheless this paper does not show 
pictures of stained epidermis, and only discusses of S100A9 expression pattern in the 
dermis. Therefore, the data on S100A9 expression in the epidermis and the keratinocytes 
as the main sources of this protein in the SSc skin are novel observations. Also in contrast 
to previous observations of S100A9 being overexpressed along with its heterodimer 
partner S100A8 in the SSc dermis and plasma, on both protein and mRNA levels (Xu et 
al., 2013b), staining and mRNA analysis presented in this thesis does not confirm that in 
SSc epidermis S100A9 forms heterodimer. Furthermore, my thesis shows additional 
novel data revealing that S100A9 stimulates proliferation and migration of SSc dermal 
fibroblasts, induces CTGF protein and mRNA in cultured dermal fibroblasts from both 
SSc and control, as well as enhances IL-6 expression in HaCaT cells. In addition, I have 
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now shown that these effects are mediated via TLR4 because I found that TAK-242 an 
inhibitor of TLR4, blocks the effects of S100A9 on CTGF protein and mRNA. 
Overall my data suggests a link between pro-inflammatory and pro-fibrotic pathways that 
may play a role in the SSc pathogenesis (Nikitorowicz-Buniak et al., 2014). It also 
emphasizes the potential for epithelial damage or activation to modulate dermal fibroblast 
properties by induction of key growth factors, and demonstrates the importance of 
interactions between epidermal keratinocytes and dermal fibroblasts. My work also adds 
to the field of knowledge implicating S100A9 in fibrotic conditions, for example the 
potential to activate lung fibroblast via RAGE (Xu et al., 2013a). Furthermore, 
considering associations of elevated S100A9 plasma levels with clinical observations 
such as pulmonary fibrosis, kidney involvement and myositis (Xu et al., 2013b), the 
finding of SSc keratinocytes as a source of this protein is consistent with an important 
role for the epidermis in SSc pathogenesis.  
My findings may have some therapeutic application as pharmacological compounds such 
as quinoline-3-carboxamide (Q compound) have recently been found to bind S100A9, 
limiting its downstream signalling (Bjork et al., 2009). This drug is currently in clinical 
trials for treatment of metastatic prostate cancer (Pili et al., 2011, Dalrymple et al., 2012). 
As currently there is no satisfactory therapy for SSc our findings suggest that Q 
compound or other drugs targeting S100A9 might have some beneficial effect, which 
could be investigated further in SSc.  
The analysis of S100A9’s impact on fibroblast and keratinocytes however has a few 
restraints, which should be considered. S100A9 is a Ca2+ binding protein and the effects 
on cellular functions ideally should be performed after optimizing Ca2+ concentration. 
Moreover, to fully verify the impact of stimulation with S100A9 on fibroblasts, the 
recombinant S100A9 should be used in combination with other factors that are 
upregulated in SSc skin, such as TGFβ1 or CTGF. This would more truly reflect the 
disease microenvironment that cells are exposed to in SSc tissues. It is possible that such 
combinations could have an additive effect to the S100A9 itself. Also autocrine effects of 
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S100A9 overexpression by SSc keratinocytes would be more effectively studied by 
creating a keratinocyte line overexpressing the gene. This could be achieved by using 
keratinocytes from a S100A9 overexpressing transgenic animal strain, or transfecting 
keratinocytes with S100A9 gene using a viral or non-viral transfection agent. However, 
keratinocytes due to constant exposure to viruses have developed mechanisms preventing 
hijacking by viruses, and thus are relatively difficult to transfect. The efficiency of 
transfection is usually low and often leads to induction of terminal differentiation, thus 
any attempts to generate the transfected line were beyond the timescale limits of this 
thesis. 
If I were not bound by the time constraints of this thesis, I would also look at S100A9 
signalling via RAGE in the SSc skin. Moreover, I would study cutaneous fibrosis and 
inflammation in transgenic mice overexpressing S100A9 under the K14 promoter, to 
ensure overexpression only in epithelial cells, treated with bleomycin to induce fibrosis. 
Such approach would not only be a better model for studying the importance of S100A9 
on different cell types relevant to SSc pathogenesis in their biological niches, but would 
also allow to look at any changes in interactions between keratinocytes, fibroblasts, 
endothelial and immune cells, for example leukocyte migration. Therefore, this would 
allow more comprehensive understanding of the relevance of S100A9 in SSc skin 
disease. 
 
6.3.2  CTGF  
Although CTGF overexpression was previously reported to be present in the skin of SSc 
patients (Igarashi et al., 1996) the report did not include comment or analysis of the 
diseased epidermis or keratinocytes. This thesis demonstrates not only enhanced levels of 
CTGF protein and mRNA in the SSc epidermis, but also shows increased release of 
CTGF by the diseased epidermis. The contribution of CTGF to the fibrosis in SSc is well 
established and its plasma and dermal interstitial fluid levels correlate with severity of 
skin disease (Dziadzio et al., 2005). Therefore, production of this key factor driving 
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fibrosis in SSc by the SSc epidermis indicates a direct contribution of the epidermis to the 
SSc pathogenesis.  
 
Moreover, a pronounced CTGF expression, detected at the epithelial/dermal junction 
especially in early stages of disease, suggests involvement of epidermal cells in 
stimulation of dermal production of CTGF. These detected differences in the CTGF 
expression could help to explain the higher serum levels in early SSc previously reported 
(Sato et al., 2000). Additionally, the increase of CTGF in early SSc samples coincides 
with higher levels of S100A9 in the epidermis, and as shown in this thesis the S100A9 
stimulation of dermal fibroblasts also results in the CTGF production. It would be 
interesting to recruit early and late SSc patients and determine whether the levels of 
S100A9, and CTGF in plasma and skin correlate. Such observation would allow to 
further understand the observed in vitro S100A9 mediated CTGF expression.  
 
The low levels of CTGF detected in the dermal explants conditioned media were not 
anticipated. However this could be caused by the CTGF being bound to ECM matrix or 
receptors and thus not as freely released as that by epidermal explants. Thus it could be 
useful to perform co-staining of the sections derived from the explants with CTGF and its 
most relevant receptors. Alternatively, co-immunoprecipitation could be performed on 
the explant tissue. 
 
6.3.3  HGF  
The secretome analysis presented in this thesis has shown an increased release of HGF 
from the SSc epidermis and dermis when compared with controls. Although the 
concentration of HGF was higher in the SSc epidermis than SSc dermis, immunostaining 
and mRNA assay results suggest that keratinocytes are a target rather than the main 
source of HGF in the SSc skin. This is consistent with the previous work showing 
increased c-Met signaling in the SSc epidermis (Aden et al., 2010). Increased presence of 
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this anti-differentiation factor could be implicated in delayed differentiation of SSc 
keratinocytes.  
Previous works showing an enhanced HGF mRNA levels in SSc skin (Frost et al., 2012), 
and amplified expression in SSc fibroblasts along with its receptor c-Met (Kawaguchi et 
al., 2002) also point at the SSc dermal fibroblasts as the main source of this growth factor 
in the SSc skin. Therefore, again it would be useful to compare levels in the media with 
the levels bound to c-Met receptor in both epidermal and dermal explants. Nevertheless 
enhanced levels of HGF demonstrated in this thesis, might be a form of compensatory 
mechanism to the fibrotic changes due to its ability to suppress collagen synthesis and 
CTGF in SSc fibroblasts (Bogatkevich et al., 2007, Jinnin et al., 2005, Sherriff-Tadano et 
al., 2006).  
 
6.4  TGFβ/Smad signaling and EMT 
In this thesis I demonstrated upregulated TGF-β signalling via Smad2/3 in the SSc 
epidermis and adjacent dermis. The active canonical TGF-β signaling in SSc skin is 
consistent with previous study showing nuclear location of phosphorylated Sman2/3 in 
the SSc skin including the epidermis (Dong et al., 2002). TGF-β signaling is known to 
promote EMT, and since activated keratinocytes are seen in SSc skin hypothetically, part 
of the increased fibroblasts population observed in SSc skin could be derived from 
epithelial cells via EMT. Studies on organs such as lungs have suggested importance of 
EMT in SSc, however the scientific community is divided as to the existence of this 
process in organs other than lungs. Revealed in this thesis elevated levels of S100A9 and 
CTGF in SSc epidermis, alongside with the widely accepted increased TGFβ signaling 
and inflammatory microenvironment in the SSc skin could lead to the initiation of the 
EMT process (Sonnylal et al., 2013, Cormier et al., 2014). Indeed some of the changes 
presented in this thesis are consistent with a partial EMT like process and supplement 
previous work carried out on EMT in SSc skin (Gillespie et al., 2011, Nakamura and 
Tokura, 2011), as the current evidence and understanding of EMT in SSc skin is limited; 
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partly because of the need to lineage trace cells to show definitely that cells of epithelial 
origin are migrating into the dermis and taking on mesenchymal properties, which would 
depend on use of animal model systems. 
 
Consistent with the phosphorylation array results this thesis reports increased 
phosphorylation of Smad2/3 in the epidermis and the papillary dermis, confirming cross 
talk between the activated epidermis and dermis. However, such enhanced TGF-β 
signalling did not lead to changes in expression of E-cadherin, type IV collagen of the 
basal membrane, FSP-1 or vimentin. Nevertheless, α-SMA was detected in the epidermis 
of some of the SSc patients, which along with increase in EMT-inducing transcription 
factor SNAI1 mRNA may suggest a partially evolved EMT process in the SSc skin.  
 
My work also shows that the expression pattern of pro-collagen type I in SSc skin 
changes with the disease duration. Early stage of SSc is characterized by extracellular 
expression, especially at the epidermal dermal junction whereas in the late stage the 
number of pro-collagen type I positive cells increase with a simultaneous reduction in the 
extracellular expression in the papillary dermis. This work contradicts previous report of 
pro-collagen in SSc skin showing increased staining within hypodermis in late SSc 
(Fleischmajer et al., 1980). Though the antibodies used in that study had multiple 
epitopes so more ECM staining was detected and the patients’ subset (lcSSc or dcSSc) is 
not specified. Therefore it is hard to compare with the results generated using a more 
specific antibody. The fact that the changes are located in the papillary dermis suggests 
that there are issues with epidermal-dermal cross talk. To better understand the collagen 
metabolism in SSc skin and epidermal involvement in the process, the levels of the pro-
peptidases responsible for the collagen processing should also be investigated. It would 
also be important to distinguish between the levels of free pro-collagen peptides and the 
unprocessed molecules.  
 
Although active Smad mediated TGF-β signaling, enhanced CTGF expression, along 
with enhanced levels of Snail1 mRNA in SSc epidermis suggest EMT changes, other 
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results did not confirm EMT in the SSc skin. Therefore in contrary to earlier published 
work, data presented in this thesis does not support idea of complete EMT in the SSc 
epidermis and rather points to activation and altered terminal differentiation program, 
which partially resembles an EMT process. Such partial EMT has been described to 
occur during wound re-epithelialisation thus further strengthening the evidence of 
similarities between SSc epidermis and wound healing. Though I have successfully 
established the EMT model using HaCaT cells treated with TGFβ1 which showed 
changes consistent with those previously reported (Rasanen and Vaheri, 2010, Lamouille 
and Derynck, 2007, Wang et al., 2012, Herfs et al., 2008, Zavadil and Bottinger, 2005), 
insufficient number of primary keratinocytes prevented me from following the in vitro 
study on EMT using SSc and control keratinocytes. If I were not bound by the time 
constraints of this thesis, I would generate immortal SSc keratinocyte lines in order to 
study in more detail if SSc keratinocytes undergo EMT more easily than control cells, 
and test whether there is any evidence of more spontaneous events of EMT in cell culture 
between the disease and control keratinocytes.  
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Appendix 1. List of primers used in qPCR assays. 
Symbol 
Accession 
number Name Function 
Primer sequence 
Housekeeping genes 
ACTB 
NM_001101 Beta actin Cytoskeletal 
structural protein 
Forward:  
CACCATGTACCCTGGCATT 
 
Reverse: 
CCGATCCACACGGAGTA 
B2M 
NM_004048 Beta-2-
microglobulin 
Beta-chain of major 
histocompatibility 
complex class I 
molecules 
Forward:  
CTCTCTCTTTCTGGCCTGGAG 
 
Reverse: 
ACCCAGACACATAGCAATTCAG 
SDHA 
NM_004168 Succinate 
dehydrogenase 
complex, subunit 
A 
Electron transporter 
in the TCA cycle 
and respiratory 
chain 
Forward:  
AGAAGCCCTTTGAGGAGCA 
 
Reverse: 
CGATCACGGGTCTATATTCCAGA 
TUBB 
NM_178014 Tubulin Major constituent 
of microtubules 
Forward:  
ACATACCTTGAGGCGAGCAA 
 
Reverse: 
TCACTGATCACCTCCCAGAA 
TBP 
NM_003194 TATA box 
binding protein 
General RNA 
polymerase II 
transcription factor 
Forward:  
GAACATCATGGATCAGAACAAC
AG 
 
Reverse: 
ATAGGGATTCCGGGAGTCAT 
Genes of interest 
COL1A1 
NM_000088.3 Collagen type I 
alpha 1 
 Extracellular 
matrix protein 
Forward:  
CCCCTGGAAAGAATGGAGAT  
Reverse: 
AATCCTCGAGCACCCTGA 
CTGF/CT
GF 
NM_001901.2 Connective tissue 
growth factor 
Pro-fibrotic Forward: 
GACCTGGAAGAGAACATTAAGA
AGG 
 
Reverse: 
TCGGTATGTCTTCATGCTGGTG  
260 
 
IL6 
NM_000600.3 Interleukin 6 Pro-inflammatory Forward: 
GGTACATCCTCGACGGCATCT 
 
Reverse: 
GTGCCTCTTTGCTGCTTTCAC 
IL8 
NM_000584.3 Interleukin 8 Pro-inflammatory Forward: 
CAGAGACAGCAGAGCACACA 
 
Reverse: 
GGCAAAACTGCACCTTCACA 
SNAI1 
NM_005985 Snail homolog 1 Transcriptional 
repressor of 
epithelial genes 
Forward:  
CAGGACTCTAATCCAGAGTTTAC
CT 
 
Reverse: 
ACAGAGTCCCAGATGAGCATTG 
SNAI2 
NM_003068 Snail homolog 2 Transcriptional 
repressor of E-box 
motifs incl. E-
cadherin 
Forward:  
GAACTGGACACACATACAGTGAT 
 
Reverse: 
GGTAGTCCACACAGTGATGG 
S100A9/
MIF/MRP
14 
NM_002965          S100 calcium 
binding protein 
A9 
Calcium binding; 
pro-inflammatory 
DAMP 
Forward:  
TGGCTCCTCGGCTTTGACAGAGT 
 
Reverse: 
TGGGTGCCCCAGCTTCACAGA 
SERPINE
1/ PAI-1 
NM_000602.4 
& 
NM_0011654
13.2 
Serpin peptidase 
inhibitor/ 
plasminogen 
activator inhibitor 
type 1, 
Inhibitor of ECM 
proteases 
(uPA/tPA/plasmin/
MMP)  
Forward: 
TCTGAAAAGTCCACTTGCTTGAC 
Reverse: 
GCTATGGGATTCAAGATTGATGA
CA 
TLR4 
NM_138554 Toll-like receptor 
4 
Pathogen 
recognition and 
activation of 
immune response 
Forward:  
CTTCTCAACCAAGAACCTGGAC 
 
Reverse: 
TTGTCTGGATTTCACACCTGGA 
NOV 
NM_002514.3 Nephroblastoma 
overexpressed 
The CCN family 
member important 
in fibrosis  
Forward:  
TACTGCCTGAGCCTAACTGC 
Reverse: 
CCTGTAAGCTGCAAGGGTAA 
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Appendix 2. Protocol for Isolation and Culture of Primary Human Keratinocytes 
On the day of biopsy 2 million γ-irradiated 3T3 fibroblasts were seed in T25 flask in the 
keratinocyte culture media consisting of modified DMEM/F12 (PAA), 10% FBS, RM+ 
supplement (with final concentration (vol/vol) of 5µg/ml transferrin, 0.4µg/ml 
hydrocortisone, 1nM cholera toxin, 10ng/ml EGF, 5µg/ml insulin and 0.2nM 
liothyronine), L-glutamine, 50U/ml penicillin and 50mg/ml streptomycin) and incubated 
at 10% CO2.  
After removing excess fat the skin biopsy sample was transfer into 2.5mg/ml dispase 
made in PBS and incubated overnight at 4°C. The next day skin was washed in PBS, and 
transferred into versene where the epidermis was separate form the dermis. The 
epidermal sheet was then cut, transferred to trypsin/versene and incubated at 37°C. Every 
2-3 min, the solution was pipetted up and down to aid keratinocyte detachment. The 
detached cells were transferred to the keratinocyte culture media, while fresh 
trypsin/versene was added to the epidermal sheet. The process was continued until 
complete disintegration of the epidermis. Cells suspension was then centrifuged at 300 x 
g for 5 min and after re-suspension in the media cells were put in a flask with the pre-
seeded γ-irradiated 3T3 and cultured at 5% CO2. Cultures were checked daily, media 
changed approximately every 3 days, and fresh γ-irradiated 3T3s were added if necessary. 
Once large colonies have formed or cells appear to be differentiating feeders were 
removed with versene, and keratinocytes trypsinised. Cells were then seed cells in flask 
with γ-irradiated 3T3 for further expansion or cryopreserved. 
 
